WELCOME TO THE 148th MEETING
OF THE NATIONAL ADVISORY COUNCIL
ON AGING.
MY NAME IS KEN SANTORA, THE
DIRECTOR OF THE DIVISION OF
EXTRAMURAL ACTIVITIES HERE AT
NIA AND THE EXECUTIVE COUNCIL.
FIRST OFF, BEFORE I TURN THE
MEETING OVER TO OUR DIRECTOR,
DR. RICHARD HODES, I'M GOING TO
DO A ROLL CALL OF OUR COUNCIL
MEMBERS.
WHEN I CALL YOUR NAME, IF YOU
COULD PLEASE INTRODUCE YOURSELF,
GIVE YOUR NAME AND AFFILIATIONS
AND WE'LL GO FROM THERE.
SO STARTING OFF, DR. BAKER.
>>OKAY, DARIN BAKER, MAYO
CLINICMENT ASSOCIATE PROFESSOR
OF BIOCHEMISTRY AND MOLECULAR
BEAMINGY AND PEDIATRIC MEDICINE,
VERY FUNNY AS BEING PART OF THE
NATIONAL ADVISORY COUNCIL ON
AGING.
I HAVE BEEN HERE ROUGHLY A
LITTLE OVER A YEAR AT THIS
POINT.
>>THANK YOU, DARIN.
SHELLY?
>>SHELLY, PROFESSOR OF MEDICINE
AT HARVARD MEDICAL SCHOOL.
I'M AN ENDOCRINOLOGIST BY
TRAINING BUT MUCH OF MY RECENT
WORK HAS BEEN IN AGING BIOLOGY.
>>THANK YOU.
DR. CASE.
>>I'M ANN CASE, AN ECONOMIST AT
PRINCETON UNIVERSITY AND MOST OF
MY RECENT WORK HAS BEEN ON MID
LIFE MORBIDITY AND MORTALITY AND
ITS MOVEMENT INTO OLD AGE.
>>THANK YOU.
DR. CRUISE.
>>GOOD MORNING.
I AM THE PRESIDENT AND CEO FOR
THE NATIONAL HISPANIC COUNCIL ON
AGING.
I HAVE A DOCTORATE IN PUBLIC
HEALTH AND MOST OF MY WORK IS
FOCUSED ON HISPANIC ISSUES AND
OLDER ADULTS.
>>THANK YOU.
DR. DRISCOL.
>>HI, GOOD MORNING.
MONICA DRISCOL.
DISTINGUISHED PROFESSOR IN THE
DEPARTMENT OF MOLECULAR BIOLOGY
AND BIOCHEMISTRY AT RUTGERS.
MY RESEARCH INTERESTS ARE IN THE
VERY FUNDAMENTAL BIOLOGY OF
AGING AND NEURODEGENERATION.
>>THANK YOU.
DR. GREENSPAN.
>>HI, I'M SUSAN GREENSPAN,
PROFESSOR OF MEDICINE AT
UNIVERSITY OF PITTSBURGH.
I'M TRAINED ENDOCRINOLOGIST AND
GERIATRICIAN AND MY FOCUS HAS
BEEN ON FRAILTY, FALLS AND
FRACTURES.
>>THANK YOU.
DR. WONG?
I'M NOT SURE IF YOU CAN
INTRODUCE --
>>I HOPE -- I GET BETTER TODAY.
SENIOR INVESTIGATOR AT -- AND
PROFESSOR AT UROLOGY UCSF.
>>THANK YOU.
>>I'M CYNTHIA HUMBLE, RETIRED
PRESBYTERIAN PASTOR.
ALZHEIMER'S AND DEMENTIA
ADVOCATE AND I HAVE BEEN A
RESEARCH PARTICIPANT FOR MORE
THAN 13 YEARS.
THANK YOU DR. WONGO?
FRANK?
ARE YOU ON?
WE'LL COME BACK TO HIM.
DR. MANLY.
>>JENNIFER MANLY.
I AM A NEUROPSYCHOLOGIST AND A
PROFESSOR IN THE DEPARTMENT OF
NEUROLOGY AT COLUMBIA
UNIVERSITY.
AND MY RESEARCH IS ON LIFE
COURSE STRUCTURAL AND SOCIAL
INFLUENCES ON COGNITIVE AGING
AND ALZHEIMER'S DISEASE.
>>THANK YOU.
DR. PETERSEN?
>>GOOD MORNING.
I'M CHARLOTTE PETERSON,
PROFESSOR AT THE UNIVERSITY OF
KENTUCKY AND MY RESEARCH -- I'M
A MOLECULAR AND CELLULAR
BIOLOGIST WITH FOCUS ON MUSCLE
WASTING, SARK PENIA AND LOSS OF
FUNCTIONAL INDEPENDENCE WITH
AGE.
>>THANK YOU.
DR. RUBIN.
>>I'M DAVE RUBIN, GERIATRICIAN
BASED AT UCLA AND MOST OF MY
WORK HAS BEEN ON HEALTH SERVICES
RESEARCH, INCLUDING
IMPLEMENTATION AND SOME LARGE
CLINICAL TRIALS, INCLUDING WITH
SHALLY.
AND THEN MY CURRENT WORK FOCUSES
ALMOST EXCLUSIVELY ON DEMENTIA
AND IMPROVING THE CARE OF PEOPLE
WHO HAVE DEMENTIA.
I HAVE A VERY CLINICAL TRIAL
WITH PCORI AT NIA WE ARE IN THE
MIDST OF.
>>THANK YOU.
DR. SNYDER?
>>GOOD MORNING, EVERYBODY.
I'M JULIE SNYDER.
-- DEPARTMENT OF PATHOLOGY.
IN OR ABOUTO PATHOLOGIST AND
ENDOCRINOLOGIST -- DISEASE
CENTER WHERE STUDY MOSTLY THE
NEUROPATHOLOGY BASIS OF DECLINE
AND MOTOR DECLINE WITH AGING.
ESPECIALLY INTERESTED IN
TRANSLATIONAL EFFORTS AND
BIOMARKERS AND MECHANISMS,
ESPECIALLY
[ INAUDIBLE ]
>>DR. BEN?
>>I'M LINDA VANELEDDIC,
DIRECTOR OF THE BROWN CENTER ON
AGING AND THE UNIVERSITY OF
KENTUCKY ALZHEIMER'S DISEASE
CENTER AND PROFESSOR OF
NEUROSCIENCE.
MY OWN RESEARCH IS ON
TRANSLATIONAL NEUROSCIENCE IN
TERMS OF DYSREGULATED BRAIN
INFLAMMATION AND USING THAT AS
THERAPEUTIC TARGETS SO I BROUGHT
COMPOUNDS INTO HUMAN TRIALS.
>>THANK YOU.
AND DR. WE'RE.
>>I'M DAVID WE'RE.
A PROFESSOR IN THE INSTITUTE FOR
SOCIAL RESEARCH AT THE
UNIVERSITY OF MICHIGAN AND
DIRECTOR OF THE HEALTH AND
RETIREMENT STUDY.
I'M INTERESTED IN JUST ABOUT
ANYTHING WE CAN LEARN ABOUT THE
LIVES OF OLDER PEOPLE.
>>THANK YOU.
AND DR. WET FIELD.
>>MORNING, EVERYONE.
I'M KEITH WHITFIELD.
I'M PROFESSOR OF PSYCHOLOGY,
PROFESSOR OF BRAIN HEALTH AS
WELL AS THE PRESIDENT OF THE
UNIVERSITY OF LAS VEGAS.
MY RESEARCH IS ON COGNITIVE
AGING IN AFRICAN-AMERICANS AS
WELL AS LONGEVITY IN
AFRICAN-AMERICANS.
THANK YOU.
>>THANK YOU.
AND BACK TO DR. LONGO.
>>MORNING, EVERYONE.
I'M FRANK LONG OH, NEUROLOGIST.
I CHAIR THE DEPARTMENT OF
NEUROLOGY AT STAMFORD.
MY RESEARCH IS FOCUSED ON
MECHANISM ELUCIDATION RELEVANT
TO SYNAPSE DEGENERATION,
ESPECIALLY IN CREATING SMALL
MOLECULE APPROACHES TO TARGET
THOSE MECHANISMS AND WE HAVE
BROUGHT COMPOUNDS FROM IN VITRO
THROUGH MICE AND INTO HUMAN
TRIALS.
>>THANK YOU.
WE ALSO HAVE OUR EX-OFFICIO
MEMBERS, DR. VAHALLA.
>>HI, GOOD MORNING.
I'M HOLLY FROM THE NATIONAL
INSTITUTE ON DISABILITY AND
INDEPENDENT LIVING AND
REHABILITATION RESEARCH.
THANK YOU.
>>THANK YOU.
DR. .
>>ANN ORD WAY, PROGRAM
SPECIALIST AT THE NATIONAL
INSTITUTE ON DISABILITY
INDEPENDENT LIVING AND
REHABILITATION RESEARCH AND I
LEAD THE RESEARCH PORTFOLIO AT
THE INTERSECTION OF DISABILITY
AND AGING.
>>THANK YOU.
AND FINALLY WE HAVE A FEW AD-HOC
MEMBERS.
THESE MEMBERS WILL BE OUR --
SOON ON-BOARDED AND BE OUR
COUNCIL MEMBERS COME MAY.
SO WE'LL INTRODUCE THEM.
DR. SPANNA?
>>GOOD MORNING.
SANJAY, UNIVERSITY
WISCONSIN-MADISON.
I'M -- PROFESSOR OF MEDICINE IN.
[ BACKGROUND NOISE ]
AT THE MEDICAL SCHOOL.
ALSO DIRECTSOR OF THE WIG
CONSIN -- AND HEAD AT THE
MEDICAL SCHOOL.
MY RESEARCH INTERESTS ARE IN
PRE-CLINICAL BIOMARKERS OF
ALZHEIMER'S DISEASE AND I HAVE
DONE A NUMBER OF CLINICAL TRIALS
INVOLVING HORMONES, COGNITION
AND DEMENTIA.
>>THANK YOU.
DR.--
>>GOOD MORNING.
I AM -- LA BETTERO.
I'M NOT A DOCTOR YET, STILL
WORKING ON MY DISSERTATION.
I AM PROFOUNDLY GRATEFUL TO BE
HERE.
AND STRENGTH END BY ALL YOUR
EXPERTISE AND INTERESTS.
I AM A LONG -- LIFELONG, I WOULD
SAY, CAREGIVER AND CARE PARTNER
FOR MY FAMILY AND MY MOTHER.
CURRENTLY WHO IS IN A NURSING
HOME.
AND I AM A PATIENT ADVOCATE,
SUPPORTER AND MY INTERESTS IN
RESEARCH ARE CONTRIBUTING ALL I
CAN TO MOVE FORWARD RESEARCH
THAT WILL GIVE US A BETTER
TREATMENT AND HOPEFULLY SOME DAY
A CURE.
THANK YOU.
FOR ALZHEIMER'S DISEASE.
THANK YOU.
>>THANK YOU.
DR. ANONI?
>>YES, HI.
I'M SHARON AND I AM REALLY
HONORED TO BE HERE.
I'M A PROFESSOR OF MEDICINE AT
HARVARD MEDICAL SCHOOL.
I'M TRAINED AS A GERIATRICIAN
AND CLINICAL EPIDEMIOLOGIST.
I'M BASED AT THE MARCUS
INSTITUTE FOR AGING RESEARCH.
AND MY RESEARCH FOCUSES ON
REVERSIBLE CONTRIBUTORS TO
COGNITIVE IMPAIRMENT, MOST
SPECIFICALLY THE INTERFACE OF
DELIRIUM AND DEMENTIA.
AND I DO STUDIES RANGING FROM
CLINICAL TO TRANSLATIONAL AND
IMPLEMENTATION RESEARCH.
THANK YOU.
>>THANK YOU.
DR. COLIN?
>>HI, GOOD MORNING.
I'M DR. KAHN.
AND THIS IS A EXTREMELY
IMPRESSIVE PANEL.
FOR THE LAST TWO DAYS I'M
THINKING WHAT AM I DOING HERE?
BUT A LITTLE BIT ABOUT ME.
I AM A TRAINED EPIDEMIOLOGIST.
WENT TO MED SCHOOL AND HAVE BEEN
WORKING WITH CHEROKEES FOR 29
YEARS.
SO THE REASON FOR ME BEING HERE
IS TO REPRESENT THE ISSUES
FACING THE CHEROKEES AND AI IN
COMMUNITIES.
AND EVERY NOW AND THEN YOU WILL
SEE MY COMMENTS THERE ARE UNIQUE
ABOUT THEIR POINT OF VIEW AND
PERSPECTIVE AND NEEDS IN TERMS
OF RESEARCH.
ALZHEIMER'S IS AN ISSUE AND
AGING AND LIMITED RESOURCES AND
I HAVE BEEN WORKING THERE FOR
QUITE A LONG TIME.
LIVED THERE IN RURAL OKLAHOMA.
SO I BRING THAT PERSPECTIVE AND
THE UNIQUE THING ABOUT ME YOU'LL
FIND OUT PRETTY SOON, I'M NOT
SHY ABOUT SHARING MY THOUGHTS.
>>VERY GOOD, THANK YOU.
AND FINALLY NANCY LYNDEN BERG.
>>HI, I'M NANCY.
CEO OF THE AMERICAN GERIATRIC
SOCIETY AND A RECOVERING
CAREGIVER.
AND A NOD TO MARISA.
I THINK A LOT OF US SHARE THAT
DUTY AND SOMETIMES BURDEN.
I AM A LAYPERSON SO I FEEL LIKE
THIS -- YESTERDAY WAS SORT OF
FUNNELING INTO THE INNER
WORKINGS OF THE NIA BUT ALSO I
WOULD SAY THAT I'M A FIERCE
CHAMPION FOR ADVANCING THE WORK
THAT IS DONE WITH FUNDING FOR
NIA INTO CLINICAL PRACTICE AND
REALLY LOOK FORWARD TO LEARNING
AND COLLABORATING WITH ALL OF
YOU.
>>GREAT.
THANK YOU VERY MUCH.
AND WELCOME TO OUR NEW MEMBERS.
ALL RIGHT, LET'S SEE.
NEXT UP, I'LL INTRODUCE
DR. RICHARD HODES, OUR DIRECTOR
OF THE NATIONAL INSTITUTE AGING.
SO I'LL TURN IT OVER TO RICHARD.
>>DR. HODES: THANK YOU.
I WILL ADD MY APPRECIATION TO
OUR CURRENT AND IN-COMING
COUNCIL MEMBERS.
IT IS AN INVESTED GROUP.
AND IMPRESSIVE EVERY TIME I SEE
THE GALLERY COME BY.
I'D LIKE TO OPEN THIS SESSION
HERE NOW BY A BRIEF STATUS
REPORT OF SOME OF THE EVENTS
THAT HAPPENED SINCE OUR LAST
MEETING.
NEXT SLIDE, PLEASE.
FIRST, WE WANT TO INTRODUCE TO
YOU, AND SHE CAN PLEASE GO ON
CAMERA AMY.
I THINK BY NOW A LOT OF YOU GOT
TO KNOW HER.
AMY KELLY IS OUR DEPUTY DIRECTOR
SINCE SEPTEMBER AND HAS BEEN
FANTASTIC IN THESE FIRST MONTHS.
SHE CAME TO US FROM MOUNT SINAI
WITH HER BACKGROUND IN HEALTH
POLICY, IN PARTICULAR GERIATRICS
AND PALLIATIVE CARE.
AMY, SAY HELLO.
>>AMY: GOOD MORNING, EVERYBODY.
IT'S WONDERFUL TO SEE YOU ALL
AND JUST FANTASTIC OPPORTUNITY
TO GET TO KNOW OUR NEW MEMBERS.
SOME ARE FAMILIAR WITH ME
ALREADY AND JUST THANK YOU ALL
FOR SUPPORTING NIA.
>>DR. HODES: THANK YOU, AMY.
NEXT SLIDE.
SO THIS IS THE FIRST COUNCIL
MEETING WE'VE HAD SINCE WE HAD
THE PASSAGE OF OUR LAST
APPROPRIATION THE FY2023 BUDGET.
IT SAW IN KEYS IN TOTAL NIH,
47.7 BILLION DOLLARS FOR NIA
WITH INCREASE TO 4.4 BILLION
DOLLARS.
THERE WERE SEVERAL TARGET
INCREASES IN THE NIH BUDGET, ONE
OF THE LARGEST WAS AGAIN FOR AD
AND ADRD RESEARCH, TOTAL OF 226
MILLION DOLLARS, 151 MILLION
DOLLARS TO NIA, 75 MILLION
DOLLARS OF WHICH TO OUR GREAT
PARTNER IN THESE EFFORTS, NINDS;
PLEASE.
WE WERE ALSO ABLE TO ANNOUNCE
THAT THE POINT IN THE YEAR, OUR
PAY LINE.
SO FAR BESIDES PROJECTIONS NOW
THAT WE KNOW OUR FUNDING AND
BUDGET.
AND BREAKING IT DOWN AS YOU SEE
HERE FIRST FOR THE CSR REVIEWED
APPLICATIONS WHICH RECEIVED
PERCENTILES, THERE IS A GENERAL
PAY LINE WHICH MEANS THAT
UNTARGETED RESEARCH NOT
SPECIFIED FOR ADADRD, FOR THE
MOST COMMON APPLICATIONS FALLS
UNDER $500,000.
WE HAVE THAT THE POINT A PAY
LINE OF UPON 15 PERCENTILE.
FOR NEW INVESTIGATORS AND
EARLY-STAGE INVESTIGATORS,
RESPECTIVELY, THE PAY LINES WILL
18-20 PERCENTILE WHICH REFLECT
OUR CONTINUING PRIORITY TO NEW
PEOPLE ENTERING THE FIELD.
THE GENERAL PAY LINE FOR THE
MORE EXPENSIVE APPLICATIONS
GREATER THAN $500,000 SET A
HIGHER BAR IN EACH CATEGORY.
IF WE LOOK AT AD/ADRD PAY LINES,
WE HAVE AGAIN FOR APPLICATIONS
EITHER BEFORE OR UNDER OR OVER
500K THEY ARE REALLY THE SAME,
THE 25th PER CERTAINLY TILE,
28 AND 30 PERCENTILE IS FOR NEW
INVESTIGATORS AND ESIs.
THAT THE POINT OF THE YEAR, IT'S
POSSIBLE AS WE LEARN MORE, WE
WILL BE ABLE TO MODIFY,
HOPEFULLY IN THE DIRECTION OF
INCREASING FURTHER OUR PAY
LINES.
BUT THESE ARE OUR ALLOCATIONS AT
THIS POINT.
AND THE NEXT SLIDE DEALS WITH
THOSE PAY LINES WHICH ARE FOR
NON CSR.
THEY ARE NIA REVIEWED
APPLICATION AND RECEIVED IMPACT
SCORE RATHER THAN PRIORITY SCORE
AND YOU CAN SEE HERE AGAIN THE
GENERAL AND ADA PAY LINES FOR
PROGRAM PROJECTS OTHER THAN NIA
RESEARCH.
FUNDED RESEARCH, CAREER
DEVELOPMENT OF A HIGHER AND
FELLOWSHIP AWARDS AT HIGHER
STILL PAY LINE IN BOTH
CATEGORIES.
NEXT, PLEASE.
THIS IS JUST TO REMIND US ALL OF
THE INCREASE WE HAVE BEEN SEEING
IN THE NIA APPROPRIATION FROM
2014 TO THE PRESENT.
AND 2015 WE WERE AT ONE BILLION
DOLLAR LEVELED AND NOW 4.4
BILLION DOLLARS.
GOOD BIT OF THIS DUE TO THE
TARGET INCREASE IN ADADRD
RESEARCH BUT NOT ENTIRELY --
SUBSTANTIAL INCREASE ACROSS OUR
GENERAL COMPONENT OF OUR
APPROPRIATION AS WELL.
NEXT, PLEASE.
SOME UPDATES.
WE WANTED TO SUMMARIZE FOR YOU
THE ACTIVITY IN NIA FUNDED A.
AND ADRD CLINICAL TRIALS.
THIS IS UPDATE OF THE ACTIVE
SUPPORTIVE TRIALS RIGHT NOW.
A TOTAL OF 459, A STRIKING
NUMBER.
THEY ARE DIVIDED AS YOU WILL SEE
HERE, FOR PHARMACOLOGIC AND NON
PHARMACOLOGIC TREATMENTS AIMED
AT PREVENTING TREATING, SLOWING
PROGRESSION OF ALZHEIMER'S.
66 PHARMACOLOGIC, ONE HUNG 52
NON PHARMACOLOGIC AND 210 THAT
ARE TARGETED AT DEMENTIA CARE
AND CARE GIVING AS WELL AS
STUDIES AIMED AT
NEUROPSYCHIATRIC SYMPTOMS AND
DIAGNOSTIC AND ASSESSMENT AND
IMAGING TOOLS.
NEXT SLIDE.
JUST TO GIVE YOU REVEALING
COMPONENTS OF WHERE THESE FALL.
FOR 66 PHARMACOLOGIC TRIALS, YOU
LOOK FIRST AT THE 7 TRIALS THAT
ARE PHASE II OR PHASE III.
THESE ARE ADVANCED TRIALS
POTENTIALLY DEFINITIVE IN
IDENTIFYING EFFECTIVE
INTERVENTIONS.
OF THE 7, 4 ARE AMYLOID
TARGETED.
3 ARE NOT AS YOU CAN SEE.
THESE REFLECT THE PREDOMINANCE
OF AMYLOID AS A TARGET STUDY
OVER PAST YEARS AND THE NUMBER
OF YEARS IT TAKES TO PROGRESS
FROM STAGE TO STAGE IN THESE
STUDIES.
IF YOU LOOK AT THE EARLIER PHASE
TRIALS, PHASE I AND PHASE II,
SOME 59 OF THEM, YOU WILL SEE
340s OF THEM ARE TO TARGETS
OTHER THAN AMYLOID.
AMYLOID REMAINS IMPORTANT BUT
THIS REFLECTS THE DIVERSITY OF
WHAT WE HAVE LEARNED THAT THE
UNDERLYING PATHOPHYSIOLOGY OF
ALZHEIMER'S AND OUR ABILITY TO
TARGET THOSE COMPONENTS, THESE
WILL BE IN THE NEXT GENERATIONS
AS THEY MOVE TO PHASE II AND
PHASE III STUDIES SHOULD THEY
PROVE PROMISING AND PHASE I AND
PHASE II.
NON PHARMACOLOGIC TRIALS, 152
BROKEN DOWN HERE BY CATEGORIES
INCLUDING EXERCISE AND IN OR
ABOUTO STIMULATION, COGNITIVE
TRAINING, SLEEP-RELATED TRIALS
AND SO ON.
SO A DIVERSITY WHICH EFFECTS A
CONVICTION OF THE FACT THAT THE
ADADRD PROCESS ITSELF IS A
COMPLEX ONE.
AND THAT BEING ABLE TO ADDRESS
MULTIPLE TARGETS ARE GOING TO
GIVE US THE BEST OPPORTUNITY TO
FIND THE BEST INDIVIDUAL OR
COMBINATION THERAPIES FOR GIVEN
INDIVIDUALS AS WE LEARN MORE AND
MORE ABOUT THE HETEROGENEITY IN
THE DISEASE PROCESSES.
NEXT, PLEASE.
AMONG THE DEMENTIA CARE AND CARE
GIVING TRIALS.
AGAIN, YOU'LL SEE THE
SUBCATEGORIES SHOWN HERE RANGING
FROM FORMAL CARE TO IMPROVING
CAREGIVER HEALTH AND WELL-BEING.
AND AGAIN THE DIVERSITY MUCH
EXPANDED.
EVERY BIT AS IMPORTANT AND
RIGOROUS AS WE TRY TO DEAL WITH
THE BEST APPROACHES AND
INDIVIDUALS CURRENT LEAD LIVING
WITH DEMENTIA, EVEN AS WE TRY TO
REDUCE THE NUMBER THROUGH
PREVENTION IN OUR STUDIES TO
UNDERSTAND BETTER THE UNDERLYING
PATHOGENESIS.
AND IMPORTANT AREAS OF
DIAGNOSTIC TOOL DEVELOPMENT AND
ASSESSMENT AND TREATMENT FOR
NEUROPSYCHIATRIC SYMPTOMS.
NEXT, PLEASE.
WOULD I WANT TO POINT YOU TO THE
ADADRD PROGRESS REPORT MOST
RECENTLY RELEASED IN NOVEMBER.
THIS IS A SUMMARY EACH YEAR OF
SCIENCE ADVANCES ACROSS MULTIPLE
RESEARCH TOPICS.
LINKS SHOWN HERE AND WE INVITE
YOU TO LOOK AT WHAT WE THINK ARE
VERY IMPRESSIVE ASPECTS OF CARE
SERVICES, UNDERLYING
PATHOPHYSIOLOGY, ADVANCES IN ALL
THESE AREAS.
NEXT, PLEASE.
AN UPDATE ON ONE OF THE NEWER
ACTIVITIES HERE AT NIA AND NIH.
THE NIH CENTER FOR ALZHEIMER'S
RELATED DEMENTIAS ARE HARD.
THIS IS ESTABLISHED THE
COLLABORATION BETWEEN.
THIS IA AND NINDS AS PART OF OUR
INTRAMURAL PROGRAM N SEPTEMBER
WE HAD A REALLY WONDERFUL
DEDICATION CEREMONY ON CAMPUS AS
IT WAS NAMED THE ROY BLUNT
CENTER FOR ALZHEIMER'S DISEASE
RELATED DEMENTIAS RESEARCH.
ROY BLUNT WHO HAS BEEN A
LONGSTANDING CHAMPION FOR
RESEARCH AT NIH VERY MUCH
INCLUDING NIA AND RESEARCH.
PRIMARY ASPECTS OF THIS CENTER
ARE A STRONG COMMITMENT TO
RESOURCE SHARING WITH NEW ONLINE
PORTAL TO DEVELOP A INITIATIVES
AS THEY COME FORWARD.
INFRASTRUCTURE AND
IDENTIFICATION OF RESEARCH TOOLS
SUCH AS THE INTRODUCTION OF A
PANEL OF INDUCED POTENTIAL STEM
CELLS.
LIBRARY BECOMES AVAILABLE TO THE
RESEARCH COMMUNITY AND SOME
UNIQUE PREMIER DEVELOPMENT
EXPERIENCE AS WELL.
AS WE ATTEMPT TO BRING IN NOT
JUST A FACULTY BUT AN ONGOING
PASSTHROUGH OF INDEPENDENT
SCIENTISTS WHO MAY SPEND PARTS
OF THEIR TIME AT CARD AND THEN
ARE PROVIDED WITH TRANSITION TO
OTHER ASPECTS OF NIH RESEARCH
AND EVEN THE CAREERS BEYOND NIH.
NEXT, PLEASE.
IN TERMS OF OUR COMMUNITY,
PROGRESS AND POTENTIAL IN
ALZHEIMER'S, ONE OF OUR
COMMUNICATION STRATEGIES HAS
BEEN TOW PUT TOGETHER A SERIES
OF VERY EFFECTIVE VIDEOS.
AND SINCE ONE OF THE AUTHORS,
ONE OF THE SPOKESPERSONS SHEAR
WITH US AS A COUNCIL MEMBER, WE
CAN SEE IF WE TAKE A MINUTE TO
SHOW YOU A PART OF JENNIFER
MANLY'S PRESENTATION.
[ MUSIC PLAYING ]
>>FOR ABOUT 25 YEARS, I HAVE
BEEN WORKING WITH
COMMUNITY-BASED COHORTS OF OLDER
ADULTS THAT LIVE AROUND COLUMBIA
UNIVERSITY IRVINE MEDICAL
CENTER.
THIS IS A REALLY DIVERSE
NEIGHBORHOOD, REALLY INTERESTING
NEIGHBORHOOD AND AN EPIC ENCLAVE
FOR CARIBBEAN HISPANICS OR
LATINX PEOPLE.
THERE IS ALSO A LONG HISTORY OF
PEOPLE WHO ARE AFRICAN-AMERICAN,
AND THEN THERE IS A GROUP OF
PEOPLE WHO DESCRIBE THEMSELVES
AS NON-HISPANIC AND WHITE.
AFRICAN-AMERICANS AND HISPANICS
ARE 1.5-TWO TIMES MORE LIKELY TO
DEVELOP ALZHEIMER'S DISEASE AND
DEMENTIA.
AND YET, THEY REPRESENT NO MORE
THAN 2% OF PARTICIPANTS IN
ALZHEIMER'S DISEASE CLINICAL
TRIALS.
PROGRESS IN ALZHEIMER'S DISEASE
RESEARCH, IT WON'T BE AS
RELEVANT AND IT WON'T BE USEFUL
UNLESS IT IS ABLE TO INCLUDE
PEOPLE WHO ARE REPRESENTATIVE OF
OLDER ADULTS IN THE UNITED
STATES.
AND IT ALSO WON'T BE AS USEFUL
IF THEIR --
>>THANK YOU.
SO SORRY TO KEEP CUT YOU OFF.
WE WANTED TO PROVIDE AN EXAMPLE
OF SOME VERY EFFECTIVE
COMMUNICATIONS TO OUR PUBLIC BY
IN ALL RESPECT ARES, A DIVERSE
GROUP OF INVESTIGATORS.
I URGE YOU TO ENJOY CLICKING ON
THESE LINKS AS WE GO FORWARD.
NEXT.
ALSO NOTEWORTHY -- SO FORMS ARE
RELEASED LIST OF WORLD'S TOP
FEMALEANIST 2022.
-- FEMALE SCIENTISTS.
AMONG IN THE LIST, INCLUDED
AMONG THE TOP 10 ARE THREE WHO
ARE SUPPORTED BY OR MEMBERS OF
PRIOR NAI.
SO VIRGINIA LEE, NEUROSCIENTIST
AT UPENN AND FORMER COUNCIL
MEMBER.
TERRY MOFFITT, SIMILARLY AND
TAMARA HARRIS, A LONG TIME
LEADER IN THE INTRAMURAL
PROGRAM.
THERE ARE MANY MORE AS WE GO
DOWN THE LIST BUT IT'S REALLY
GRATIFYING AND TESTIMONY TO OUR
ABILITY TO RECRUIT THESE
OUTSTANDING PEOPLE TO OUR
PROGRAMS.
SO CONGRATULATIONS TO YOU AND TO
ALL IN THIS.
NEXT, PLEASE.
IN TERMS OF OUR COMMUNICATING
WITH THE PUBLIC, THIS IS JUST A
LISTING BY THE NUMBERS OF THE
NUMBER OF RELEASES WE HAVE HAD
AND RESEARCH HIGHLIGHTS AND
BLOGS, ANNOUNCEMENTS.
IN TERMS OF THE ACTIVITIES FROM
MYSELF AND I GUESS NOW IT'S
DOCTOR KELLY AND AMY AND MELANED
OVER THIS PAST MONTH.
THESE ARE OUR CONVERSATIONS WITH
STAKEHOLDER ADVOCACY GROUPS AS
WELL AS OUR SIX CONGRESSIONAL
BRIEFINGS WITH MORE TO COME.
MANY OF YOU INVOLVED WITH
RESEARCH ARE VERY, PERHAPS ALL
TOO AWARE OF THE IMPACT THAT WE
ARE GOING TO HAVE POSITIVELY AND
WITH THE COST IN TERMS OF
EFFORT, OF ENACTING THE NIH
POLICY FOR DATA MANAGEMENT AND
SHARING.
PRINCIPLES ARE, WITHOUT DEBATE,
CRITICAL AND IMPORTANT.
THAT IS TO MAKE MOST BROADLY
AVAILABLE THE OUTCOMES OF OUR
RESEARCH TO THE BIOMEDICAL
COMMUNITY.
IT APPLIES TO ALL RESEARCH
FUNDED BY NIH.
TWO KEY REQUIREMENTS ARE
SUBMISSION OF THE DATA
MANAGEMENT AND SHARING PLAN.
THAT'S A PART OF APPLICATIONS
COMING FROM EXTRAMURAL
SCIENTISTS.
AND THIS IS ALSO NOW WORK, OUR
INTRAMURAL SCIENTISTS ARE
ENGAGED IN AS WELL.
AND THEN COMPLIANCE ULTIMATELY
WITH A PLAN THAT IS APPROVED.
IT WILL BE A LOT OF WORK TO
BRING IT TOGETHER AND WE'LL DO
OUR VERY BEST TO GUIDE THE
RESEARCH COMMUNITY IN AN
EXTRAORDINARILY VALUABLE
ENHANCEMENT OF COMMUNICATION OF
OUR DATA GENERATED THROUGH
RESEARCH.
NEXT, PLEASE.
NIH WIDE STRATEGIC PLAN FOR
DEIA.
THAT'S A DIVERSITY EQUITY AND
INCLUSION AND ACCESSIBILITY.
IT'S BEEN DEVELOPED OVER THESE
PAST MONTHS AND IT IS -- WE ARE
HERE AT PHASE V, DUE TO BE
RELEASED.
THIS IS NOT THE BEGINNING.
IT'S THE CULMINATION OF A
PLANNING PROCESS AND A FURTHER
SERBALLIZATION AND COMMITMENT
ACROSS ALL OF NIH, THE
PRIORITIES OF DEIMENTED A.
VERBALIZATION.
IN TERMS OF TURNOVER AT NIH.
WITHOUT EXAGGERATION THE EVENT
WAS THE RETIREMENT OF TONY FAUCI
AS NIAID DIRECTOR N THAT
POSITION FOR 38 YEARS.
ADVISED AND SERVED SEVEN
PRESIDENTS ACROSS BOTH PARTIES.
EXTRAORDINARY.
THE DEPUTY DIRECTOR AT NIAID IS
CURRENTLY ACTING CAPACITY AND WE
ARE IN THE PROCESS NOW RAFT
SEARCH FOR A NEW DIRECTOR OF
NIAID.
IT'S BEEN IMPORTANT TO THE
NATION AND A DEPARTMENT PARTNER
WITH NI.
IN AGE-RELATED RESEARCH.
NEXT, PLEASE.
ANOTHER NEW APPOINTMENT NAMED
THE INAUGURAL DIRECTOR OF ARMA
H.
AND AS YOU WILL SEE IN THE
PROGRAM, AND HAVE A CHANCE TO
SPEAK WITH THE FIRST FOUNDING
DEPUTY DIRECTOR TO LEARN MORE
ABOUT THE PROGRAM.
JUST A WAY IN WHICH OUR TWO
AGENCIES ARE GOING TO INTERACT
AND DEVELOP OVER TIME BUT A
CRITICAL OPPORTUNITY TO EXPAND
OUR OVERALL RESEARCH EFFORTS.
UP COMING EVENTS.
POINT YOU TO COMING UP QUICKLY,
MARCH, THE CARE AND SERVICES FOR
PERSONS LIVING WITH DEMENTIA AND
THEIR PARTNERS.
THIS WILL BE A VIRTUAL MEETING
AND I ENCOURAGE THOSE OF YOU TO
REGISTER AND PARTICIPATE.
IT'S A MEANS FOR HUNDREDS OF
HAVINGS FROM PROFESSIONAL TO LAY
AND THOSE INTERESTED.
MAKE THEIR CONTRIBUTIONS THROUGH
THE AIRPORT GREATED PLANNING
EFFORTS FOR RESEARCH IN THIS
FIELD.
AND THE YEARS TO COME, WE'LL
HAVE THE OTHER SUMMITS, THE
ALZHEIMER'S RESEARCH SUMMIT AND
THE ALZHEIMER'S RELATED DEMENTIA
RESEARCH SUMMIT.
NEXT, PLEASE.
THE FOURTH SUM LIT OCCUR THIS
YEAR.
IT IS SCHEDULED TO BE IN PERSON
AND HYBRID ON THE NIH BETHESDA
CAMPUS IN APRIL.
YOU SHOULD SOON BE SEEING THE
AGENDA AND ENCOURAGE
PARTICIPATION HERE.
THIS INVOLVES NOT JUST NIA BUT A
CONSORTIUM OF MOST OF THE
INSTITUTES ACROSS NIH WITH NIA
DOING AN IMPORTANT ROLE IN
LEADERSHIP.
I TRIED TO TIE THE BIOLOGY,
BEHAVIOR OF AGING IN A WAY WHICH
IT TIES TO THE RISKS AND
PREVENTION OF DISEASE AND
DISORDERS.
NEXT, PLEASE.
WILLIAM SCHOLARS PROGRAM WILL BE
OCCURRING AGAIN THIS YEAR.
FOR THE PAST TWO YEARS IT
OCCURRED REMOTELY AND IT HAS
BEEN SUCCESSFUL IN THAT
CAPACITY.
IT'S SCHEDULED FOR AUGUST 23-25.
APPLICATIONS ARE DUE APRIL 21.
WE ARE ENCOURAGING JUNIOR
FACULTY AND RESEARCHERS IN THE
FIELD OF AGING TO PARTICIPATE IN
WHAT HAS BEEN AN OUTSTANDING,
PRODUCTIVE COUNTRY-DEFINING
EVENT AND PATRICIA JONES IS
TAKING A LEAD IN THIS.
AND WE WILL BE DELIGHTED TO HEAR
IF YOU HAVE QUESTIONS.
THE LINK IS HERE.
AND THE APPLICATIONS ARE BEING
RECEIVED.
NEXT, PLEASE.
AND NOW, WE TURN TO SOMETHING IN
PERSON AND HAVE A CHANCE TO LET
THE NEW RECRUITS, STAND UP AND
INTRODUCE THEMSELVES BUT WE'LL
DO IT ALL REMOTELY.
SO WE'LL DO THIS DIVISION BY
DIVISION.
WE'LL START WITH THE AB.
>>SHOULD I DO THAT, RICHARD?
>>YES, PLEASE.
>>THANK YOU.
SO WE WELCOME TWO NEW PROGRAM
OFFICERS TO THE DIVISION OF
AGING BIOLOGY.
DR. FU JOIN US IN SEPTEMBER OF
2022 TO MANAGE RESEARCH
PORTFOLIO FOCUSED ON MOLECULAR
EPIDEMIOLOGY IN AGING WHICH
TIMES BROADEN THE UNDERSTANDING
OF AGING AS A RISK FACTOR FOR
FUNCTIONAL DECLINE.
AND THAT WAS FUNCTIONAL DECLINES
PERMISSIVE OR CONTRIBUTE TO
DYSFUNCTION DEFICIT,
ACCUMULATION AND MORBIDITIES.
PREVIOUSLY, SHE HELD POSITIONS
AT THE OFFICE OF BIOSTATISTICS
RESEARCH AT THE NATIONAL HEART
AND LUNG BLOOD INSTITUTE AND
ALSO WORKED EXTENSIVELIED IN
ANALYSIS OF THE FRAMINGHAM HEART
STUDY.
SHE RECEIVED HER DOCTORATE IN
EPIDEMIOLOGY FROM UNIVERSITY OF
OF TEXAS AT HOUSTON AND
POSTDOCTORAL RESEARCH AT THE
NATIONAL CANCER INSTITUTE.
DR. AMANDA BOYS IS A NEW BRANCH
CHIEF FOR THE AGING PHYSIOLOGY
BRANCH IN THE DIVISION OF AGING
BIOLOGY.
SHE RECEIVED HER BACHELOR'S
DEGREE FROM THE UNIVERSITY OF
TEXAS AT AUSTIN AND COMPLETED
HER PH.D. IN CELL BIOLOGY AND
RESEARCH AT THE UNIVERSITY OF
ALABAMA AT BIRMINGHAM.
AND THEN POSTDOCTORAL RESEARCH
AT THE NATIONAL INSTITUTED OF
ARTHRITIS AND MUFFIN LOW
SKELETAL AND SKIN DECEASES WHERE
SHE WAS INTRAMURAL RESEARCHER
FOR A NUMBER OF YEARS AND THEN
CAME TO THE PROGRAM SIDE N2006
SHE CAME TO US IN 2022.
SHE HAS A PORTFOLIO OF
NEUROMUSCULAR AND CONNECTIVE
TISSUE WHICH HAS EMPHASIS ON
MUSCLE FUNCTIONING AND THE
DECLINE IN MUSCLE FUNCTIONING IN
AGING.
THANK YOU.
>>HELLO, EVERYONE I OF I'M LIZ
NIELSEN FROM THE DIVISION OF
BEHAVIORAL AND SOCIAL RESEARCH.
IT'S MY PLEASURE TO INTRODUCE
OUR NEW STAFF.
THE FIRST IS -- WHO JOINED VSR
AS A PROGRAM OFFICER IN THE
PROCESSES BRANCH TO MANAGE A
PORTFOLIO IN OUR GROWING
COGNITIVE AGING PROGRAM SPREAD
ACROSS SEVERAL PROGRAM DIRECTORS
IN THE DIVISION.
SHE COMES TO US FROM NCCIH WHERE
SHE SUPPORTED TRAINING AND
CAREER DEVELOPMENT INITIATIVES.
SHE COMPLETED A POSTDOCTORAL
FELLOWSHIP AT THE NATIONAL
CANCER INSTITUTE AND RECEIVED
HER PH.D. IN COGNITIVE
PSYCHOLOGY FROM THE UNIVERSITY
OF HOUSTON.
HER WORK HAS FOCUSED ON BRIDGING
THE GAP BETWEEN BASIC COGNITIVE
SCIENCE AND CLINICAL
NEUROPSYCHOLOGY TO ADVANCE
COGNITIVE MEASUREMENT,
PARTICULARLY FOCUSED ON CANCER
SURVIVORS.
AND SHE SERVES AS A
REPRESENTATIVE TO THE COGNITIVE
SCIENCE AND CANCER-RELATED
COGNITIVE IMPAIRMENT NETWORK.
SECOND PROGRAM OFFICER ALSO IN
THE INDIVIDUAL BEHAVIORAL
PROCESS BRANCH IS ELISE RICE WHO
JOINS FROM THE BEHAVIORAL AND
SOCIAL RESEARCH BRANCH AT THE
NATIONAL INSTITUTE OF DENTAL AND
CRANIOFACIAL RESEARCH.
SHE HAS BEEN HIRED TO HELP US
DEVELOP OUR PORTFOLIO IN
COMMUNICATEDY AND BEHAVIORAL
ENTER VENTIONS ALIGNED WITH THE
NIH STAGE MODEL.
SHE SERVES ALSO AS CO-LEAD ON
THE NIH HEALTH BEHAVIOR THEORIES
WORKING GROUP OUT OF OBSSR.
SHE EARNED HER PH.D. IN
PSYCHOLOGY FROM THE UNIVERSITY
OF NORTH CAROLINA AT CHAPEL HILL
AND WILL A POSTDOCTORAL
FELLOWSHIP AT THE NATIONAL
CANNER INSTITUTE, A THEME WE ARE
HEARING IN OUR NEW STAFF.
WE THANK NCI FOR SENDING US
THEIR GREAT POSTDOCS.
HER RESEARCH GREW OUT OF SOCIAL
PSYCHOLOGY AND FOCUSED ON HOW
POSITIVE SPONTANEOUS THOUGHTS
UNDERLIE APPROACH MOTIVATION FOR
HEALTH BEHAVIORS AND OTHER
ASPECTS OF EVERYDAY LIFE.
NEXT SLIDE, PLEASE.
ALSO LIKE TO INTRODUCE DR. JOHN
WHO IS AN ASSISTANT PROFESSOR IN
THE HEALTH SCIENCES AT
NORTHEASTERN UNIVERSITY AND WHO
HAS JOINED US IN NOVEMBER AS ANG
IPA IN THE INDIVIDUAL BEHAVIORAL
PROCESS BRANCH TO HELP US
DEVELOP OUR DIGITAL HEALTH
PORTFOLIO.
DR. JOHN IS A TRAINED EXERCISE
PHYSIOLOGIST AND EXPERT IN THE
APPLICATION OF WEARABLE SENSORS
TO MEASURE AND MODIFY PHYSICAL
DAVE AND HOW TO ACCURATELY
QUANTIFY PHYSICAL ACTIVITY AND
SEDENTARY BEHAVIOR.
HE WILL BE REPRESENTING US ON
MULTIPLE DIGITAL HEALTH WORKING
GROUPS, INCLUDING COLLABORATIONS
WITH NSF ON SMART AND CONNECTED
HEALTH AND HELPING TO SUPPORT
OUR GROWING SBIR PROGRAM OF
TECHNOLOGICAL SOLUTIONS TO
SUPPORT ADAPTIVE AGING.
AND THEN LAST BUT NOT LEAST,
DORI SULLIVAN JOINED US IN
NOVEMBER AS A PATHWAYS INTERN
WORKING WITH OUR ADMINISTRATIVE
TEAM.
SHE IS CURRENTLY PURSUING HER
MPH AT THE GEORGE WASHINGTON
UNIVERSITY SCHOOL OF PUBLIC
HEALTH AND PRIOR TO JOINING, SHE
RECEIVED HER BS IN BEHAVIORAL
COMMUNITY HEALTH AT THE
UNIVERSITY OF MARYLAND AND WAS
PREVIOUSLY AN INTERN WITH NIA'S
OFFICE OF PLANNING,INALIS AND
EVALUATION.
THANK YOU.
>>GOOD MORNING.
I'M FROM THE DIVISION OF
NEUROSCIENCE IT'S ALSO MY
PLEASURE TO WELCOME THE NEW TEAM
MEMBERS TO THE DIVISION OF
NEUROSCIENCE.
FIRST, RICHARD KWOK WHO JOINED
THE POPULATION STUBBEDDIES ON
GENETICS BRANCH.
RICHARD COMES NIHS AND HAS
TREMENDOUS EXPERIENCE ON
ENVIRONMENTAL EXPOSURE RESEARCH
EXPOSOME RESEARCH.
HE IS WORKING ON MANAGING A
PORTFOLIO THAT IS RELATED TO
EPIDEMIOLOGY OF ENVIRONMENTAL
EXPOSURE, GLOBAL HEALTH,
POPULATION STUDIES AND SO FORTH.
AND ALSO JOINING THE DIVISION OR
THE POPULATION STUDIES AND
GENETICS BRANCH IS DR. GHALEH.
SHE COMES FROM NINDS ALSO WITH A
VERY STRONG BACKGROUND IN
RESEARCH AND NEUROSCIENCES.
AND SHE WILL BE MANAGING
PORTFOLIOS ON EPIDEMIOLOGY OF
ALZHEIMER'S DISEASE AS WELL AS
GLOBAL HEALTH.
BOTH OF THEM COME TO
TREMENDOUSLY REINFORCE OUR
EFFORTS TOWARD EXPANDING
POPULATION STUDIES IN ADADRD.
AND NEXT, ALSO JOINING THE
DIVISION, SASHA.
SHE COMES FROM NIMH AND SASHA
JOINED AS PART OF THE TEAM
MANAGING THE ALZHEIMER'S DISEASE
RESEARCH CENTER, THE CENTERS
HAVE CONTINUED TO GROW
TREMENDOUSLY, NOW UP TO 35
CENTERS.
AND SHE ALSO WILL BE HELPING IN
THE IMPLEMENTATION OF THE DATA
MANAGEMENT AND SHARING PLANS AND
ALL CLINICAL RESEARCH RELATED TO
NEUROSCIENCE IN THE CONTEXT OF
THE ALZHEIMER'S STANDARDS.
AND IN TERMS OF THE NEUROBIOLOGY
OF AGING AND NEURODEGENERATION
BRANCH, JOE POTTACKAL RECENTLY
JOINED US.
HE CAME FROM A UNIVERSITY OF
MARYLAND, ALSO WITH A BACKGROUND
IN NEUROSCIENCE, VERY STRONG
BACKGROUND NEUROSCIENCES.
AND HE IS GOING TO BE WORKING ON
THE BRANCH PROVIDING SUPPORT ON
PROGMALTIC RESEARCH ON VARIOUS
AREAS OF NEUROBIOLOGY OF AGING,
ALZHEIMER'S DISEASE AND ADRD IN
SUPPORT OF THE OVERALL EFFORTS
OF THE BRANCH.
AND FINALLY, JERRY BOWER IS OUR
NEW PATHWAY INTERN.
HE ALSO COMES FROM A UNIVERSITY
OF MARYLAND BALTIMORE COUNTY.
AND HE WILL BE WORKING ON OUR
ADMINISTRATIVE PROGRAMS AND
SUPPORT AS A PATHWAY FELLOW.
THANK YOU.
>>ALL RIGHT, SO IT'S MY
PLEASURE TO INTRODUCE THE NEW
MEMBERS TO THE DIVISION OF
EXTRAMURAL ACTIVITY.
FIRST, IN OUR OFFICE OF CLINICAL
RESEARCH, WE HAVE TWO NEW
FEDERAL EMPLOYEES.
FIRST IS DR. SHAH.
SHE IS GOING TO BE A SUPERVISORY
PROGRAM OFFICER.
SHE IS JOINING US FROM NIAID,
ALLERGY AND INFECTIOUS DISEASE.
IN THEIR DIVISION OF AIDS
RESEARCH AND SHE IS GOING TO BE
PROVIDING A LOT OF SUPPORT FOR
OUR CLINICAL RESEARCH OFFICE,
ESPECIALLY IN REGULATORY AFFA
AFFAIRS.
WE ALSO HAVE GENE JAHVARIS
GIBSON.
SHE IS GOING TO BE A HEALTH
COMMUNICATION SPECIALIST AND SHE
HAS BEEN PREVIOUSLY A CONTRACTOR
WITH US IN THE OFFICE OF
CLINICAL RESEARCH BUT CONVERTED
TO FEDERAL EMPLOYEE, FINALLY.
AND SHE IS GOING TO HELP DEVELOP
MATERIALS FOR ONE OF OUR MAJOR
TOOLS FOR RECRUITMENT OUTREACH
PRO.
AND HELP OTHER CLINICAL TRIAL
WORKGROUP STRATEGIES WITHIN THE
OFFICE.
NEXT SLIDE.
WE HAVE TWO NEW SROs,
SCIENTIFIC REVIEW OFFICERS IN
THE SCIENTIFIC REVIEW BRANCH.
FIRST WE HAVE -- JOINING US FROM
BAILOR SCOTT AND LIGHT HEALTH.
SHE IS GOING TO BE ONE OF THE
TWO NEW SCIENTIFIC REVIEW
OFFICERS.
ALSO WE HAVE IVAN REBUSTINI.
HE IS JOIN US US FROM THE EYE
INSTITUTE AS A SCIENTIFIC REVIEW
OFFICER.
NEXT.
AND ALSO WE HAVE TWO NEW MEMBERS
OF OUR OFFICE OF STRATEGIC
EXTRAMURAL PROGRAMS.
THIS IS THE OFFICE THAT HANDLES
OUR SMALL BUSINESS AND OUR
TRAINING PROGRAMS.
FIRST WE HAVE DR. JOSHUA HOOKS.
HE IS A AAAS SCIENCE AND
TECHNOLOGY POLICY FELLOW AND HE
IS JOINING US FROM JOHNS HOPKINS
UNIVERSITY SCHOOL OF MEDICINE.
SO SHE GOING TO BE WORKING WITH
US ON OUR VARIOUS TRAINING
PROGRAMS FOR SMALL BUSINESS AND
START UPS FOR NEW ENTREPRENEURS
AND HE WILL DO A LOT OF OUR
EVALUATION FOR OUR PROGRAMS,
ESPECIALLY TO DIVERSIFY OUR
AGING TECHNOLOGY AND RESEARCH
WORKFORCE.
WE ALSO, JUST THIS WEEK, STARTS
DR. KUMAR.
HE IS JOINING US FROM LAYOLA
UNIVERSITY MARYLAND.
HE IS GOING TO BE COORDINATING
OUR SMALL BUSINESS FUNDING
OPPORTUNITIES AND HE IS GOING TO
HELP WITH IDENTIFYING BIOMEDICAL
INNOVATIONS AND DEVELOP NEW
INITIATIVES FOR SMALL BUSINESS.
NEXT SLIDE.
WE HAVE ONE NEW MEMBER IN OUR
CONTRACTS MANAGEMENT BRANCH.
WE WELCOME LAURA PEOPLE WHO WILL
BE A SUPERVISOR, GRANTS
MANAGEMENT SPECIALIST.
SHE IS ALSO JOINING US FROM NI
AIA AND SHE IS GOING TO BE
SUPERVISING SEVERAL OF OUR GRANT
SPECIALISTS BUT ALSO COORDINATE
A LOT OF OUR COMPLEX GRANT
PORTFOLIO THAT WE MANAGE IN OUR
GRANTS PROGRAM.
THANK YOU.
>>GOOD MORNING, PATRICK IN THE
EXECUTIVE OFFICE.
TWO NEW MEMBERS TO OUR FINANCIAL
MANAGEMENT BRANCH.
LAURA LAIN AND CUDDY COBARNETT.
THESE ARE THE FOLKS THAT MAKE
SURE THAT THE DATA THAT WE
PROVIDES IN ANALYSIS IS
ACCURATE, TIMELY AND AVAILABLE
FOR RICHARD AND AMY.
WE ARE EXCITED TO HAVE THEM.
LAUREN JOINS US FROM THE
CLINICAL CENTER AT NIHED AND HE
JOINS US FROM THE NAVAL RESEARCH
LABORATORY OPERATIONS.
THE NEXT BRANCH, WORKFORCE
ADMINISTRATOR MANAGEMENT BRANCH,
AS YOU'RE SEEING THIS, A LOT OF
HIRING AND STAFFING GOING ON
ACROSS THE NIA IN SUPPORT OF THE
IMPORTANT MISSION WE HAVE AND
ANDREA AND BETH ARE IN THAT TEAM
AND OPPORTUNITY WORK TO MAKE
SURE WE CAN ON BOARD AND BRING
THE STAFF NECESSARY TO SUPPORT
THE ACTIVITIES BOTH INTERN TO
SUPPORT STAFF AND GET NEW FOLKS
ONBOARD.
SO THANK YOU.
EXCITED TO HAVE THEM.
THIS IS A NEW OPERATION THAT WE
STOOD UP WITH CONTRACTS
ACCUSATION AND PROCUREMENT
BRANCH.
THESE ARE FOLKS THAT ARE
PREPARING TO SEE INCREASES IN
OUR WORKLOAD REACTED TO R&D
CONTRACTS, SO OUTWARD FACING, AS
WELL AS CONTRACTS WE NEED
INTERNALLY TO SUPPORT THE
GROWTH.
AND TONY AND DIANA COME FROM
OTHER PARTS OF THE NIH.
AND MICHELLE IS A BRAND NEW FAN
AND LOOKING FORWARD TO HER
CREATIVITY AND INNOVATION IN
THIS SPACE.
AND OUR INFORMATION TECHNOLOGY
BRANCH HAS A COUPLE OF NEW
FOLKS.
THESE ARE THE TEAMS THAT SUPPORT
MEETINGS LIKE THIS ACROSS THE
ORGANIZATION AND SUPPORT OUR
WORKPLACE FLEXIBILITY DURING THE
PANDEMIC.
WE HAVE A NEW INFORMATION
SECURITY SYSTEMS OVERS, DAVE.
HE COMES FROM US FROM THE
OUTSIDE AS A CONTRACTOR.
WE ARE EXCITED TO HAVE HIM JOIN
US WITH HIS EXPERIENCE AND
SELENA COMES TO US AGAIN FROM AN
OUTSIDE COMPANY WITH HER
CREATIVITY AND VISION TO SUPPORT
FUTURE AUTOMATION AND
DIGITIZATION ACROSS THE NIH
OPERATIONS.
THANK YOU.
>>THANK YOU.
MY NAME IS OLIVIA KENT.
I LEAD THE DIGITAL MEDIA BRANCH
IN THE OFFICE OF COMMUNICATIONS
AND PUBLIC LIASON AT NIA.
I'M EXCITED TO INTRODUCE DERRICK
WHO JOINED THE TEAM THE WEEK OF
THANKSGIVING AND HAS ALREADY
BEEN MAKING AN IMPACT IN MANY
AREAS.
HE HAS A BACKGROUND IN GRAPHIC
AND WEB DESIGN SO SHE OUR
FIRST-EVER IN HOUSE GRAPHIC
DESIGNER.
AND YOU WILL LIKELY SEE THE
OUTPUT OF HIS WORK AT THE NEXT
MEETING.
HE IS ALREADY WORKING ON AN
UPDATED SLIDE PRESENTATION DECK
AS WELL AS A COUPLE OF OTHER WEB
PROJECTS AROUND DOING CONTENT
AUDITING FOR US.
SO VERY HAPPY TO HAVE DERRICK
ONBOARD.
>>--
[ INAUDIBLE ]
I'M GOING TO PRESENT THE FIVE
PEOPLE THAT WILL JOIN TODAY --
LET ME GET THIS OPPORTUNITY TO
WISH YOU HAPPY NEW YEAR.
SO NATALIE LANDECK FORMERLY WAS
A FELLOW IN THE LABORATORY OF
NEUROGENETICS FOCUSING ON
INNOVATION HOW PARKINSON'S
DISEASE AFFECT NEURONAL FUNCTION
AND IS BECOMING A RESEARCH
FELLOW.
AND THEN CHELSEA WALTER AND
MONICA SULLIVAN, THE FIRST
COMING FROM THE ADMINISTRATION
WHERE SHE WAS A SUPPORT
ASSISTANT AND FREQUENTLY MEDICAL
INSTITUTE WHERE SHE WAS
PROVIDING ADMINISTRATIVE HELP.
AND THEY ARE BOTH SUPPORTIVE
OFFICERS THAT WILL BE MOSTLY
FOCUSING ON HANDLING TRAVEL, AND
SOME TRAINING FOR EMPLOYEES.
NEXT SLIDE.
ALSO A POSTDOCTORAL FELLOW.
HE IS AN EXPERT IN HEMATOPOIETIC
STEM CELL IN GENERAL.
ALSO IN HUMAN AND FOCUSING ON EP
GENOMICS.
AND HE WILL BE REALLY HELPING
THE ENTIRE TEAM AND TRAINING
POSTDOC AND WITH MANUSCRIPT
WRITING AND REVIEWING.
AND HE IS NOW RESEARCH FELLOW.
THE LAST BUT NOT LEAST, DAHLIA
MARZOUK, THE NEW ADMINISTRATIVE
MANAGER OF THE LABORATORY OF
CARDIOVASCULAR SCIENCE AND SHE
BASICALLY HANDLES THE ENTIRE
INFRASTRUCTURE OF THE LABORATORY
BY LOOKING AT TRAVEL PLANS AND
SUPERVISING ALL THE
ADMINISTRATION PERSONNEL THAT IS
IN THE LABORATORY.
AND SHE JOINS US IN SAINT LUKE'S
HEALTH SYSTEM.
>>LET ME JUST PAUSE AT THIS
POINT TO EXPRESS OUR EXCITEMENT
AND ENTHUSIASM FOR THE FACT WE
HAVE BEEN ABLE TO RECRUIT
TALENTED AND COMMITTED PEOPLE TO
THE INSTITUTE.
THEY WILL JUST ADD TO THE
RICHNESS OF OUR CREATIVITY AND
PRODUCTIVITY AND WELCOME ALL
AGAIN.
WISH THEY WERE HERE IN THE ROOM
FOR A ROUND OF PLAYS AND SOME
FURTHER RECOGNITION, BUT WE LOOK
FORWARD TO YOUR CHANCE TO
INTERACT WITH THEM IN THE TIMES
COMING.
FINALLY WE HAVE HERE SOME OF THE
LINKS TO WAYS IN WHICH YOU CAN
STAY INFORMED WITH WHAT NIA IS
DOING.
FIRST OF THOSE IS FOR ALL ACTIVE
FUNDING OPPORTUNITIES.
HERE THEY ARE FOR YOU TO PERUSE
AND CONFORM YOUR OWN RESEARCH
DECISIONS AND PLANS.
AND THEN LATEST APPROVED
CONCEPTS, MANY OF COME WILL BE
FINALIZING IN TERMS OF CONCEPT
APPROVAL THAT THE COUNCIL.
THESE ARE CONCEPTS APPROVED TO
GO FORWARD.
MANY OF THEM WILL TURN INTO
FUNDING OPPORTUNITIES.
AND THEN AS THE MOST PROACTIVE
WAY TO KEEP IN TOUCH WITH WHAT
IS HAPPENING AT THE INSTITUTE, I
ENCOURAGE YOU TO SUBSCRIBE TO
THE BLOG SO IT COMES TO YOU
GENERALLY WEEKLY BASIS.
DESCRIBING A LOT OF THE LATEST
INFORMATION OF RELEVANCE TO THE
RESEARCH COMMUNITY AND THE
BROADER PUBLIC.
THANK YOU.
I'M HAPPY TO ADDRESS ANY
QUESTIONS YOU MAY HAVE.
OTHERWISE IT'S BACK TO A TALK
ABOUT FUTURE MEETINGS AND WHAT
COMES NEXT.
>>THANK YOU.
ANY QUESTIONS FOR DR. HOSED?
HE WILL BE ON HAND THROUGHOUT
THE MEETING.
IF YOU HAVE ANY QUESTIONS LET US
KNOW AND WE'LL CONTINUE ON.
FOR EVERYONE'S KNOWLEDGE, OUR
FUTURE MEETINGS FOR 2023 AND
2024 ARE POSTED HERE.
WE WILL BE HAVING AN IN-PERSON
MEETING.
OUR ATTEMPT IS FOR MAY AND
SEPTEMBER COUNCILS.
THIS WILL BE ON OUR MAIN CAMPUS
BUILDING 45 HERE AT THE NIH
CAMPUS.
WE LOOK FORWARD TO MEETING
PEOPLE IN PERSON IN THE NEAR
FUTURE.
NEXT UP --
>>CAN I ASK A QUESTION BEFORE
YOU MOVE ON FROM THAT?
>>SURE, GO AHEAD.
>>SO, SOME OF US NEVER HAD AN
IN-PERSON AS PART OF THE COUNCIL
BEFORE.
AND SO RELATED TO ALL OF THE
TRAVEL THAT WOULD BE ASSOCIATED
WITH THAT, THAT WOULD ALL BE
FIRST ORIGINATING FROM PEOPLE AT
NIA COMING TO US OR SHOULD WE DO
THINGS ON OUR OWN SIDE?
>>ABSOLUTELY.
YES, SO YOU WILL BE RECEIVING A
DETAILED E-MAIL FROM LINDA
ADDISON HARVEY FROM OUR TEAM AND
JASMINE.
AND IT WILL OUTLINE EXACTLY WHAT
YOU NEED TO DO FOR TRAVEL.
AND THEY WILL BE HANDLING THE
TRAVEL.
>>BUT WAIT FOR IT TO ORIGINATE
FROM YOUR SIDE BEFORE DOING
ANYTHING?
>>YES, CORRECT.
>>GOT IT.
THANK YOU.
>>KEN ALSO IN THE CHAT, MARISA
IS ASKING ABOUT AVAILABILITY OF
THESE SLIDES AND LINKS.
ABSOLUTELY WE WILL SEE THAT
THESE ARE MADE AVAILABLE.
>>YES.
ABSOLUTELY.
NEXT UP, IT'S OUR CONSIDERATION
OF THE MINUTES FROM OUR LAST
SEPTEMBER 2022 COUNCIL.
THESE ARE AVAILABLE IN THE
ELECTRONIC COUNCIL BOOK.
I JUST LIKE TO THEN GET A MOTION
TO APPROVE THE MINUTES FROM THE
LAST MEETING.
>>SO MOVED.
>>SECOND?
>>SECOND.
>>ALL IN FAVOR.
>>AYE.
>>ANY OPPOSED?
NOT HEARING ANY.
WE HAVE APPROVAL OF THE MINUTES.
R. FROM THE 2022 SEPTEMBER
COUNCIL.
THANK YOU VERY MUCH.
NEXT UP IS OUR REPORT FROM OUR
TASK FORCE ON MINORITY AGING.
I'M TURN THIS OVER TO DR. MANLY.
>>DR. MANLY: I'M GOING TO SHARE
SOME SLIDES, IF THAT'S OKAY.
HOPEFULLY IF YOU CAN SEE MY
SCREEN RIGHT NOW --
>>YES.
>>DR. MANLY: AND JUST WANT TO
ORIENT LISTENERS THAT JUST LIKE
THE NACA COUNCIL ADVISES THE
SECRETARY OF HHS, THE DIRECTOR
OF NIH AND DR. HOSED ON NIA'S
MISSION, THE TASK FORCE FOR
MINORITYEDS AGING RESEARCH
COMMITTEE IS A SUBCOMMITTEE OF
NACA.
ALL COUNCIL MEMBERS ARE ACTIVE
MEMBERS OF OUR TASK FORCE
SUBCOMMITTEE AND THE TASK FORCE
HAS A SPECIAL ROLE TO ADVISE NIH
AND DR. HOEDS ABOUT OUR
UNDERSTANDING OF HOW AGING
RESEARCH CAN ADDRESS HEALTH
INEQUALITIES FOR MINORITY WOMEN,
MINORITY GROUPS AND PEOPLE WITH
DISABILITIES.
WE HAVE DR. PATRICIA JONES, THE
DIRECTOR OF THE NIA OFFICE OF
SPECIAL POPULATIONS WHO WORKS
WITH THE TASK FORCE TO ACHIEVE
ITS GOALS, AND DR. YANIRA CRUZ
ARE THE CO-CHAIRS.
DR. HEALTH WHITFIELD THIS IS HIS
LAST MEETING AT COUNCIL, WHICH
IS A VERY SAD THING.
BUT DR. CRUZ IS STEPPING UP TO
TAKE PART IN AS A CO-CHAIR.
AND WHAT WE DO IN THE TASK
FORCE, IS WE TRY TO HIGHLIGHT
INNOVATIVE AND IMPACTFUL HEALTH
RESEARCH FUNDED BY NIA
THROUGHOUT EACH OF THE
DIVISIONS, ESPECIALLY THE
RESEARCH THAT USES THE NIA
HEALTH DISPARITIES FRAMEWORK.
AND WE ALSO TRY TO ENGAGE IN A
DISCUSSION ABOUT SUPPORT FOR
TRAINING AND OTHER NIA RESOURCES
THAT CAN HELP TO ACCELERATE AND
ADVANCE HEALTH AND AGING
RESEARCH.
AND SO, PRIOR TO EVERY NACA
MEETING, THE CO-CHAIRS AND
DR. JONES MEET TO TRY TO COME UP
WITH WHAT WE ARE GOING TO DO AT
THIS MEETING.
AND THIS TIME WE CHOSE TWO
SPEAKERS TO PRESENT TO COUNCIL
TO HIGHLIGHT THE CONTRIBUTION OF
BIOLOGICAL RESEARCH OR BASIC
BIOLOGY RESEARCH AND BIOLOGICAL
MECHANISMS TO UNDERSTANDING
HEALTH AND AGING DISPARITIES
RESEARCH.
SO LET ME TELL YOU ABOUT THOSE
TALKS RIGHT NOW AND I'M GOING
SHOW YOU SLIDES FROM THE
PRESENTERS.
THESE ARE NOT MY SLIDES.
THESE ARE SLIDES FROM THE
PRESENTERS.
OUR FIRST TALK WAS FROM
DR. CHANTAL MARTIN WHO IS AN
ASSISTANT PROFESSOR OF
EPIDEMIOLOGY AT THE GILLINGS
SCHOOL OF GLOBAL AND PUBLIC
HEALTH.
SHE IS A SOCIAL EPIDEMIOLOGIST
WHO FOCUSES ON SOCIAL AND
STRUCTURAL DRIVERS OF HEALTH AND
EQUALITIES IN COGNITIVE DISEASE
RISK ACROSS THE LIFE COURSE.
AND THE POTENTIAL UNDERLYING
BIOLOGICAL MECHANISMS.
AND SHE BEGAN HER TALK BY
PROVIDING AN OVERVIEW FOR US OF
STRUCTURAL RACISM AS A
FUNDAMENTAL CAUSE OF HEALTH
DISPARITIES.
SHE PROVIDED A QUOTE TO US FROM
ZIN WE HAVE BAILEY, AN EXPERT ON
STRUCTURAL RACISM AND HEALTH AND
THAT BASICALLY SAYS THAT
STRUCTURAL RACISM IS
INTERCONNECTED INSTITUTIONS
WHOSE LINKAGES ARE HISTORICALLY
ROOTED AND CULTURALLY ENFORCED.
IT'S THE TOTALITY OF WAYS IN
WHICH THE SOCIETIES FOSTER
RACIAL DISCRIMINATION THROUGH
MUTUALLY REINFORCING I BELIEVE
EQUITABLE SYSTEMS AND --
INEQUITABLE SYSTEMS AND
REINFORCE DISCRIMINATORY
BELIEFS, VALUES AND DISTRIBUTION
OF RESOURCES WHICH TOGETHER
AFFECT THE RISK OF ADVERSE
HEALTH OUTCOMES.
SO DR. MARTIN DESCRIBED HER WORK
TO US TO UNDERSTAND HOW
STRUCTURAL RACISM THAT I JUST
GAVE YOU A DEFINITION FOR, IN
PARTICULAR RESIDENTIAL
SEGREGATION INFLUENCES CHANGES
IN BIOLOGICAL, PHYSIOLOGICAL,
PSYCHOLOGICAL, BEHAVIORAL AND
SOCIAL FUNCTIONING.
ONE OF THE INNOVATIVE WAYS THAT
RESEARCHERS HAVE BEEN TRYING TO
UNDERSTAND THESE INFLUENCES IS
BY MEASURING BIOLOGICAL AGING
AND ESSENTIALLY THIS IS
BIOMARKERS THAT PREDICT THE
FUNCTIONAL CAPABILITY OF A
PERSON OR THEIR ORGANS AND HOW
IT CHANGES WITH AGE.
SO, COMMON MEASURES OF
BIOLOGICAL AGING INCLUDE ALOE
STATIC LOAD, TELOMERE LENGTH AND
IMMEW MUNE FUNCTION BUT
DR. MARTIN TOLD US ABOUT DNA
METHYLATION WHICH IS BIOMARKER
OF BIOLOGICAL AGING THAT IS
RESPONSIVE TO ENVIRONMENTAL
STRESSORS.
IT OFFERS INSIGHT INTO POTENTIAL
MOLECULAR PATHWAYS THAT LINK
STRESS AND THE ENVIRONMENT TO
HEALTH IN THE BODY.
AND LET PLEASE JUST QUICKLY SHOW
YOU SOME OF HER RESULTS.
SHE LOOKED AT THE ASSOCIATION --
ASKED THE QUESTION HOW IS THIS
TO STRUCTURAL RACISM AND ADVERSE
NEIGHBORHOOD CONDITIONS
CONTRIBUTE TO EP GENELNETIC
CHANGES AND ACCELERATED AGING
THROUGHOUT THE LIFE COURSE.
SHE FOUND USING THE DETROIT
NEIGHBORHOOD HEALTH AND AGING
STUDY THAT NEIGHBORHOOD QUALITY
WAS ASSOCIATED WITH ACCELERATED
DNA METHYLATION AGING.
IN MODELS THAT WERE STRATIFIED
ON SOCIAL COHESION, THE
ASSOCIATION OF NEIGHBORHOOD
DISORDER WITH DNA METHYLATION
REMAINED ELEVATED FOR PEOPLE
LIVING IN NEIGHBORHOODS WITH
LOWER SOCIAL COHESION BUT WERE
NULL FOR PEOPLE WHO LIVED IN
NEIGHBORHOODS WITH HIGHER SOCIAL
COHESION.
SO, DR. MARTIN'S RESEARCH
SUGGESTED THAT LIVING IN AN
ADVERSE NEIGHBORHOOD ENVIRONMENT
CAN SPEED UP THIS EPIGENETIC
AGING WHILE POSITIVE
NEIGHBORHOOD ATTRIBUTES MAY
BUFFER THOSE EFFECTS.
LET ME MOVE ON QUICKLY TO THE
NEXT TALK THAT WE HEARD
YESTERDAY.
DR. GERMANE DAVIS IS AN
ASSISTANT PROFESSOR IN THE
DEPARTMENT OF BIOCHEMISTRY,
CANCER BIOLOGY AND NEUROSCIENCE
AT THE HARRY MEDICAL COLLEGE AND
IS A MEMBER OF THE CENTER FOR
STRUCTURAL BIOLOGY AT
VANDERBILT.
HE IS A PH.D. IN BIOCHEMISTRY
AND MOLECULAR BIOPHYSICS AND IS
AN ALUMNUS AT THE BUTLER WILLIAM
SCHOLAR PROGRAM, ONE OF THE KEY
ACTIVITIES OF THE OFFICE OF
SPECIAL PROGRAMS AT NIA.
AND ONE IMPORTANT PART OF WHAT
DR. DAVIS DOES IS TRIES TO
UNDERSTAND THE CONTRIBUTION OF
GENETICS TO THE DISPARITY IN
ALZHEIMER'S DISEASE RISK BETWEEN
AFRICAN-AMERICANS AND
NON-HISPANIC WHITES, WHICH VIDEO
ME JUST SAID ABOUT 20 MINUTES
AGO, 20 OR 30 MINUTES AGO, IN
THE VIDEO.
AND DR. DAVIS IS TRYING TO
UNDERSTAND GENETIC VARIANTS THAT
ARE ASSOCIATED WITH ALZHEIMER'S
DISEASE THAT ARE MORE PREVALENT
IN EUROPEANS OF AFRICAN DECENT
THAN THEY ARE IN PEOPLE OF
EUROPEAN ANCESTRY.
SO HE IS TRYING TO UNDERSTAND
THIS A7 GENE, WHICH HAS BEEN
SHOWN TO HAVE STRONGER
ASSOCIATIONS WITH AD RISK IN
PEOPLE WITH AFRICAN ANCESTRY
THAN IN PEOPLE WITH EUROPEAN
ANCESTRY.
IN FACT, IT HAS A STRONGER
EFFECT ON AD RISK THANG THE
APOE4 GENE OR ALLELE IN
AFRICAN-AMERICANS.
SO HE IS TRYING TO UNDERSTAND
THIS TRANSMEMBRANE PROTEIN
THAT'S INVOLVED IN LIPID
HOMEOSTAYSIS AND PHAGOCYTOSIS,
AND THE DYSFUNCTION OF THE ABC
A7 JEAN IS ASSOCIATED WITH
INCREASED AMYLOID BETA
PRODUCTION, REDUCED AMYLOID BETA
CLEARS, IMPAIRED MICROGLIAL
RESPONSE TO INFLAMMATION AND
ENDOPLASMIC RETICULUM STRESS.
SO, LET ME SHOW YOU MY LAST
SLIDE, WHICH IS ALSO FROM
DR. DAVIS'S TALKS.
SO THIS IS DR. DAVIS'S SLIDE AND
DATA.
SOME OF IT WAS PRESENTED IN
AAIC.
AND THE QUESTION THAT HE HAS
WAS, HOW A7 CONTRIBUTES A DO.
A MOLECULAR LEVEL.
HE SHOWED US HOW HE ISUDING A
COMBINATION OF STRUCTURAL AND
CELL BIOLOGY TECHNIQUES TO DO
THIS.
HE IS LOOKING AT HOW THE ABC A7
VARIANT MAY CONTRIBUTE
ALZHEIMER'S DISEASE BY REDUCING
THE LEVEL OF THIS SUBSTANCE
CALLED, PIP 2 IT'S A
PHOSPHOLIPID REPORTED TO BE
DECREASED IN THE AD BRAIN.
SO THAT VERY INTERESTING WORK
WAS PRESENTED BY HIM YESTERDAY.
IN ADDITION TO THE CAREFUL AND
INNOVATIVE WORK HE IS DOING TO
UNDERSTAND THESE GENETIC
CONTRIBUTIONS, THE KNACK COUNCIL
WAS VERY IMPRESSED WITH HIS
EMPHASIS ON COMMUNITY
ENGAGEMENT.
-- NACA -- THIS IS A RESEARCHER
WHO ALWAYS KEEPS IT REAL WITH
THE COMMUNITY.
HE ENGAGES THEM ABOUT HIS
RESEARCH AND RESEARCH
PARTICIPATION, AND THROUGH THE
MEMBERS OF HIS LAB AND HIS WORK,
HE EMPHASIZES THE IMPORTANCE OF
EMBEDDING HIS SCIENCE IN THE
CONCERNS OF THE COMMUNITIES WE
ARE TRYING TO SERVE.
SO THAT IS MY REPORT.
LET ME JUST ASK DR. CRUZ IF YOU
HAVE ANYTHING TO ADD?
>>THANK YOU DR. MANLY.
I THINK YOU HAVE DONE A VERY
NICE JOB JUST COVERING WHAT WE
HEARD YESTERDAY.
IT WAS FASCINATING PRESENTATION
AND I THINK A GREAT OPPORTUNITY
TO CONTINUE TO DO GOOD WORK TO
ADDRESS HEALTH EQUITIES IN OUR
SOCIETY.
>>DR. MANLY: THANK YOU.
>>THANK YOU DR. MANLY AND
DR. CRUZ.
ANY OTHER COMMENTS OR QUESTIONS
FROM OUR PANEL?
>>THIS IS SANJAY.
THAT WAS A BEAUTIFUL SUMMARY,
JENNIFER.
JUST A COMMENT AND I THINK MANY
OF YOU ARE AWARE THAT SOME WORK
BY DR. AMY KLEIN HAS SHOWN THAT
PEOPLE WHO RESIDE IN POOR
NEIGHBORHOODS ACTUALLY HAVE
WORSE COGNITIVE PERFORMANCE,
CARDIOATROPHY ON MRI SCANS AND
ALSO INCREASED AMYLOID BURDEN AS
A MEASURE TO BIOMARKER.
THERE SEEMS TO BE DIRECT
RELATIONSHIP BETWEEN
NEIGHBORHOOD DISADVANTAGE AND
SOME BIOLOGY AS WELL.
IT NEEDS TO BE CONFIRMED IN
ADDITIONAL STUDIES.
I WONDER IF YOU MIGHT HAVE SOME
INSIGHT INTO THE -- DR. MARTIN'S
PRESENTATION.
I WONDER IF AS PEOPLE MOVE FROM
ONE NEIGHBORHOOD TO ANOTHER
DURING THEIR LIFE COURSE, AND IF
THEIR LIVING CONDITIONS IMPROVE,
WOULD THAT AFFECT THE BIOLOGICAL
AGING MARKERS THAT DR. MARTIN
TALKED ABOUT?
WILL YOU HAVE ANY SENSE ABOUT
THAT?
>>DR. MANLY: I MEAN, I THINK
WHAT I WOULD SAY IS THAT I DON'T
THINK WE KNOW THE ANSWER TO YOUR
QUESTION YET.
AND PART OF WHAT OUR DISCUSSION
IS MOVING FORWARD IS, WHAT
CAN -- WHAT OPPORTUNITIES, WHAT
STUDIES CAN BE LEVERAGED?
SO YOU SAW DR. MARTIN LEVERAGE
THE DETROIT STUDY.
SHE IS ALSO A FREQUENT USER OF
THE ADD HEALTH STUDY, WHICH IS A
LONGITUDINAL STUDY OF
ADOLESCENTS.
THESE FOLKS ARE GETTING UP THERE
NOW.
I THINK THAT IT ARE ABOUT MY
AGE.
SO THESE ARE THE KINDS OF DATA
RESOURCES THAT WE NEED TO
UNDERSTAND THE ANSWER TO YOUR
QUESTION.
OBVIOUSLY IF WE HAVE A GROUP OF
PEOPLE WHO ARE IDENTIFIED WHO
LIVE IN A PARTICULAR
NEIGHBORHOOD LIKE THE ONE THAT I
WORK IN IN WASHINGTON HEIGHTS,
THERE ARE PEOPLE WHO ARE THERE
WHO LIVED THERE THEIR WHOLE
LIVES AND THERE ARE PEOPLE WHO
MOVED THERE FROM THE SOUTH OR
IMMIGRATED FROM OTHER COUNTRIES.
AND SOY, THIS IS THE RICH KIND
OF LIFE COURSE TRAJECTORY WE
NEED TO UNDERSTAND.
AND ONE KEY PART OF THAT IS TO
GET A RESIDENTIAL HISTORY FROM
PEOPLE.
AND THAT TAKES A WHILE.
SO THAT TAKES RESOURCES.
AND THE FLIP SIDE IS TO BE ABLE
TO LINK PEOPLE TO ADMINISTRATIVE
RECORDS OF WHERE THEY HAVE LIVED
AND THEN ONE OTHER -- LIKE ADD
HEALTH, WHICH IS ESSENTIALLY
FOLLOW PEOPLE FROM A VERY YOUNG
AGE, VISIT THEM EVERY 2-3 YEARS
AND FIND OUT -- MEASURE DIRECTLY
FROM THEM.
THAT'S HOW I WOULD ANSWER YOUR
QUESTION.
AND I SEE THAT THERE IS ANOTHER
HAND UP.
>>HI, JENNIFER.
WONDERFUL FEATURING OF THIS
EXCITING WORK.
I WAS WONDERING, AD-HOC RIGHT
NOW, I DIDN'T HAVE ACCESS TO THE
BRIEFING BOOK, BUT WILL WE GET,
AS COUNCIL MEMBERS, FILLED IN ON
HOW NIA IS DOING ON DEIA
INITIATIVES AND JUST IN GRANTS
THAT ARE FUNDED ACROSS THE
ORGANIZATION ABOUT INVESTIGATORS
AT DIFFERENT STAGES OF THEIR
CAREERS?
IS THAT SOMETHING WE WILL BE
GETTING BRIEFED ON?
>>DR. MANLY: YES, BUT I THINK
IT'S ALSO SOMETHING THAT COUNCIL
MEMBERS NEED TO ASK FOR.
AND SINCE WE ARE ALL MEMBERS OF
THIS TASK FORCE, WE NEED TO SORT
OF ASK SPECIFICALLY FOR
INFORMATION ABOUT THESE
PROGRAMS.
AND ASK FOR THE LEVEL OF DETAIL
THAT WE NEED TO UNDERSTAND
WHETHER THERE HAS BEEN PROGRESS
AND WHAT HAS BEEN EFFECTIVE.
SO LET'S TALK SOME MORE.
ANY FEEDBACK THAT COUNCIL
MEMBERS HAVE FOR US ABOUT WHAT
FUTURE AGENDA SHOULD BE FOR THE
TASK FORCE, WE WOULD LOVE THAT.
DR. KAHN?
>>DR. KAHN: DR. MANLY, I WAS
CURIOUS IF ANY COMPARABLE
RESEARCH HAS BEEN DONE IN RURAL
COMMUNITIES, ESPECIALLY
UNDERSERVED COMMUNITIES.
JUST THIS MORNING I GOT THE WORD
THAT ONE OF MY CHEROKEE FRIENDS,
HER MOM, PASSED AWAY AND SHE WAS
SUFFERING FROM ALZHEIMER'S FOR
YEARS.
AND I KNOW THE STRUGGLE OF HER
AND HER FAMILY GETTING CARE FOR
HER.
ANY SUPPORT WAS JUST QUITE AN
EXPERIENCE FOR THEM.
SO JUST CURIOUS TO KNOW.
>>DR. MANLY: ABSOLUTELY.
AND I'M VERY SORRY ABOUT YOUR
FRIEND'S LOSS.
I THINK THAT THERE ARE A NUMBER
OF INITIATIVES.
I'M A PART OF ONE AND I'LL JUST
TALK ABOUT THAT VERY QUICKLY.
THE -- AND I THINK SOMEBODY PUT
SOMETHING IN THE CHAT.
LET ME READ THAT IN A MINUTE.
BUT THE REGARD STUDY, IS AN
NINDS-FUNDED STUDY.
IT HAS NIA SUPPORT AS WELL TO
LOOK AT BRAIN HEALTH IN PEOPLE
WHO LIVE ACROSS THE UNITED
STATES.
AND THEY OVERSAMPLE PEOPLE IN
THE STROKE BELT, MUCH OF WHICH
IS RURAL.
AND ONE OF THE SPIN OFF STUDIES
FROM THAT IS CALLED, RURAL, THE
RURAL STUDY, TO UNDERSTAND
HEALTH IN RURAL ENVIRONMENTS.
LET ME READ THIS CHAT JUST IN
CASE.
OKAY, LIZ, THANK YOU.
COMES TO THE RESCUE.
INTERDISCIPLINARY NETWORK ON
RURAL POPULATION HEALTH AND
AGING.
SHE PROVIDES A LINK FOR THAT.
BUT, RURAL RESIDENTS IS ONE OF
THOSE KEY SORT OF FUNDAMENTAL
GEOGRAPHIC PLACE AND SPACE
DRIVERS OF HEALTH.
AND SO IT'S SOMETHING THAT I
THINK THERE IS A NUMBER OF
PEOPLE OUT THERE TRYING TO
UNDERSTAND THOSE MECHANISMS.
>>ALL RIGHT.
THANK YOU VERY MUCH, JEN.
APPRECIATE THE RESPONSES TO THE
COMMENTS.
I THINK WE WILL MOVE ON.
NEXT UP WE HAVE A REPORT ON
WORKING GROUP ON PROGRAM.
SO I'LL TURN THIS OVER TO MONICA
DRISCOLL.
MONICA?
>>DR. DRISCOLL: THANK YOU VERY
MUCH.
SO, YESTERDAY WE STARTED OFF OUR
WORK WITH A PRESENTATION FROM
STEVE WHO IS KIND OF OVERSEEING
THE EFFORT TO REVIEW THE
DIVISION OF GERIATRICS AND
CLINICAL GERONTOLOGY.
SO I THINK WE WERE ALL IMPRESSED
WITH THE PANEL CREDENTIALS AND
THEIR EXPERIENCE, THE
ORGANIZATION AND THE PROGRESS
THAT THIS GROUP HAS MADE AND
WITH THE FINAL ANTICIPATED
REPORT FOR MAY.
SO YOU CAN ALL HAVE THAT TO LOOK
FORWARD TO AT THE NEXT MEETING.
WE THEN TURNED TO CONCEPT
CLEARANCES.
AND AGAIN I'LL JUST START BY
THINKING THE NIA FOR PUTTING
TOGETHER A REALLY TERRIFIC SET
OF EXCITING AND IMPORTANT
INITIATIVES AND THANKING THE
COUNCIL MEMBERS FOR THEIR HARD
WORK AND THOUGHTFUL COMMENTS.
WHAT WE'LL DO TODAY IS JUST,
I'LL CALL ON THE PRIMARY
REVIEWER TO REVIEW THE --
SUMMARIZE THE DISCUSSION.
AND THEN WE WILL VOTE AT THE END
ON BLOCK FOR THE ACCEPTANCE OF
THESE.
SO, LET'S BEGIN WITH THE
DIVISION OF BEHAVIORAL AND
SOCIAL RESEARCH ON THE INITIAL
CONCEPT CLEARANCE CALLED
BEHAVIORAL AND SOCIAL RESEARCH
ON THE ROLE OF IMMIGRATION ON
LIFE COURSE HEALTH AND AGING
INCLUDING AD/ADRD.
THE PRIMARY VIEWER OF DR. MANLY,
SECONDED WAS DR. WE'RE.
DR. MANLY IF YOU COULD SUMMARIZE
FOR US.
>>DR. MANLY: SURE, SO THIS WAS
AN EXCELLENT CONCEPT CLEARANCE,
VERY CLEARLY WRITTEN AND
JUSTIFIED.
IT WOULD BE A NEW INITIATIVE FOR
OUR PHASE FOR RESEARCH ON LIFE
COURSE SOCIAL AND STRUCTURAL
FACTORS THAT SHAPE AGING, HEALTH
AND ALZHEIMER'S DISEASE AND
RELATED DISORDERS AMONG BLACK,
LATINO AND ASIAN IMMIGRANT
GROUPS IN THE UNITED STATES.
THERE WAS A RECENT NATIONAL
ACADEMY OF SCIENCES WORKSHOP
THAT RECOMMENDED THAT IN ORDER
TO UNDERSTAND INEQUALITIES AND
HEALTH AND AGING, NOT ONLY DO WE
NEED A TRANSDISCIPLINARY LENSE
AND LIFE COURSE MODELS BUD ALSO
RESEARCH THAT DISAGGREGATES MY
NORMAL TIESED GROUPINGS BEYOND
SOCIOECONOMIC STATUS.
SO THE DIVISION OF SOCIAL AND
BEHAVIORAL RESEARCH HAS DECIDED
THAT ONE WAY TO DO THAT IN ORDER
TO RESPOND TO THAT REPORT, IS TO
FOCUS ON THE ROLE OF IMMIGRA
IMMIGRATION.
AS ONE ASPECT OF THAT
DISAGGREGATION.
MANY PEOPLE WHO ARE LISTENING
MAY KNOW THAT THERE ARE
SOMETHING CALLED THE IMMIGRANT
HEALTH PARADOX, WHICH IS THAT
MORE RECENT IMMIGRANTS HAVE
BETTER HEALTH THAN PEOPLE WHO
ARE U.S. BORN OR IMMIGRATED
LATER IN LIFE.
BUT AS OUR RESEARCH IN THIS AREA
GROWS, THERE IS SOME STUDIES
THAT SHOW THE OPPOSITE, WHICH IS
THAT RECENT IMMIGRANTS, HEALTH
IS WORSE AND IT DEPENDS ON WHAT
THE HEALTH OUTCOME IS, HOW YOU
STUDY IT, WHEN YOU STUDY IT.
SO THIS NEEDS TO BE LOOKED INTO
FURTHER.
AND THAT IS WHAT IS CALLED FOR
IN THE CONCEPT CLEARANCE.
THE CONCEPT CLEARANCE IS FOR
BOTH RO1 AND R21 MECHANISMS WITH
A STRONG RATIONAL FOR EACH
MECHANISM BEING USEFUL IN
CONDUCTING THIS WORK.
R21s MAY BE USEFUL IN DOING
SOME OF THE COMMUNITY-BASED AND
MIXED METHODS APPROACHES THAT
MAYBE MOST IDEALLY SUITED TO
UNDERSTAND SOME OF THE
MEASUREMENT ISSUES IN THE
POPULATION AND THE CONCEPT ALSO
ENCOURAGED LEVERAGING OF
EXISTING NIA STUDIES LIKE THE
HEALTH AND RETIREMENT STUDY AND
THE HARMONIZED COGNITIVE
ASSESSMENT PROTOCOL, HAD.
RS SISTER STUDIES AROUND THE
WORLD AND ADD HEALTH.
BUT PRIMARY DATA COLLECTION IS
ALSO POSSIBLE.
THIS CONCEPT INDIVIDUAL A SET
ASIDE FUNDS AND ALSO A
SPECIALIZED REVIEW.
AND THIS IS IMPORTANT BECAUSE
THE CONCEPT CLEARANCE SHOWED
DATA AT THE LAST TIME NIA SIGNED
ON TO A ANNOUNCEMENT, FUNDING
ANNOUNCEMENT TO ADDRESS HEALTH
DISPARITIES AMONG IMMIGRANT
POPULATIONS.
VERY FEW APPLICATIONS WERE SENT
IN FOR THAT THAT WERE NIA,
FOCUSED.
ALL THE STUDIES WENT TO EXISTING
STUDY SECTIONS AND ALL OF THEM
WERE SCORED ABOVE THE CURRENT
PAY LINE.
SO THIS IS AN OPPORTUNITY FOR
PEOPLE WHO ARE DOING RESEARCH OR
WHO WANT TO DO RESEARCH IN
IMMIGRANT GROUPS TO HAVE THIS
OPPORTUNITY TO SUBMIT TO SPECIAL
REVIEW GROUP.
AND THE COUNCIL WAS ENTHUSIASTIC
ABOUT THIS CONCEPT CLEARANCE.
>>GREAT, THANK YOU VERY MUCH.
THE SECOND CONCEPT THAT WE
CONSIDERED WAS ENHANCING USE OF
HCAP DATA.
THE PRIMARY REVIEWER OF
DR. WE'RE AND THE SECONDARY WAS
DR. MANLY.
DR. WE'RE IF YOU COULD SUMMARIZE
THE DISCUSSION FOR US.
>>DR. WE'RE: HCAP IS THE
HARMONIZED COGNITIVE ASSESSMENT
PROTOCOL THAT JEN JUST
MENTIONED.
THAT IS AN ASSESSMENT AIMED AT
RESEARCH DIAGNOSIS OF DEMENTIA
AND MILD COGNITIVE IMPAIRMENT
DEVELOPED WITHIN THE HEALTH
RETIREMENT STUDY TO ADDRESS THE
NEED FOR MORE COST EFFECTIVE
APPROACHES IN LARGE POPULATIONS
STUDIES.
IT WAS DONE IN CONSULTATION WITH
SEVERAL OF THE INTERNATIONAL
PARTNER STUDIES.
THE NIA HAS SUPPORTED NOW TWO
WAVES OF HCAP IN THE HRS WE'LL
IN MULTIPLE OTHER COUNTRIES
AROUND THE WORLD SO THERE IS A
ESTABLISHED AND GROWING BODY OF
DATA.
AND THIS CONCEPT AIMS TO
LEVERAGE THAT INTO REAL
RESEARCH.
THOSE STUDIES WERE FUNDED TO
CREATE THE RESOURCE NOT TO
REALLY EXPLOIT IT.
SO THIS IS A TARGETED SET OF
RO1s THAT WILL USE THE HCAP,
RESOLVE SOME OF THE CHALLENGES
TO INTERNATIONAL CULPABILITY AND
MOVE THE FIELD FORWARD TAKING
ADVANTAGE OF THE INFORMATION
ABOUT LIFE EXPERIENCES AND
ENVIRONMENTAL CONTEXT THAT YOU
CAN GET FROM INTERNATIONAL
COMPARISONS FROM ANY ONE
COUNTRY.
SO STRONG SUPPORT.
>>THANK YOU SO MUCH.
THE NEXT CONCEPT THAT WE
CONSIDERED IS GRAND CHALLENGE;
PREDICTING EARLY ALZHEIMER'S
DEAND RELATED DEMENTIAS.
DR. MANLY WAS THE PRIMARY
REVIEWER AND DR. WHITFIELD WAS
THE SECONDARY.
DR. MANLY IF YOU COULD SUMMARIZE
THE DISCUSSION FOR US.
>>DR. MANLY: SORRY FOLKS,
TRYING TO SHUFFLE MY DIGITAL
PAPERS HERE.
THIS WAS A CONCEPT CLEARANCE WE
SEEN A YEAR AGO AND THE GOAL OF
THIS CONCEPT IS TO SUPPORT A
CONTRACT THAT WOULD PROVIDE THE
INFRASTRUCTURE FOR DEVELOPMENT,
COORDINATION AND ADVERTISEMENT
OF COMPETITIONS THAT ADDRESS THE
GRAND CHALLENGE OF PREDICTING
EARLY ALZHEIMER'S DISEASE AND
RELATED DEMENTIAS.
SO ESSENTIALLY THIS CONTRACTOR
WOULD ENGAGE EXPERT ADVISORS AND
PROVIDE SCIENTIFIC DIRECTION,
IDENTIFY HIGH-PRIORITY DATA
SOURCES FOR POTENTIALLY USE FOR
THIS.
AI CHALLENGE, WHICH IS TO TAKE A
BUNCH OF DATA AND PREDICT WHO
WILL GET ALZHEIMER'S DISEASE, TO
ESTABLISH CLOUD SPACE FOR
COMPETITIONS AND TO EVALUATE
THOSE COMPETITIONS.
THIS IS ESSENTIALLY A COMMUNITY,
RESEARCH COMMUNITY BUILDING
GRANT.
IT DOESN'T DESCRIBE HOW EXACTLY
THE CHALLENGE WILL BE MET BUT IT
IS A CRITICAL INFRASTRUCTURE AND
HUMAN CAPITAL BUILDING STEP.
AND THE GOAL IS TO ENGAGE A
DIVERSE SCIENTIFIC COMMUNITY TO
BEGIN TO COLLABORATE SO THE
CHALLENGE CAN BE MET IN THE BEST
WAY POSSIBLE.
AND BY DIVERSE, I MEAN AI
RESEARCHERS AND ENGINEERS, DATE
SCIENTIFIC, NEUROSCIENTISTS,
PSYCHOLOGISTS, SOCIOLOGISTS, AND
CITIZEN SCIENTISTS AND COMMUNITY
PARTNERS INCLUDING SMALL
BUSINESS.
AND THEY WANT TO ENGAGE PEOPLE
IN THEIR CAREERS ALL THE WAY
FROM STUDENTS, TRAINEES, EARLY
INVESTIGATORS, ALL THE WAY TO
MORE SEASONED INVESTIGATORS.
THE COUNCIL THOUGHT THIS WAS
EXTREMELY TIMELY.
THEY WERE ENTHUSIASTIC ABOUT
THIS RESOURCE BUILDING CONCEPT
CLEARANCE AND RECOMMENDED IT.
S.
>>THANK YOU VERY MUCH.
OKAY, THE NEXT ONE THAT WE
CONSIDERED IS THE CONSORTIUM FOR
PAYMENT UTILIZATION AND ACCESS
FOR DEMENTIA CARE.
THE PRIMARY REVIEWER WAS
DR. CASE AND THE SECONDARY WAS
DR. WE'RE.
DR. CASE IF YOU COULD SUMMARIZE
FOR US.
>>DR. CASE: SURE.
THE CONCEPT MADE A STRONG CASE
FOR THE NEED FOR RESEARCH IN
ADDRESSING THE EXTRAORDINARY
ARRAY OF DECISIONS AND
DIFFICULTIES FACED IN PROVIDING
CARE FOR PEOPLE LIVING WITH
DEMENTIA.
THE PROPOSAL IS FOR A CONSORTIUM
WITH A COORDINATING CENTER
THROUGH A U54 AND SIXER R1s TO
ADDRESS SPECIFIC AD/ADRD
MILESTONES SUCH AS HOW FEDERAL
POLICIES AND PAYMENT MODELS
EFFECT CARE FOR PEOPLE LIVING
WITH DEMENTIA, HOW CARE VARIES
ACROSS INSTITUTIONAL SETTINGS,
HOW PAYMENT MECHANISMS AFFECT
UTILIZATIONAL SERVICES, AND
ACCESS TO CARE.
SO THE CONCEPT IS TIMELY.
THE MOTIVATION IS CLEAR.
THE U54 WILL PLAY A POWERING UP
COORDINATING ROLE ACROSS THE
RO1s COORDINATING MEETINGS AND
STAKEHOLDER ENGAGEMENT,
IDENTIFYING COMMON DATA
ELEMENTS, IDENTIFY TRAINING
PROGRAMS, TRANSLATION AND
AVAILABILITY OF RESOURCES.
AND THE COORDINATING CENTER CAN
ALSO SOLICIT STUDIES TO DIRECTLY
ADDRESS MILESTONES THAT AREN'T
ALREADY BEING ADDRESSED BY THE
FUNDED RL1s.
SO THERE WAS A GREAT DEAL OF
ENTHUSIASM FOR THIS CONCEPT
CLEARANCE.
>>THANK YOU VERY MUCH.
THE NEXT CONCEPT DISCUSSED IS
TITLED DEMENTIA CARE
COORDINATION RESEARCH CENTER.
DR. RUBIN WAS THE PRIMARY
REVIEWER AND DR. WHITFIELD WAS
THE SECONDARY.
DR. RUBIN IF YOU COULD SUMMARIZE
THE DISCUSSION FOR US.
>>DR. RUBIN: THIS IS A CONCEPT
THAT STEMMED FROM THE 2020
DEMENTIA CARE SUMMIT.
AND THE RATIONAL FOR IT IS THAT
THERE IS AN URGENT NEED TO
BETTER UNDERSTAND WHAT WORKS IN
TERMS OF THE BENEFIT CARE
COORDINATION AND CARE TRANSITION
COMMUNITY SETTINGS.
THIS IS GOING TO BE A U54
MECHANISM AND IT'S TO SUPPORT
DEMENTIA CARE INTEGRATION
RESEARCH NETWORK.
IT WILL BE A CENTER FOR
ORGANIZING PARTNERSHIPS WITH
REGIONAL DATA PROVIDERS AND
RESEARCHERS.
AND A DATA HUB FOR DATA SHARING
THAT WILL INCLUDE PILOTS.
IT WILL ALSO RECOGNIZE THE
MULTIPLE STAKEHOLDERS THAT ARE
INVOLVED, INCLUDING STATES,
INCLUDING HEALTH CARE
ORGANIZATIONS, INCLUDING
COMMUNITY-BASED ORGANIZATIONS,
INCLUDING INSURERS.
SO IT IS VERY BROAD, ESPECIALLY
SET ASIDE IS REQUESTEDS AS WELL
AS SPECIAL EMPHASIS PANEL.
AND WITH SOME WORD SMITHING AND
SOME REVISION, THE CONCEPT WAS
APPROVED UNAN HUESLY BUT A FINAL
VERSION WILL BE DISTRIBUTED TO
COUNCIL FOR FINAL APPROVAL.
>>GREAT.
THANK YOU VERY MUCH FOR THE
SUMMARY.
THE NEXT CONCEPT THAT WE
CONSIDERED IS ENTITLEDDED
LEVERAGING SOCIAL NETWORK TO
PROMOTE WIDESPREAD INDIVIDUAL
BEHAVIOR CHANGE.
DR. RUBIN WAS THE PRIMARY
REVIEWER AND DR. WHITFIELD WAS
THE SECONDARY.
DR. RUBIN IF YOU COULD SUMMARIZE
THE DISCUSSION FOR US.
>>DR. RUBIN: THIS WAS A VERY
INTERESTING AND WELL-RECEIVED
CONCEPT.
IT RECOGNIZES THE POTENTIAL OF
SOCIAL NETWORKS TO PROMOTE
BEHAVIORAL CHANGE INCLUDING
TARGETING INITIAL DOCTORS AND AS
WELL AS MODIFICATION OF NETWORK
STRUCTURE COMPOSITION.
AND THIS IS PARTICULARLY TIMELY
BECAUSE OF THE EXPLOSION OF
SOCIAL NETWORKING THROUGH THE
WIDESPREAD ADOPTION OF SOCIAL
MEDIA, WHICH PRESENTS BOTH
OPPORTUNITIES AND CHALLENGES IN
THE MANAGEMENT OF OLDER PERSONS
WITH RESPECT TO THE BEHAVIORAL
CHANGES.
THIS WAS ENTHUSIASTICALLY
EMBRACED BY COUNCIL AND WE ARE
EXCITED ABOUT IT.
IT WILL BE RO1 MECHANISM.
>>GREAT.
THANK YOU VERY MUCH FOR THAT
CONCISE SUMMARY.
THE NEXT CONCEPT WE CONSIDERED
IS NETWORKS TO DEVELOP
BEHAVIORAL AND SOCIAL SCIENCE
RESEARCH IN AGING AND AD/ADRD.
PRIMARY REVIEWER WAS
DR. WHITFIELD AND THE SECONDARY
WAS DR. CASE.
DR. WHITFIELD, IF YOU COULD
SUMMARIZE THE DISCUSSION FOR US.
>>DR. WHITFIELD: CERTAINLY,
THIS CONCEPT PROPOSAL WAS
INTENDED TO OFFER A NIMBLE MEANS
TO SUPPORT HIGH PRIORITY AREAS
OF RESEARCH FOR BSR.
THE CONCEPT WOULD ADDRESS SEVEN
DIFFERENT OPPORTUNITIES THAT
WERE RECOMMENDATIONS FROM THE
2019BSR REVIEW AS WELL AS THE
NAI,AD/ADRD MILESTONES.
THIS CONCEPT CLEARANCE WOULD USE
R24 MECHANISM.
SO AWARD RESEARCH THROUGH
SUPPORT NETWORKS THAT WOULD BE
THE BASIS FOR THE CREATION OF
THE INNOVATIVE RESEARCH GROUPS
THAT WOULD LEAD FROM
DISCOVERING, SUPPORTING,
IDENTIFYING EMERGING RESEARCH
AND THINKING ABOUT CONSIDERING
AND ELUCIDATING OTHER RESEARCH
RESOURCES.
THE AREAS OUTLINED FROM THE
2019BSR REVIEW WILL PROVIDE
IMPORTANT PLATFORMS FOR
INTERESTING RESEARCH NETWORKS TO
BE CREATED.
THE R24 MECHANISMS EXCELLENT
MECHANISM FOR FOSTERING
INTER
DISCIPLINARY GROUPS OF GROUPS
SENATOR SCIENTISTS AND TO THINK
ABOUT IMPORTANT AREAS IN SUPPORT
OF ADVANCING NEUROSCIENCE.
THIS CONCEPT AS WE DISCUSSED IT
IS CLEARLY PROVIDE AN ENTREE AND
FACILITATE THE ABILITY TO HAVE
COLLABORATIONS BOTH WITHIN BS R
AND ACROSS DIVISIONS.
AND WITH THAT, THE DISCUSSION
WAS VERY SUPPORTIVE AND WE
APPROVE THIS CONCEPT.
>>THANK YOU SO MUCH.
THE NEXT ONE THAT WE CONSIDERED
IS MEASURE SYSTEM FINANCIAL
HARDSHIP AMONG PEOPLE AND
FAMILIES LIVING WITH AD/ADRD.
DR. CASE WAS THE PRIMARY
REVIEWER AND DR. WE'RE WAS
SECONDARY.
DR. CASE, IF YOU COULD SUMMARIZE
THE DISCUSSION FOR US.
>>DR. CASE: SURE.
THIS CONCEPT STARTS WITH THE
OBSERVATION THAT PEOPLE WITH
AD/ADRD ARE NOT OR EVENTUALLY
WILL NOT BE IN A POSITION TO
REPORT THE FULL RANGE OF
FINANCIAL STRESS AND STRAIN AND
ASSET COMPLETION AND COSTS THAT
AD/ADRD BRING WITH IT.
AND THAT THEY DO NOTE BEAR THE
ENTIRE COST FOR THE SUPPORT THEY
RECEIVE.
AND THAT AS A RESULT, THE
EXISTING FINANCIAL WELLNESS
SCREENERS ARE NOT REALLY ABLE TO
CAPTURE THE COSTS ASSOCIATED
FULLY CAPTURE THE COSTS
ASSOCIATED WITH THE DEGREE.
THE DISCUSSION, THERE WAS SOME
CONFUSION, PRIMARILY MY OWN, ON
EXACTLY WHAT THE CONCEPT WAS
CALLING FOR.
BUT THE CONCEPT IS FOR A CALL
FOR RO1 PROPOSALS TO FIND WAYS
TO CHARACTERIZE THE NETWORK OF
SUPPORT RECEIVED AND TO FIND
WAYS TO CAPTURE THE FINANCIAL
STRESS AND STRAIN AND COSTS BORN
BY THE NETWORK OF PEOPLE,
FAMILY, FRIENDS, OTHER SOCIAL
CONTACTS, THAT SUPPORT A PERSON
DIAGNOSED AND LIVING WITH
DEMENTIA.
SO, THERE WAS ENTHUSIASM ON SE
SEEING THIS TAKEN FORWARD.
WITH SOME SUGGESTION ON MAKING
IT CLEARER, PRECISELY WHAT
THE -- WHAT IS BEING CALLED FOR
IN TERMS OF DEVELOPING METHODS
FOR UNDERSTANDING THE
ELICITATION OF THE COSTS
ASSOCIATED WITH PROVIDING CARE
FOR PEOPLE WITH AD/ADRD.
>>THANK YOU VERY MUCH.
THE NEXT ONE THAT WE CONSIDERED
IS NATIONAL HEALTH AND AGING
TRENDS, AND NATIONAL STUDY OF
CARE GIVING.
THIS CONCEPT WAS REVIEWED BY
DR. WE'RE AND DR. CASE.
DR. WE'RE, IF YOU COULD
SUMMARIZE FOR US.
>>DR. WE'RE: SURE.
THIS CONCEPT WAS FOR RENEWAL OF
THE STUDY AND ITS COMPANION
STUDY OF CAREGIVERS.
THE NHATS IS A SUCCESSOR TO THE
NATIONAL LONG-TERM CARE SURVEY
WHICH WENT FOR 20-SOMETHING
YEARS PRIOR TO THAT.
SO IT CONTINUES A VERY LONG
TRADITION OF ASSESSMENT OF
DISABILITY IN THE OLDER
POPULATION AND THE DEMANDS FOR
CARE.
WHAT'S EXCITING ABOUT NEAR
FUTURE IS THAT NIA HAS
RESTRUCTURED GOVERNANCE FOR THIS
STUDY WITH EFFECTIVE DATA
MONITORING COMMUNITY WHICH HAS
BROUGHT NEW FOCUS TO ADADRD
CONCERNS GIVEN TRADITIONAL
STRENGTHS AND UNDERSTANDING
DISABILITY AND ADAPTATION TO
DISABILITY, EXTENDING THIS TO
THE NEEDS FOR ALZHEIMER'S
PATIENTS.
SO LIKE A REAL WINNER FOR NIA.
SO, WE WERE STRONGLY SUPPORTIVE
OF CONTINUING.
>>THANK YOU VERY MUCH FOR THAT
CONCISE SUMMARY.
WE'LL CONTINUE WITH THE DCG
CONCEPT CLEARANCES.
NEXT IS DEVELOPMENT AND
VALIDATION OF HARMONIZED
METHODOLOGIES TO MEASURE NAD
PLUS AND RELATED LEVELS IN
CLINICAL TRIALS.
THE PRIMARY REVIEWER WAS
DR. VASEEN AND THE SECONDARY WAS
DR. GREENSPAN.
DR. BHASIN IF YOU COULD
SUMMARIZE THE DISCUSSION FOR US.
THANK YOU.
>>THANK YOU.
SO THIS CONCEPT PROPOSAL
DEVELOPING VALIDATION OF
HARMONIZED METHODOLOGIES TO
MEASURE NAD, SEEKS TO SUPPORT
STUDIES TO DEVELOP AND VALIDATE
METHODS FOR ACCURATE MEASUREMENT
OF NAD+ AND RELATED METABOLITES
IN HUMAN BLOOD AND TISSUES.
THERE HAS BEEN A LOT OF
EXCITEMENT ABOUT NAD EVEN THOUGH
NAD HAS BEEN KNOWN FOR THE ROLE
IN SYNTHESIS FOR 60-70 YEARS.
MORE RECENT INVESTIGATIONS OVER
THE LAST 15 YEARS HAVE REVEALED
MUCH MORE EXPANSIVE ROLE OF NAD
IN EMERGING BIOLOGY.
AND THE NUMBER OF STRATEGIES ARE
BEING DEVELOPED THROUGH AUGMENT
NAD AS A -- AS A THERAPEUTIC
INTERVENTION TO PREVENT AND
TREAT A NUMBER OF AGE-RELATED
DISEASES.
NAD PRECURSORS HAVE BEEN
INVESTIGATED IN PRE-CLINICAL AS
WELL AS AT SOME EARLY PHASE
HUMAN STUDIES AND THE DATA FROM
THESE EARLY STUDIES ARE
TANTALIZING AND HAVE SHOWN THE
PROMISE OF THIS STRATEGY.
BUT THERE IS ALSO BEEN
DIFFICULTIES IN THIS DATA
BECAUSE OF MET LOGIC PROBLEMS IN
MEASURING NAD AND ITS
METABOLITES IN THE SERUM AND IN
OTHER TISSUES, PARTICULARLY IN
TISSUES.
THERE ARE THREE TYPES OF
DIFFICULTIES, HOW TO STABILIZE
NA.
AND METABOLITES, PARTICULARLY
NADA, NADPH AND DOWNSTREAM
METABOLITES IN THE HUMAN SERUM
AS WELL AS IN TISSUES PRIOR TO
MEASUREMENT.
AND SECOND, HOW TO HARMONIZE THE
VARIOUS ASSAYS TO MINIMIZE IN
THE LABORATORY HETEROGENEITY AND
FINALLY, CAN WE MEASURE NAD AND
METABOLITES IN SIT YOU USING
MAGNETIC RESONANCE SPECTROSCOPY?
AND THEN THERE IS A NEED TO
HARMONIZE THESE METHODS SO THE
EVALUATION BEING REPORTED BY
DIFFERENT LABORATORIES ARE
COMPARABLE AND ARE BEING
BENCHMARKED WITH HIGHER ORDER OF
CALIBRATOR.
SO THIS PARTICULAR INITIATOR
THAT HAS BEEN PROPOSED IN THIS
CONCEPT CLEARANCE AS A UL1
MECHANISMS IS VERY URGENTLY
NEEDED TO PROMOTE RESEARCH IN
THIS SPACE.
IT WAS A LOT OF ENTHUSIASM FOR
SUPPORTING THIS CONCEPT.
>>GREAT.
>>AND THE NEED FOR SPECIAL
EMPHASIS ALSO IS WELL JUSTIFIED.
>>THANK YOU VERY MUCH.
THE NEXT CONCEPT THAT WE
CONSIDERED IS CALLED ELUCIDATING
VARIABILITY OF PHYSIOLOGIC AND
FUNCTIONAL RESPONSES TO EXERCISE
TRAINING IN OLDER ADULTS.
THE PRIMARY REVIEWER IS
DR. GREENSPAN AND THE SECONDARY
IS DR. BHASIN.
DR. GREENSPAN, IF YOU COULD
RECOUNT THE DECISION FROM
YESTERDAY, PLEASE.
>>DR. GREENSPAN: THANK YOU,
MONICA.
ALTHOUGH THERE ARE SIGNIFICANT
EVIDENCE THAT THERE IS BOST
EXERCISE AND PHYSICAL ACTIVITY
FOR PREVENTION OF DISEASE IN
OLDER ADULTS, THERE IS ALSO
SIGNIFICANT VARIABILITY IN
INDIVIDUALS RESPONSE TO
EXERCISE.
AND THERE HAVE BEEN SEVERAL KEY
STUDIES THAT HAVE DEMONSTRATED
THIS VARIABILITY INCLUDING ONE
VERY LARGE NIA-SUPPORTED STUDY,
THE LIFE TRIAL, THAT SHOWED A
REDUCTION IN THE TRANSITION TO
MOBILITY DISABILITY, BUT 1/3 OF
THE PARTICIPANTS HAD A DECLINE
IN GAIT SPEED AND DECLINE IN
OTHER FUNCTIONAL TESTS.
THERE WAS AN NIH WORKED SHOP IN
APRIL OF 2022 THAT HIGHLIGHTED
THE HETEROGENEITY OF RESPONSE TO
EXERCISE TRAINING AND FOUND THAT
THERE WERE KEY GAPS IN
ELUCIDATING THE RELATIONSHIPS
BETWEEN EXOGENOUS AND INTRINSIC
VERSUS EXOGENOUS, EXTRINSIC
FACTORS UNDERLYING THE
VARIATIONS IN THIS RESPONSE TO
EXERCISE.
FURTHERMORE, THEY NOTED THAT A
POSITIVE OUTCOME IN ONE DOMAIN
DID NOT ALWAYS PROVIDE A
POSITIVE RESPONSE IN ANOTHER
IMPORTANT OUTCOME OR DOMAIN.
SO THIS CONCEPT WILL BE AN RFA
FOR RL1s, SET ASIDE FUNDS TO
DESIGN CONTROL STUDIES WITH
MULTIDISCIPLINARY TEAMS
UTILIZING INNOVATIVE APPROACHES.
THE CONCEPT WILL SUPPORT NEW
STUDIES TO UNDERSTAND THE
MECHANISM UNDERLYING THE
RESPONSE AND VARIABILITY TO
EXERCISE TRAINING IN OLDER
ADULTS.
IT WAS SUGGESTED THAT
INVESTIGATORS DESIGN TRIALS THAT
CONTROL FOR EXERCISE EXPOSURE,
THE ENVIRONMENT, EXAMINE TEMP
ASPECTS, EXAMINE THE
INTERACTIONS OF DRUG AND
EXERCISE INTERACTIONS, LOOK AT
THOSE WITH MULTIPLE CHRONIC
CONDITIONS, HOW THEY RESOLVE THE
RESULTS AND MECHANISMS OF SEX
AND AGE DIFFERENCES ALONG WITH
OTHER CONFOUNDERS AND FACTORS.
WE FELT THAT THIS WAS A TIMELY
AND IMPORTANT RFA THAT WILL
DIRECT INVESTIGATORS TO EXAMINE
A HOST OF THESE FACTORS THAT
LEADS TO THIS VARIABILITY IN THE
EXERCISE RESPONSE.
THERE WAS A GOOD DISCUSSION AND
A LOT OF ENTHUSIASM FOR THIS
CONCEPT.
>>THANK YOU, SO MUCH.
THE LAST ONE FROM THE DGCG IS
CLONAL HEMATOPOIESIS IN AGING
HUMANS, DETECTION, RISK FACTORS
AND RELATIONSHIPS TO
AGING-RELATED PATHOPHYSIOLOGY
AND CONDITIONS, AND CLINICAL
UTILITY IN SCREENING AND
PROGNOSIS.
DR. BAKER WAS THE PRIMARY
REVIEWER AND DR. HUANG WAS THE
SECONDARY.
DR. BAKER IF YOU COULD SUMMARIZE
THE DISCUSSION FOR US.
>>DR. BAKER: ABSOLUTELY.
SO THIS CONCEPT IS FOR A NEW RFA
FUNDING MECHANISM THAT IS
LOOKING TO GET RO1s WITH THE
3-5 YEAR PERIOD TO INVESTIGATE
CLONAL HEMATOPOIESIS IN AGING
HUMANS.
WITH THE INTENTION TO DETECT,
IDENTIFY RISK FACTORS, ESTABLISH
RELATIONSHIPS TO AGE-RELATED
PATHOPHYSIOLOGY AND CONDITIONS
AND DAUGHTER-IN-LAW THE CLINICAL
UTILITY AND SCREENING AND
PROGRESSINOSIS FOR PATIENTS --
DETERMINE -- IT WAS A JOINT
PROPOSAL.
FOR A LONG PERIOD, MOST OF THE
STUDIES HAVE FOCUSED PRIMARILY
ON PRE CANCEROUS ALTERATION THAT
IS SUPPORT NEOPLASTIC
TRANSFORMATION TO BLOOD-TYPE
CANCERS.
ABOUT 15-20% OF PEOPLE OVER THE
AGE OF 70 HAVE BLOOD CELLS WITH
CANCER ASSOCIATED CHANGES BUT
THEY DO NOT THEMSELVES DEVELOP
TUMORS.
SO WITH ADVANCES IN SEQUENCING
TECHNOLOGIES AND REDUCTIONS IN
THE INVESTMENT NEEDED TO ENTER
INTO THE SPACE, THERE IS AMPLE
OPPORTUNITY TO FURTHER
UNDERSTAND HOW THESE VARIATIONS
THAT OCCUR WITH AGE AND HOW THEY
ALSO MAYBE ARE OCCURRING IN
DIVERSE POPULATIONS AND TO THIS
END, MORE THAN 60,000
PARTICIPANTS HAVE BEEN
INVESTIGATED FOR CLONAL
HEMATOPOIETIC ALTERATIONS OF
INDETERMINATE POTENTIAL AND
GENERALLY LONG-LIVED PATIENTS
TEND TO HAVE FEWER CLONAL
CHANGES.
THERE WAS A WORKSHOP TO EXPLORE
THIS RELATIONSHIP IN 2021.
A LOT OF EXCITEMENT AROUND THIS.
LARGELY THIS RFA IS COMING FROM
THE OUTCOMES FROM THAT
PARTICULAR WORKSHOP.
IT SEEMS TO FITTED WELL WITHIN
THE BEING HIGH PRIORITY WITH THE
NIA AND THERE WAS NO HESITATION
WITHIN THE COUNCIL FOR
SUPPORTING THIS PARTICULAR
INITIATIVE.
>>GREAT.
THANK YOU VERY MUCH.
WE WILL MOVE ON TO NOW THE
DIVISION OF NEUROSCIENCE CONCEPT
CLEARANCES.
THE FIRST ONE IN THAT GROUP WE
CONSIDERED WERE NEURONAL AND NON
NEURONAL MECHANISMS, UNDERLYING
GAIT AS A PRE-CLINICAL MARKER
FOR ALZHEIMER'S DISEASE AND
ALZHEIMER'S DISEASE RELATED
DEMENTIAS.
DR. BHASIN WAS PRIMARY REVIEWER
AND DR. RUBIN WAS SECONDARY.
DR. BHASIN IF YOU COULD
SUMMARIZE THE DISCUSSION FOR US.
>>DR. BHASIN: THANK YOU VERY
MUCH.
THIS CONCEPT PROPOSAL SEEKS SET
ASIDE FUNDS TO ENCOURAGE
RESEARCH IN ELUCIDATING THE
NEURAL AS WELL AS NON-NEURAL
MECHANISMS THAT UNDERLIE THE
ASSOCIATION BETWEEN MOBILITY AND
COGNITION IN AGING AND ADRD.
THERE IS WIDE AGREEMENT THAT
IMPAIRED MOBILITY PRECEDES AND
PREDICTS IMPAIRED COGNITION AND
ALSO PREDICTS AN INCREASE RISK
OF DEVELOPING ALZHEIMER'S
DISEASE.
THE PREDICTIVE ABILITY OF GAIT
SPEED IS MARKER OF HEALTH AND
PHYSICAL DISABILITY, COGNITIVE
DECLINE AND ALZHEIMER'S AND
MORTALITY IS WIDELY RECOGNIZED.
EVEN THOUGH THE NEURAL AS WELL
AS NON-NEURAL MECHANISMS THAT
LINK WALKING AND OTHER MOTOR
FUNCTIONS WITH COGNITION AND
SUBSEQUENT DECLINE IN COGNITION
AND DEVELOPMENT OF ALZHEIMER'S
DISEASE ARE INCOMPLETELY
UNDERSTOOD.
THAT IS WHAT IS BEING ENCOURAGED
IN THIS PARTICULAR CONCEPT
PROPOSAL.
SO THE PROPOSAL SEEKS TO SET
ASIDE FUNDS AND SPECIAL EMPHASIS
PANEL TO REVIEW THE RESULTING
GRANT APPLICATIONS.
THERE WAS GENERAL ENTHUSIASM
THAT THIS IS A VERY IMPORTANT
AREA FOR INVESTIGATION THAT
NEEDS TO BE SUPPORTED AND THIS
MECHANISM SEEMS APPROPRIATE.
THERE WAS LIVELY DISCUSSION
AROUND THIS AND SOME SUGGESTION
WERE MADE TO NEURODOWN THE FOCUS
OF THE INITIATIVE AND FOCUS ON
THE NEURAL MECHANISMS.
BUT THERE WAS WIDE SUPPORT AND
ENTHUSIASM FOR THIS CONCEPT
PROPOSAL.
>>THANK YOU SO MUCH.
THE NEXT ONE THAT WE CONSIDERED
IS ANALYTICAL AND CLINICAL
VALIDATION OF BIOMARKERS FOR
ALZHEIMER'S DISEASE AND RELATED
DIMENS YALS.
PRIMARY REVIEWER WAS DR. SNYDER
AND THE SECONDARY WAS
DR. VANELEDIC.
DR. SNYDER, IF YOU COULD REVIEW
THE DISCUSSION FOR US.
ED.
>>DR. SNYDER: SO THIS IS
CONCEPT CLEARANCE --
[ LOW AUDIO ]
[ INAUDIBLE ]
FOCUSES ON HIGH QUALITY, COST
EFFECTIVENESS AND UNDER
REPRESENTED COMMUNITIES AND
WHILE IT'S NOT RESTRICTED TO LOW
BIOMARKERS, THERE IS SPECIFIC --
OF PROMISE OF BIOMARKERS -- NEED
FOR CLINICAL UTILITY STUDY.
ALSO BIOMARKERS -- FRAMEWORK
INCLUDES THE FRAMEWORK AND
BIOMARKERS FOR TOOLS FROM
MEDICAL DEVICE DEVELOPMENT -- SO
PRETTY WIDE OPEN INCLUDING
FLUID, PLASMA, IMAGING AND
REALLY FOCUS ON THE ANALYTICAL
AND CLINICAL VALIDITY.
UL1 MECHANISM WHICH WE THOUGHT
WAS APPROPRIATE MECHANISM THAT
ALLOWS COOPERATIVE AGREEMENT AND
WITH NIA MILESTONES AND INPUT,
THE TYPE -- REALLY IMPORTANT
BECAUSE REALLY THE ULTIMATE BUT
NOT REQUIRED GOAL IS TO APPLY
FOR FDA BIOMARKER -- PROGRAM.
SO VERY -- RESPONSIVE TO THE
STRATEGIC PLAN.
OVERALL WE THOUGHT IT WAS TIMELY
AND MUCH-NEEDED INITIATIVE
STANDARDS REQUIRED VIA FDA.
WE LIKED IT BECAUSE BIOMARKERS
AND REALLY ACROSS -- WE WERE
SUPPORTIVE.
THERE WERE A FEW QUESTIONS
EASILY ANSWERED BY PROGRAM AND
WE ARE EXCITED.
>>THANK YOU.
THE NEXT APPLICATION IS ENTIT
ENTITLED -- CHIMERIC ANTIGEN
RECEPTOR APPROACHES.
THE PRIMARY REVIEWER WAS
DR. HUANG AND THE SECONDARY WAS
DR. BAKER.
DR. HUAN GOVERNMENT IS
STRUGGLING WITH LOSING HIS VOICE
SO DR. BAKER TOOK ON THE VERGEAL
PRESENTATION.
AND I THINK THAT -- NOT SURE WHO
WILL TELL US ABOUT TODAY --
>>I CAN TAKE IT.
SO YES, BASICALLY WE WERE VERY
MUCH IN AGREEMENT ON THIS WORN.
>>[ INDISCERNIBLE ]
>>CAN YOU HEAR ME?
THIS CONCEPT CLEARANCE IS FOR A
NEW R61R33 MECHANISMS FOR
CHIMERIC ANTIGEN RECEPTOR
APPROACHES.
WE ARE AVAILABLE WITH CAR AND MA
SLUG CEASE SO IN THIS CASE WHAT
THEY ARE TRYING TO DO IS GO
AFTER MORE PROOF OF PRINCIPLE
THAT IS SIMILAR APPROACH
COUPLING CHIMERIC ANTIGEN
RECEPTORS AGAINST THINGS THAT
ARE RELEVANT FOR ALZHEIMER'S
DISEASE AND ALZHEIMER'S
DISEASE-RELATED PATHOLOGIES TO
BE POTENTIALLY USEFUL.
SO IN ESSENCE, THAT WAS THE MAIN
THING IT'S GOING TO BE EXISTING
IN TWO STAGES.
R61 IS DURING THE FIRST TWO
YEARS OF THE FUNDING CYCLE WHERE
THERE ARE MILESTONES PEOPLE WILL
NEED TO MEET AND THEN
SUBSEQUENTLY LEADING INTO R33
MECHANISMS FOR THE REMAINING
THREE YEARS OF FUNDING FOR THIS.
OVERALL, THERE WAS THIS FEELS
LIKE IT FIDDLE A VERY IMPORTANT
PRIORITY AND TO DEVELOP NEW
ANIMAL MODELS THAT MAY HAVE HIGH
PREDICTIVE VALUE FOR THINGS THAT
COULD BE USEFUL FOR DRUG
DEVELOPMENT FOR TRANSLATIONALLY
RELEVANT TREATMENT OPPORTUNITIES
FOR PEOPLE.
NO HESITATIONS WITH SUPPORT OF
THIS.
AGAIN A VERY WELL WRITTEN RFA
REQUEST.
>>GREAT.
THANK YOU VERY MUCH.
THE NEXT CONCEPT WAS BUILDING
NEUROSCIENCE RESEARCH
INFRASTRUCTURE FOR ALZHEIMER'S
DISEASE AND RELATED DEMENTIAS IN
AFRICA.
DR. WE'RE, IF YOU COULD
SUMMARIZE THE DISCUSSION FOR US.
>>SURE.
WE FELT THIS WAS A DYNAMIC AND
TIMELY INITIATIVE T REPRESENTS A
COOPERATION BETWEEN DN AND THE
SPONSOR AND DBSR.
THE FOCUS IS ON SUB-SAHARAN
AFRICA WHICH IS A REGION THAT IS
GREATLY UNDERSTUDIED AND IS A
POTENTIALLY GREAT VALUE TO
GENETIC RELEVANCE AND DIVERSITY,
DUE TO THE UNIQUE DISEASE AND
ENVIRONMENTAL EXPOSURES IN THAT
PART OF THE WORLD.
SO WE FELT THAT FOCUS WAS WELL
JUSTIFIED IT'S TIMELY IN THAT
THERE HAS BEEN NOW STUDIES IN
SOUTH AFRICA AND IN KENYA
COLLABORATING WITH THE NETWORKS
TO BUILD COMPARABLE DIAGNOSTIC
TOOLS.
THERE WAS MEETING SPONSORED IN
NAIROBI WELL ATTENDED BY
SCIENTISTS FROM THE U.S. AND
AFRICA.
SO THE POTENTIAL REALLY DOES
SEEM TO BE THERE NOW FOR THINGS
TO START HAPPENING.
THE MECHANISM IS STAGE UG3UH3 IN
WHICH THERE WILL BE MILESTONES
IN THE START UP PHASE AND ONLY
SUCCESSFUL PROJECTS WILL GO
FORWARD.
AND THE MAIN CRITERION WHICH
SUCCESS WILL BE EVALUATED IS THE
BUILDING OF CAPACITY IN AFRICA.
SO THIS IS NOT TO FINANCE DRIVE
BY STUDIES FROM U.S.
INVESTIGATORS.
IT'S REALLY TO PARTNER AND
DEVELOP CAPACITY ON A MORE
PERMANENT BASIS IN AFRICA.
SO WE HAVE GREAT ENTHUSIASM FOR
THIS PROJECT.
>>THANK YOU SO MUCH.
GREAT.
THE NEXT CONCEPT THAT WE
CONSIDERED IS ARTIFICIAL
INTELLIGENCE IN PRE-CLINICAL
DRUG DEVELOPMENT FOR AD/ADRD.
DR. LONGO WAS THE PRIMARY
REVIEWER AND DR. H.
ANG WAS SECONDARY.
DR. LONG OH, IF YOU COULD
SUMMARIZE THE DISCUSSION FOR US.
>>DR. LONGO: SURE.
THIS IS A UH2/UH3 MODEL TO
DEVELOP AI APPROACHES FOR
PRE-CLINICAL DRUG DEVELOPMENT.
SO WHAT THIS TECHNOLOGY ALLOWS
ONE TO DO IS DESIGN SMALL
MOLECULES OR OTHER ENTITIES IN A
MORE EFFICIENT WAY LIKELY
EFFECTIVE WAY, TO DESIGN THEM TO
INTERACT WITH GIVEN TARGET THAT
MIGHT BENEFIT ALZHEIMER'S AND
RELATED AREAS.
SO, THIS IS A VERY TIMELY
PROPOSAL FOR TWO REASONS, ONE IS
THE CAPABILITIES IN AI FOR DRUG
AND THERAPEUTIC DESIGN
CONTINUING TO ACCELERATE AND
BECOME MORE AND MORE EFFECTIVE
AND CRITICAL TOOLS IN THE FIELD
AT THIS POINT.
NUMBER 2, OTHER NIA PROGRAMS,
INCLUDINGASM AD, TREAT AD, ARE
BEING SUCCESSFUL IN FINDING
NOVEL TARGETS, NOVEL NON AMYLOID
TARGETS THAT MIGHT BE OF
BENEFIT.
AND SO THIS APPROACH WILL ALLOW
THESE TARGETS TO BE MORE QUICKLY
EFFICIENTLY EFFECTIVELY
ADDRESSED.
IT'S APPROPRIATELY STAGE
PROGRAMS WHERE THE APPROACHES
ARE DEVELOPED IN THE UH2 AND
THEN APPLIED EITHER CONCEPTUALLY
OR WITH EXPERIMENTS IN THE UH3.
SO I THINK WE THOUGHT THAT THIS
WOULD DEVELOP INTO ENHANCING THE
DEVELOPMENT OF THERAPEUTICS.
>>GREAT.
THANK YOU VERY MUCH.
THE NEXT CONCEPT THAT WE
CONSIDERED WAS SMALL RESEARCH
GRANT PROGRAM FOR THE NEXT
GENERATION OF RESEARCHERS IN
AD/ADRD RESEARCH.
DR. SNYDER WAS THE PRIMARY
REVIEWER AND DR. MANLY WAS THE
SECONDARY.
DR. SNYDER IF YOU COULD
SUMMARIZE THE DISCUSSION FOR US.
>>DR. SNYDER: THANK YOU MONICA
AND LET ME KNOW IF YOU CAN'T
HEAR ME.
>>YOU SOUND PERFECT NOW.
THANK YOU.
>>GOOD.
I CHANGED MY MICROPHONE.
SO THE CONCEPT PROPOSED HERE IS
A RE-ISSUANCE OF THE NEXT
GENERATION PROGRAM.
THE OVERALL GOAL OF THIS FOA IS
RESEARCH IN VARIOUS MEETING FOR
SCIENTIFIC INVESTIGATIONS
FOCUSING ON PREVENTION,
DIAGNOSIS AND TREATMENT.
SO BROAD RANGE OF TOPICS.
THE MAIN THEME IS TO ENCOURAGE
THE NEXT GENERATION AS IN THE
TITLE,FUL RESEARCHERS THEIR
RESEARCH ACADEMIC CAREERS IN
ADADRD.
ANOTHER AIM IS LIKE NOVEL
RESEARCH IDEAS IN OTHER FIELDS.
SO THIS IS A RE-ISSUANCE BUT
IT'S CHANGED.
INSTEAD OF BEING MULTIPLE
DIFFERENT MECHANISMS, SMALL
GRANTER OPPORTUNITIES, IT'S ALL
WITHIN NOW RFA AND THE GOAL IS
TO GET -- ALSO CHANGED THAT IT
IS REALLY TO GET NEW
INVESTIGATORS.
OR INVESTIGATORS WHO HAVE NOT
HAD RO1 FUNDING.
SO THAT'S A TAKE FROM THE
ORIGINAL.
THE ORIGINAL WAS VERY PRODUCTIVE
AND DID QUITE WELL, HOWEVER,
THEY DID WANT TO KIND OF REFOCUS
ON THIS NEW NEXT GENERATION
BECAUSE SOME OF THESE PEOPLE
WERE MORE SENIOR.
SO THEY ARE EXPECTING NOW THAT
ABOUT HALF WILL BE EARLY-STAGE
INVESTIGATORS TO ACHIEVE THE
GOAL OF FOSTERING NEW
DEVELOPMENT.
AGAIN SUCH THAT THEY CAN'T HAVE
A SEPARATE STUDY SECTION BUT
THEY WILL HAVE SET ASIDE FUNDS
FOR THESE RESEARCH GRANTS.
SO WE'RE REALLY ENTHUSIASTIC
ABOUT THIS.
ENTRY OF PROMISING NEW
INVESTIGATORS IN THE AGING
RESEARCH, ENCOURAGE THE
ESTABLISHED INVESTIGATORS TO
ENTER NEW AREAS OF AGING
RESEARCH AND GOING TO BE USED AS
PILOTS THAT HOPEFULLY WILL LEAD
TO RO1s FOCUSED ON AGING AND
SIGNIFICANT AGING RESEARCH.
SO WE WERE HIGHLY SUPPORTIVE OF
THIS.
>>THANK YOU VERY MUCH.
SO THE NEXT ONE THAT WE
CONSIDERED IS SEAMLESS EARLY
STAGE CLINICAL DRUG DEVELOPMENT
FOR NOVEL THERAPEUTIC AGENTS FOR
THE SPECTRUM OF ALZHEIMER'S AND
ALZHEIMER'S-RELATED DEMENTIAS.
THE PRIMARY REVIEWER WAS
DR. VANELEDIC AND THE SECONDARY
WAS DR. LONGO.
IF YOU COULD SUMMARIZE THE
DISCUSSION FOR US.
>>YES, THANK YOU.
SO THIS CONCEPT PROPOSES A NEW
UG3/UH3 PHASED AWARD INITIATIVE
AIMED AT STREAMLINING EARLY
STAGE EVALUATION OF PROMISING
NOVEL PHARMACOLOGICAL
INTERVENTIONS.
AND THE WAY THEY ARE GOING TO DO
THIS IS TO FUND PHASE I CLINICAL
TRIALS FIRST AND THEN SEAMLESSLY
MOVE TO PHASE I B2A TRIALS BASED
ON PRE-SPECIFIED GO-NO-GO SAFETY
AND TOLERABILITY CRITERIA IN
PHASE I.
THE THERAPEUTIC CANDIDATES MUST
TARGET NON AMYLOID AND CAN BE
TESTED IN INDIVIDUALS ACROSS ANY
STAGE OF DISEASE PROGRESSION.
AND THERE ARE ALSO REQUIREMENTS
FOR DIVERSITY WITHIN THE TRIAL
COHORTS AND DATA AND BIOSAMPLE
SHARING.
WE THOUGHT THIS WAS A VERY
IMPORTANT INITIATIVE BECAUSE IT
WILL ALLOW TIMELY TESTING AND
PRIORITIZATION OF PROMISING
INTERVENTIONS WITHOUT THE USUAL
SIGNIFICANT FUNDING DELAY
BETWEEN CONCLUSION OF PHASE I A
TRIALS AND THE START OF PHASE
1B2A STUDIES.
THE REQUIREMENT FOR NON AMYLOID
NON TAU INTERVENTIONS WAS GOOD
BECAUSE THERE IS ALREADY
SIGNIFICANT EFFORT BY PHARMA AND
BIOTECH TO TARGET AMYLOID AND
TAU AND THERE ARE SO MANY OTHER
POTENTIAL DISEASE MECHANISMS
THAT NEED TO BE EXAMINED AND
PRIORITIZED EITHER MOVED FORWARD
OR MOVED OFF.
ALSO, FINALLY THE REQUIREMENTS
FOR COHORT DIVERSITY AND DATA
SAMPLE SHARING ARE CRITICAL TO
ENSURE BROAD APPLICABILITY AT
THE RESULTS.
SO WE WERE VERY HIGHLY
SUPPORTIVE OF THIS CONCEPT.
>>THANK YOU VERY MUCH FOR THAT
SUMMARY.
WE WILL MOVE ON TO THE DIVISION
OF EXTRAMURAL ACTIVITY AND
OFFICE OF COMMUNICATIONS AND
PUBLIC LIASON.
WHO PRESENTED TWO CONCEPTS,
NATIONAL IN INSTITUTE ON THE
AGING CLINICAL SUPPORT SERVICES.
PRIMARY REVIEWER WAS
DR. GREENSPAN.
IF YOU COULD SUMMARIZE FOR US.
>>THANK YOU, MONICA.
SO THE NIA HAS A RESPONSIBILITY
TO MANAGE CLINICAL RESEARCH
GRANTS AND THE RESPONSIBILITY
HAS BEEN INCREASING
EXPONENTIALLY.
AND A REPORT IN 2021 FOUND THERE
WAS BROAD SUPPORT FOR SOME KIND
OF CENTRALIZED CLINICAL RESEARCH
MANAGEMENT ACROSS THE INSTITUTE.
THE PROPOSAL WILL PROVIDE
CONTRACT TO EXPAND, CENTRALIZE
AND INTEGRATE ADMINISTRATIVE
REGULATORY, STATISTICAL SUPPORT
TO MANAGE NIA CLINICAL RESEARCH
STUDIES.
THIS WILL STREAMLINE THE SERVICE
AND ENSURE CONSISTENCY ACROSS
THE INSTITUTE AND MOREOVER, IT
WILL REDUCE THE BURDEN ON BOTH
THE STAFF AND ON INVESTIGATORS.
SO THE SPECIFIC TASKS WILL
INCLUDE REGULATORY OVERSIGHT AND
SUPPORT, FOR EXAMPLE HELP WITH
IDENTIFYING A DATEY SAFETY
MONITORING BOARD, RISK
ASSESSMENT, TRACKING COMPLIANCE,
TRACKING TRAINING FOR GOOD
CLINICAL PRACTICE, MAKING SURE
THAT THEY ARE MAINTAINING A
DATABASE, HELPING WITH
RECRUITMENT AND RETENTION,
REALLY TO HELP IDENTIFY BEST
PRACTICES AND PARTICULARLY
MAKING SURE THAT THEY ARE
ENROLLING UNDER REPRESENTED
POPULATIONS.
ASSURING A QUALITY ASSURANCE FOR
CLINICAL RESEARCH OPERATIONS.
PROVIDING STATISTICAL AND
METHODOLOGICAL CONSULTATIONS,
MAINLY FOR PROGRAM AND TRAINING
THE STAFF IN CLINICAL REACH
PROCEDURES.
THERE WAS A LOT OF ENTHUSIASM
FOR THIS.
THERE WAS A NEED FOR NIA TO
OVERSEE A WIDE RANGE OF CLINICAL
TRIALS THAT INCLUDE MANY
COMPLICATION AND -- COMPLICATED
AND DIVERSE POPULATIONS.
AND THIS IS EXPANDED WITH THE
INCREASE IN AD AND ADRD RESEARCH
CLINICAL TRIALS.
WE FELT THAT THIS WOULD BE A
GREAT BENEFIT FOR BOTH NIA AND
INVESTIGATORS TO SUPPORT THE
OVERALL PROGRAM.
SO THERE WAS A LOT OF ENTHUSIASM
FOR THIS.
>>GREAT.
THANK YOU VERY MUCH.
AND OUR FINAL IS NIA INFORMATION
RESOURCE CENTERS.
DR. SNYDER WAS THE PRIMARY
REVIEWER AND DR. HUMBLE WAS THE
SECONDARY REVIEWER.
D. SNYDER IF YOU COULD SUMMARIZE
THE DISCUSSION FOR US.
>>DR. SNYDER: THIS IS FOR THE
RENEWAL OF A CONTRACT WHICH IS
ONGOING SINCE 1990.
BROADLY TO THE PUBLIC, HEALTH
CARE PROFESSIONALS AND
SCIENTIFIC COMMUNITY.
IT PROVIDES COMMUNICATION
SUPPORT TO ADVANCE NIA'S
DISSEMINATION OF INFORMATION.
IT'S A SMALL ACCIDENT SET
ASIDE -- SMALL BUSINESS SET
ASIDE AND TWO INFORMATION
RESOURCE CENTERS.
THERE IS THE CONGRESSIONALLY
MANDATED -- WHICH IS RELATED TO
EDUCATIONAL REFERRALS AND THE
NIA INFORMATION RESOURCE CENTER.
SO THE CONTRACT PROVIDES PUBLIC
INQUIRY RESPONSE, WEBSITE
DESIGN, PUBLIC DEVELOPMENT --
PUBLICATION DEVELOPMENT OF
PRINTING, WAREHOUSING EDITORIAL
SCIENCE WRITING, DATABASE
DEVELOPMENT, COMMUNICATION
RESEARCH.
SO ALSO CONFERENCE SUPPORT AND
OTHER COMMUNICATION SUPPORT
SERVICES.
SO IT DOES QUITE A BIT.
WE WERE VERY ENTHUSIASTIC ABOUT
RENEWING THIS CONTRACT BOTH
DR. HUMBLE AND MYSELF HAD A FEW
QUESTIONS.
I THINK DR. HUMBLE POSED GREAT
QUOS REGARDING UTILIZATION AND
THEY WERE ABLE TO COME BACK WITH
REALLY THE GREAT JOB THAT THEY
ARE DOING WITH REACHING OUT TO
PEOPLE AND MAKING THEM AWARE OF
WHAT IS HAPPENING IN THE
ALZHEIMER'S FIELD.
AND JUST GREAT PROGRESS WITH
REACHING OUT NOT ONLY TO THE
PUBLIC BUT ALSO TO PHYSICIANS.
SO, IT APPEARS THAT THAT THERE
REALLY ARE ON TRACK TO CONTINUE
GREAT WORK AND REALLY HIGHLY
SUPPORTIVE OF CONTINUING THE
SUPPORT INITIATIVE.
>>GREAT.
THANK YOU VERY MUCH VERY, VERY
MUCH.
SO, THAT CONCLUDES THE SUMMARY
OF THE CONCEPTS THAT WE
CONSIDERED YESTERDAY.
AT THIS POINT, I'LL ASK FOR
MOTION TO VOTE UNBLOCK FOR
APPROVAL OF THE RECOMMENDED
CONCEPTS WITH A VERY TINY
ASTERISK TO REMIND YOU THAT WE
ASK FOR A TRANSIENT DEFERRAL FOR
THE DEMENTIA CARE COORDINATION
PROPOSAL PENDING ADDITION OF A
LITTLE BIT MORE INFORMATION AND
REFINEMENT.
BUT THAT WAS THE SUMMARY OF THE
RECOMMENDATION THAT I WOULD LIKE
SOMEONE TO GO FOR THAT MOTION.
>>SO MOVED.
>>AND SO SECOND?
>>SECOND.
>>OKAY.
ANY -- ALL THOSE IN FAVOR?
>>AYE.
>>ANY OPPOSED?
NOT SEEING ANY.
THE COUNCIL ENTHUSIASTICALLY
VOTES TO MOVE THESE CONCEPTS
FORWARD AND THANKS PROGRAM FOR
ALL THEIR HARD WORK.
AND I THANK ALL THE MEMBERS OF
COUNCIL FOR THEIR VERY NICE
CONCISE SUMMARIES YESTERDAY AND
TODAY AND GREAT DISCUSSION.
SO THANK YOU.
>>THANK YOU VERY MUCH, MONICA.
JUST ALSO WANT TO REITERATE AND
SEND MY THANKS TO ALL OUR
COUNCIL MEMBERS FOR THEIR
CONCEPTS AND THE PROGRAM PEOPLE
FOR ALL THEIR HARD WORK PUTTING
INTO THESE CONCEPTS.
JUST TO REMIND THE PUBLIC, THESE
CONCEPTS WILL BE POSTED ON OUR
WEB PAGE AS OUTLINED AND BY
DR. HOEDINGS SLIDE.
THERE IS A LINK FOR THESE
CONCEPTS AND PROBABLY WITHIN THE
WEEK, THESE WILL BE ALL LISTED
ON OUR WEBSITE.
SO TAKE ADVANTAGE OF THE AFFECT
THAT THESE ARE POTENTIAL FUNDING
OPPORTUNITIES IN THE NEAR FUTURE
AND START THINKING ABOUT
APPLICATIONS.
I WANT TO THANK DR. MONICA
DRISCOL FOR BEING THE CHAIR OVER
THE PAST YEARS OF OUR WORKING
GROUP.
MONICA WAS REALLY A PLEASURE
WORKING WITH YOU ALL THESE
YEARS, ESPECIALLY THROUGH OUR
COVID YEARS AND BEING ON LINE
INSTEAD OF IN PERSON ALL THIS
TIME.
SO WE THANK YOU VERY MUCH.
AND WE ALSO WELCOME
DR. GREENSPAN AS OUR NEW CHAIR
OF THE WORKING GROUP.
>>AND THANK YOU ALL SO MUCH.
A COMPLETE HONOR AND PRIVILEGE
TO BE ABLE TO MEET ALL OF YOU
AND HEAR ALL OF THIS EXCITING --
ALL THESE EXCITING THINGS COMING
UP FOR NIA.
IT'S FANTASTIC.
SO THANK YOU.
>>KEN, SORRY, CAN I JUST ASK --
I KNOW THAT THE -- THIS
ATTENDANCE OF THIS MEETING WAS
PUT ON AN AGENDA FOR THE
DIRECTORS YESTERDAY.
AND HOPEFULLY THEY PASSED IT ON
TO SOME OF THEIR GRANTEES.
AND WHAT I GET ASKED A LOT IS,
SO YOU DID THESE CONCEPT
CLEARANCES, NOW WHAT?
WONDERING IF -- I KNOW YOU JUST
SAID THAT THESE ARE GOING TO BE
PUT ON THE WEBSITE AND YOU GAVE
THE DIRECTIONS HOW TO DO THAT.
AND YOU SAID, THIS IS SORT OF A
NOTICE TO THE RESEARCH COMMUNITY
ABOUT WHAT MIGHT BE OUT THERE.
AND SO PEOPLE MIGHT WANT TO
START THINKING ABOUT IT.
BUT, I'M WONDERING IF YOU COULD
GIVE A LITTLE MORE DETAIL.
SHOULD RESEARCHERS POTENTIALLY
TALK WITH PROGRAM OFFICERS ABOUT
IT?
LIKE MAYBE YOU CAN EXPAND A
LITTLE BIT ON WHAT IT MEANS FOR
CONCEPT CLEARANCE TO BE OUT
THERE AND WHAT RESEARCHERS MIGHT
DO TO PREPARE.
>>OKAY.
GREAT QUESTION, JEN.
HAPPY TO ADDRESS THAT.
SO NOW THAT THESE CONCEPTS HAVE
BEEN APPROVED, THEY ARE IN THE
PUBLIC DOMAIN TOO, AND WE
ENCOURAGE EVERYONE TO START
DISSEMINATING THIS INFORMATION
TO EVERYONE AND START THINKING
ABOUT POTENTIAL PROJECTS AND
BUILDING TEAMS, ET CETERA.
BUT YES, PLEASE ON THE WEBSITE,
EACH OF THESE CONCEPTS WILL HAVE
THE PROGRAM OFFICER WHO IS IN
CHARGE OF EACH OF THESE CONCEPTS
LINKED TO EACH OF THE CONCEPTS.
SO YOU ABSOLUTELY CAN GET IN
TOUCH WITH THEM, START
DISCUSSING YOUR IDEAS, ET CET
ET CETERA.
HOWEVER, ONE OF THE CAVEATS IS,
THERE IS REALLY NO GUARANTEE
THAT A FUNDING OPPORTUNITY WILL
BE GENERATED FROM THESE
CONCEPTS.
IT REALLY DOES DEPEND ON OUR
FISCAL SITUATION THROUGHOUT THE
YEAR.
WE NEVER KNOW.
DIFFERENT PRIORITIES MAYBE COME
IN.
WE MIGHT HAVE TO SHIFT FOCUSES,
ET CETERA.
SO THERE ARE POTENTIALS.
BUT, YOU KNOW, THERE IS A VERY
HIGH LIKELIHOOD THAT THESE WILL
BE TURNED INTO FUNDING
OPPORTUNITIES AS WITH HISTORICAL
KNOWLEDGE OF OUR PAST PRACTICES,
ALL THE CONCEPTS HAVE BEEN IN
THE PAST TURNED INTO FUNDING
OPPORTUNITY ANNOUNCEMENTS.
UNLESS THERE HAVE BEEN ISSUES
WITH COUNCIL AND WE DECIDED NOT
TO MOVE THEM FORWARD.
SO, YES, PLEASE GET IN CONTACT
WITH THE PROGRAM OFFICERS.
YES, DEFINITELY START THINKING
ABOUT THE POTENTIAL IDEAS FOR
APPLICATIONS IN THE FUTURE AND
KEEP THAT CONVERSATION GOING.
ALL RIGHT.
WE HAD TWO SPEAKERS COMING UP
NEXT.
BUT I WOULD LIKE TO GIVE OUR
COUNCIL, EVERYONE A 5-MINUTE
BREAK AT THIS POINT, TO JUST TO
HAVE A SHORT BREAK BEFORE WE
START OUR TWO SPEAKERS.
SO IF EVERYONE COULD JUST MUTE
AND STOP THEIR VIDEO, WE'LL TAKE
A 5-MINUTE BREAK AND BE BACK TO
HEAR OUR FIRST SPEAKER WHO IS
DR. ERIC ORWOLL.
>>GOOD AFTERNOON, EVERYONE.
IT'S MY GREAT PLEASURE TO
INTRODUCE DR. ERIC ORWOLL, HE IS
PROFESSOR OF MEDICINE IN THE
DIVISION OF ENDOCRINOLOGY
DIABETES AND CLINICAL NUTRITION
AT OREGON HEALTH AND SCIENCE
UNIVERSITY.
HE IS AN INTERNATIONALLY
RECOGNIZED EXPERT IN THE AREA OF
AGE-RELATED CHANGES AND
MUSCULOSKELETAL HEALTH INCLUDING
SARKO PENIA.
DR. ERIC ORWOLL HAS BEEN THE PI
OF MANY NIH-SUPPORTED STUDIES
AND SO TODAY, WE ARE GOING TO
HEAR ABOUT THE WIDE RANGING
IMPACT OF THE STUDY OF
OSTEOPRIORITYIC FRACTURES IN MEN
STUDY OR Mr. OS ON AGING
RESEARCH.
INITIATED IN 1999 AND LED BY
DR. ERIC ORWOLL, Mr. OS WAS
ONE OF THE FIRST PROSPECTIVE
STUDY OF RISK FACTORS IN OLDER
MEN AND AS THE COHORT
TRANSITIONED TO OLDER AGES, ITS
AIMS EXPANDED TO ADDRESS
IMPORTANT GERIATRIC OUTCOMES
SUCH AS SLEEP, FALLS, PHYSICAL
PERFORMANCE AND FUNCTIONAL
DECLINE.
MORE RECENTLY, THE WEALTH OF
EXISTING LONGITUDINAL TYPIC DATA
FROM THE COHORT, THE GWAS DATA
AND BIOSPECIMEN COLLECTION HAVE
BEEN LEVERAGED FOR STUDIES OF
EXCEPTIONAL LONGEVITY AND HEALTH
SPAN.
I'D LIKE TO THANK DR. ERIC
ORWOLL FOR JOINING US TODAY AND
THE TITLE OF HIS TALK IS
Mr. OS, A 20+ YEAR STUDY OF
AGING IN OLDER MEN.
ERIC?
>>ERIC ORWOLL: THANK YOU VERY
MUCH.
LET ME SEE IF I CAN SHARE MY
SCREEN.
SO PROGRAM ASKED THAT I REVIEW
SOME OF THE PROGRESS MADE WITH
Mr. OS, WHICH IS A
LONGITUDINAL STUDY OF AGING IN
OLDER MEN.
I'D START WITH THE BASIC STUDY
DESIGN, HIGHLIGHT SOME OF THE
PROGRESS MADE OVER THE COURSE OF
THE STUDY AND FINISH WITH SOME
RECENT FINDINGS IN SEVERAL
AREAS, INCLUDING SARK PENIA AND
PROTEOMICS AND BIKE ROW BIOME.
Mr. OS WAS DESIGNED PRIMARILY
TO UNDERSTAND MUSCULOSKELETAL
AGING, OSTEOPOROSIS AND FRACTURE
BUT COVERED BROAD AREAS OF AGING
AS WELL.
IT STARTED WITH THE RECRUITMENT
OF ABOUT 6000 MEN OVER THE AGE
OF 65 AT SIX CLINICAL SITES
ACROSS THE U.S.
THE MEAN AGE AT BASELINE WAS 74
YEARS WITH A WIDE RANGE.
THERE WERE FEW EXCLUSION
CRITERIA SO THE COHORT IS FAIRLY
REPRESENTATIVE OF MEN AT THAT
AGE, ALTHOUGH SOMEWHAT MORE
HEALTHY THAN RANDOMLY SELECTED
COHORTS LIKE NHANES.
AT BASELINE, MEN WERE PHENOTYPED
WITH EMPHASIS ON MUSCULOSKELETAL
TRAITS AND SERUM, URINE, DNA AND
IMAGE LIBRARY.
PARTICIPANTS HAVE BEEN FOLLOWED
REGULARLY WITH QUESTIONNAIRES
EVERY FOUR MONTHS AND REGULAR
IN-CLINIC EVALUATIONS WHERE
ADDITIONAL PHENOTYPING AND
SPECIMEN COLLECTION.
RETENTION HAS BEEN OUTSTANDING
WITH CONTENT MAINTAINED WITH
GREATER THAN 95% OF SURVIVORS
AND Mr. OS WAS EXPANDED EARLY
ON TO INCLUDE 3000 MEN IN SWEDEN
AND 2000 MEN IN HONG KONG.
OVER THE YEARS, Mr. OS HAS
BEEN VERY PRODUCTIVE.
MANY, MANY INVESTIGATORS HAVE
BEEN INVOLVED.
MORE THAN 1000 ANALYSIS PLANS
HAVE BEEN ENACTED.
500 PEER-REVIEWED PUP
INDICATIONS HAVE RESULTED AND AT
PRESENT, THERE HAVE BEEN 89
INDEPENDENTLY-FUNDED ANCILLARY
STUDIES IN ADDITION TO THE NIH
SUPPORT FOR THE PARENT STUDY.
OF COURSE THE COHORT HAS AGED
OVER THE 20 YEARS OF FOLLOW-UP
SO THE MEAN AGE OF SURVIVORS ON
THE LEFT IS NOW MORE THAN 90 AND
ON THE RIGHT, MORE THAN 80% OF
THE PARTICIPANTS HAVE DIED THUS
Mr. OS NOW IS A COHORT OF A
BIT LESS THAN 1000 VERY ELDERLY
MEN, WHICH CONTINUES TO OFFER
UNIQUE ONGOING RESEARCH
OPPORTUNITIES.
WE ARE JUST IN THE MIDDLE OF THE
LATEST CYCLE OF NIA FUNDING.
Mr. OS CONTRIBUTED TO A
VARIETY OF ISSUES RELATED TO
AGING.
IT'S BEEN A MAJOR SOURCE OF
KNOWLEDGE ABOUT MUSCULOSKELETAL
AGING LIKE OST YORE PROSIS AND
SARCOPENIA.
BUT ALSO ACTIVE IN A NUMBER OF
OTHER AREAS AS ARE LISTED.
ON THE RIGHT ARE SHOWING SOME OF
THE PARADIGM CHANGING WORK WHICH
Mr. OS HAS BEEN A MAJOR
FACTOR.
A UNIQUE CONTRIBUTION OF
Mr. OS IS THE COLLABORATION
WITH THE STUDY OF OSTEOFRACTURES
WHICH IS A SIMILAR NIA-FUNDED
STUDY OF ABOUT 9000 WOMEN OF THE
SAME AGE RANGE AS Mr. OS.
INTENTION ALLEY, Mr. OS WAS
DESIGNED TO INCLUDE PHENOTYPIC
MEASURES THAT WERE IN MOST CASES
IDENTICAL TO THOSE IN THE SOF,
ENABLING A VARIETY OF SEX
COMPARISONS.
FOR INSTANCE HERE ON THE LEFT,
COMBINED ANALYSIS OF Mr. OS
AND SOF REVEALED THAT BOTH LOW
TRAUMA AND HIGH TRAUMA FRACTURES
HAVE THE SAME RELATIONSHIP TO
LOW BONE MINERAL DENSITY.
FINDING THAT SOME FUNDAMENTALLY
CHANGED HOW WE CONSIDER
FRACTURES IN OLDER PEOPLE BOTH
CLINICALLY AND IN RESEARCH
SETTINGS.
ON THE RIGHT, A SIMILAR ANALYSIS
IN SO.
AND Mr. OS SHOWS THAT
FRACTURES IN OLDER MEN ARE MUCH
MORE LIKELY TO BE RELATED TO
HIGH ACTIVITY AND TRAUMA
COMPARED TO WOMEN, FINDING WHICH
INFLUENCES IMPORTANT PUBLIC
HEALTH PREVENTIVE STRATEGIES.
Mr. OS HAS BEEN THE PLATFORM
FOR THE DEVELOPMENT OF IMPORTANT
NEW METHODS FOR EVALUATING
MUSCULOSKELETAL HEALTH.
ONE EXAMPLE IS THE USE OF
CENTRAL QCT IN FINITE ELEMENT
ANALYSIS OF BIOMECHANICAL BONE
STRENGTH AS AN ASSESSMENT OF
FRACTURE RISK.
ANOTHER MORE RECENT DEVELOPMENT
IS NOVEL WAY TO MEASURE MUSCLE
MASS.
THE SUMMARY OF THOSE RESULTS ARE
SHOWN HERE.
BASICALLY, MUSCLE MASS MOST
OFTEN HAVE BEEN ESTIMATED BY
USING DEXABASED MEASURES OF LIEN
MASS, AN APPROACH THAT IS
FUNDAMENTALLY FLAWED BECAUSE
LIEN MASS IS MADE UP OF A
VARIETY OF TISSUES OTHER THAN
MUSCLE.
TO REMEDY THIS, BILL EVANS AND
MARK HELLERSTEIN AT BERKLEY TOOK
ADVANTAGE OF THE FACT THAT
CREATINE IS VIRTUALLY ENTIRELY
LOCALIZED IN CONTRACT ON MUSCLE
AND DEVELOPED AN APPROACH THAT
USES D3 CREATINE TO MEASURE THE
CREATINE POOL AND ENHANCE
ACCURATE LEMUSEL MASS IN-VIVO.
AND THIS TECHNIQUE WAS APPLIED
INITIALLY ON A LARGE-SCALE IN
Mr. OS AND WE USED IT TO
INVESTIGATE A VARIETY OF
QUESTIONS.
AND THE UPPER MIDDLE PANEL, I
HAVE ILLUSTRATED HOW D3 CREATINE
MUSCLE MASS AND DEXAMEASURES
COMPARE AS A PERCENT OF BODY
WEIGHT IN ABOUT 1400 Mr. OS
MEN.
MUSCLE MASS BY D3 CREATINE IS IN
DARK BLUE WITH MEN ARRAYED
ACROSS THE AXIS HERE, HIGH
MUSCLE MASS ON THE LEFT, LOWER
MUSCLE MASS ON THE RIGHT.
DEXAMESS BASED MEASURES ARE
SHOWN, INCLUDING BONE MASS IN
BLACK AT THE TOP, FAT MASS AND
TOTAL LEAN MASS.
OBVIOUSLY D3 CREATINE MUSCLE
MASS IS VERY DIFFERENT THAN
TOTAL LEAN MASS AND POORLY
CORRELATED WITH IT.
AND SHOWN IN THE YELLOW DOTS AND
IN THE SCATTER PLOT IN THE UPPER
RIGHT, IS SHOWN THAT D3 CREATINE
MUSCLE MASS IN LEAN MASS ARE NOT
CORRELATED.
BASICALLY THEY ARE QUITE
DIFFERENT MEASURES.
IN THE BOTTOM GRAPHS, ARE THE
RELATIONSHIP OF WALKING SPEED
AND LOWER EXTREMITY POWER TO
QUARTILES OF D3 CREATINE MUSCLE
MASS IN THE OPEN BARS.
AND QUARTILES OF LEAN MASS IN
THE GRAY BARS.
CLEARLY A MEASURE -- THESE
MEASURES OF PHYSICAL FUNCTION
ARE MUCH MORE RELATED TO D3
CREATINE MUSCLE MASS THANG TO
LEAN MASS.
WE HAVE SHOWN THERE IS SIMILAR
RELATIONSHIPS THAT D3 CREATINE
MUSCLE MASS WITH FRACTURES,
DISABILITY, FRAILTY AND
MORTALITY ED.
BASICALLY THESE MEASURES OF
MUSCLE MASS HAVE VERY MUCH
CHANGED THE FIELD OF SARCOPENIA
RESEARCH.
D3 CREATINE MEASURES HAVE ALSO
ALLOWED US TO RECONSIDER THE
CONCEPT OF MUSCLE QUALITY.
IT'S LONG BEEN KNOWN THAT MUSCLE
PERFORMANCE DECLINES WITH AGE.
IN THE ABSENCE OF MAJOR CHANGES
IN LEAN MASS, A FINDING THAT HAS
BEEN INTERPRETED AS EVIDENCE
THAT MUSCLE QUALITY DECLINES
INDEPENDENT OF MUSCLE MASS.
HOWEVER, WHEREAS MEASURES OF
LEAN MASS CHANGE LITTLE OVER
TIME IN Mr. OS, AS IS SHOWN BY
THE LEFT HAND BARS ON THE GRAPH,
D3 CREATINE MUSCLE MASS IN THE
MIDDLE BARS DECLINES QUICKLY AND
IN PROPORTION TO THE DECLINES IN
PERFORMANCE MEASURES, WALKING
SPEED IN THE RIGHT BARS.
THUS CONTRARY TO PREVIOUS
BELIEF, THIS FINDING SUGGESTS
THE PRIMARY IMPORTANCE OF CHANGE
IN MUSCLE MASS IN DETERMINING
THE DECLINE IN PHYSICAL
PERFORMANCE WITH AGE.
THIS DOESN'T MEAN THAT MUSCLE
QUALITY ISN'T IMPORTANT.
AND THE AVAILABILITY OF ACCURATE
MUSCLE MASS MEASUREMENTS WITH D3
CREATINE ALLOWS US TO MORE
EFFECTIVELY CALIBRATE THE
CONTRIBUTIONS OF MUSCLE MASS
VERSUS QUALITY.
FOR INSTANCE, ON THE RIGHT, IS
SHOWN THE PERCENT OF Mr. OS
MEN WITH ABNORMAL WALKING SPEED
ON THE Y AXIS.
AS A FUNCTION OF QUARTILES OF
BOTH D3, CREATINE MUSSEL MASS ON
THE RIGHT.
AND TO THE MUSCLE DENSITY BY CT
ON THE BOTTOM.
LOW MUSCLE DENSITY BY QCT IS A
REFLECTION OF MUSCLE FAT
ACCUMULATION WHICH IS IT LINKED
TO MUSCLE QUALITY AND
PERFORMANCE.
HERE, ITS CLEAR THAT THE MEN
WITH THE LOWEST MUSCLE MASS AND
THE LOWEST US MUSCLE DENSITY
HAVE THE WORST WALKING SPEED.
AND THAT BOTH MEASURES
CONTRIBUTE INDEPENDENTLY TO
WALKING SPEED.
WALKING SPEED IS SHOWN HERE BUT
WE FOUND SIMILAR RELATIONSHIPS
WITH OTHER MEASURES OF
PERFORMANCE AS WELL AS
DISABILITY AND MORTALITY.
THIS IS ANOTHER EXAMPLE OF HOW
Mr. OS RECONFIGURING
SARCOPENIA RESEARCH.
THE ABILITY OF THE Mr. OS
BIOBANK WITH LONGITUDINAL
PHENOTYPING MAKES POSSIBLE
UNIQUE OPPORTUNITIES TO EXAMINE
THE BIOLOGICAL UNDERPINNINGS OF
AGING.
ONE DIRECTION WE HAVE TAKEN IS
TO USE LARGE-SCALE PROTEOMICS.
IN ABOUT 2015, WE UNDERTOOK WHAT
WAS AT THAT POINT THE LARGEST
POPULATION BASED PROTEOMICS
EXPERIMENT.
WE USED A NOVEL HIGH-THROUGHPUT
MASS SPEC BASED PROTEOMICS
APPROACH DEVELOPED AT SPECIFIC
NORTHWEST NATIONAL LABS TO
MEASURE THE ABUNDANCE OF SERUM
PROTEINS IN ABOUT 2500 MEN AT
BASELINE AND EXAMINED THEIR
ASSOCIATIONS WITH INCIDENT
LONGEVITY, DEFINED THOSE
REACHING AT LEAST THE 90th
PERCENTILE OF SURVIVAL DURING 15
YEARS OF FOLLOW-UP FOLLOWING
BASELINE.
WE IDENTIFIED A GROUP OF
PROTEINS ASSOCIATED WITH
LONGEVITY SHOWN IN THE VOLCANO
PLOT.
MOST OF THESE PROTEINS WERE
LOWER ABUNDANCE IN THE
LONG-LIVED MEN, COMPARED TO MEN
WHO DIED EARLIER.
WE MAPPED THESE PROTEINS TO
BIOLOGICAL PATHWAYS AND MANY
WERE RELATED TO INFLAMMATION.
AS SHOWN IN THE TABLE ON THE
RIGHT, THESE PROTEINS WERE ALSO
ASSOCIATED WITH BETTER STATUS IN
ADDITION TO LONGEVITY.
IN A DIFFERENT TO LONGEVITY, WE
EXAMINED ASSOCIATIONS OF SERUM
PROTEINS WHERE OTHER PHENOTYPES,
INCLUDING MORTALITY WITHIN FIVE
YEARS OF BASELINE AND BONE LOSS
FOLLOWING BASELINE.
INTERESTINGLY, THERE WERE
CONSIDERABLE OVERLAP IN THE
PROTEINS ASSOCIATED WITH THE
THREE PHENOTYPES AS IS SHOWN.
AND PERHAPS NOT UNEXPECTEDLY, AS
SHOWN IN THE HEAT MAP, THE
ASSOCIATIONS WITH MORTALITY AND
BONE LOSS WERE IN THE OPPOSITE
DIRECTION FROM THOSE WITH
LONGEVITY.
ADDITIONAL FINDINGS WAS THAT AS
DEATH APPROACHED, THE ABUNDANCE
OF THOSE PROTEINS ASSOCIATED
WITH LONGEVITY, TENDED TO
INCREASE ON THE LEFT AND TO
REVERT TO LEVELS SEEN IN CONTROL
MEN.
THE PROTEINS NOT SOCIALED WITH
LONGEVITY DID NOT CHANGE.
THIS FINDING IF REPLICATED HAS
OBVIOUS IMPLICATIONS FOR THE
UNDERSTANDING OF THE BIOLOGY OF
LONGEVITY AND MORTALITY.
BUT ALSO THE UNDERSTANDING OF
HOW PROTEOME CHANGES WILL
IMPLEMENTS WE IDENTIFY
BIOMARKERS OF IMPORTANT
AGE-RELATED OUTCOMES.
THESE PROTEOMICS CHANGES IN
Mr. OS WERE AN IMPORTANT PART
OF THE DESIGN OF THE CURRENT
CYCLE OF THE LONGEVITY
CONSORTIUM.
THE LONGEVITY CONSORTIUM IS A
LARGE NIA-FUNDED UNDERTAKING
THAT HAS ANIMAL COHORT BASE AND
COMPUTATIONAL PROJECTS.
THERE ARE ALL UNDERSTANDING THE
BIOLOGY OF LONGEVITY AND
IDENTIFYING POSSIBLE
INTERVENTION TO INCREASE HEALTH
PROTEOMICS IS A IMPORTANT PART
OF THE WORK AND MASS SPEC
PROTEOMICS IS BEING DONE ON
SERUM OBTAINED FROM FOUR
COHORTS, Mr. O16789, SOF,
HEALTH AB R AND CHS -- Mr. OS.
TO COMPARE LONG-LIVED
INDIVIDUALS TO CONTROLS.
METABOLOMICS IS ALSO BEING DONE
AND SYSTEMS APPROACHES ARE BEING
USED TO ANALYZE THE COMBINED
DATA PRELIMINARY ANALYSIS OF THE
PROTEOMICS FINDINGS LOOKS LIKE
TWO-THIRDS OF THE PROTEINS THAT
WE PREVIOUSLY FOUND TO BE
ASSOCIATED WITH LONGEVITY IN
Mr. OS ARE ALSO ASSOCIATED IN
COMBINED COHORTS AND WE ARE ONCE
AGAIN SEEING THE
PREVIOUSLY-NOTED CHANGES
ASSOCIATED WITH IMPENDING DEATH.
WE HOPE THESE STUDIES WILL
CONSIDERABLY INCREASE OUR
UNDERSTANDING OF THE BIOLOGY OF
LONGEVITY INCREASE BIOMARKER
DISCOVERY AND DESIGN
INTERVENTIONS.
FINALLY, THE IMPORTANCE OF A
MICROBIOME TO HUMAN HEALTH HAS
BECOME OBVIOUS BUT THERE IS
LIMITED UNDERSTANDING OF HOW THE
GUT MICROBIOME CHANGES
THROUGHOUT ADULTHOOD.
AND HOW THOSE CHANGES INFLUENCE
HOST PHYSIOLOGY.
ALMOST 10 YEARS AGO WE COLLECTED
STOOL SAMPLES FROM ABOUT 1000
MEN IN Mr. OS AND UNDERTOOK 16
GENOTYPING.
A NUMBER OF ANALYSIS HAVE BEEN
PUBLISHED, INCLUDING THE
ASSOCIATIONS OF THE MICROBIOME
WITH THE MEASURES ON THE RIGHT.
I'LL SPECIFICALLY MENTION ONE
COLLABORATION WITH THE GROUP AT
THE INSTITUTE FOR SYSTEMS
BIOLOGY IN SEATTLE IN WHICH WE
EXAMINED THE MICROBIOME AND AG
AGING.
THE CURRENT CONCEPT OF HOW THE
GUT MICROBIOME REALITIES TO
AGING AND HEALTH IS SHOWN THE
LEFT.
ESSENTIALLY AS AGING INCREASES,
THOSE WHO AGE WELL PRESUMABLY
HAS A LESSER ACCUMULATION OF
DETRIMENTAL BACTERIAL SPECIES OR
PATHOBIOMES.
ACQUIRE MORE PROTECTEDDIVE
SPECIES AND AS A RESULT, HAVE
LESS INFLAMMATION AS ONE MAJOR
RESULT.
WE EXAMINED THIS ISSUE IN
CONCERT WITH THE COHORT FROM
SEATTLE, ABOUT 3600 ADULTS
HEAVILY PHENOTYPED AND OF A
BROAD AGE RANGE AND DATA FROM
THE AMERICAN GUT PROJECT, ABOUT
1600 ADULTS WITH A BROAD AGE
RANGE AS WELL.
THE MAJOR FINDINGS OF OUR
ANALYSIS WERE FIRST THAT
INDIVIDUAL GUT MICROBIOMES
BECAME INCREASING MORE UNIQUE TO
EACH INDIVIDUAL WITH AGE
STARTING IN MID TO LATE
ADULTHOOD AS SHOWN ON THE LEFT.
THE GRAY CURVE IS UNIQUENESS
SCORE INCREASED WITH AGE AT THE
BOTTOM AND IN THE HUMAN GUT
PROJECT, ABOVE.
THIS UNIQUENESS WAS POSITIVELY
ASSOCIATED WITH MICROBIAL
METABOLIC MARKERS PREVIOUSLY
IMPLICATED IN IMMUNE REGULATION,
INFLAMMATION, AGING AND
LONGEVITY.
INCLUDING A NUMBER OF END GOALS.
SECOND UNIQUENESS WAS ASSOCIATED
WITH MORE HEALTHY AGING.
IN THE UPPER RIGHT GRAPH, THE
RELATIVE ABUNDANCE OF ONE OF THE
CORE TAX DECREASE WITH AGE IS
PLOTTED WITH AGE IN Mr. OS.
HEALTHY INDIVIDUALS ON THE LEFT
SHOW A DECLINE IN THIS WHEREAS
THIS PATTERN WAS ABSENT IN THOSE
WHERE WORSE HEALTH.
FINALLY IN THE OLDEST Mr. OS
MEN RETENTIONFUL HIGH RELATIVE
ABUNDANCES AND LOW GUT
MICROBIOME UNIQUENESS.
BOTH ASSOCIATED WITH
SIGNIFICANTLY DECREASED SURVIVAL
IN THE COURSE OF A FOUR-YEAR
FOLLOW-UP.
THE ASSOCIATION WITH UNIQUENESS
TO MORTALITY IS SHOWN IN THE
LOWER RIGHT.
THE HYPOTHESES WE FORMED FROM
THIS WORK ARE SHOWN HERE WITH
HEALTHY AGING BEING ASSOCIATED
WITH REDUCTIONS AND CORPS TAXA
AND THE ACCUMULATION OF UNIQUE
TAXA WITH ASSOCIATED METABOLIC
CHANGES WHILE LESS HEALTHY AGING
IS NOT.
THIS IS OBVIOUSLY STILL A VERY
INVESTIGATION SO THE STORY
CONTINUES TO UNFOLD.
THE MICROBIOME WORK IN Mr. OS
HAD A MULTIPLIER EFFECT.
Mr. OS ANALYSIS OF THE GUT
MICROBIOME ASSOCIATIONS WITH
BONE MASS AND STRUCTURE LED TO A
FOLLOW ON RO1 IN A COLLABORATION
BETWEEN Mr. OS AND FRAMINGHAM
WHERE THERE ARE SHARED BONE
PHENOTYPES AND AVAILABLE STOOL
SPECIMENS.
AS PART OF THAT COLLABORATION WE
ARE LEVERAGING MORE IN-DEPTH
MEHTA GENOME SEQUENCING AT THE
BRODE TO DIG DEEPER INTO THE
MICROBIOME BONE RELATIONSHIPS.
AS WELL WITH THAT SHARED MEHTA
GENOME DATA, RESEARCHING A
NUMBER OF AREAS RELEVANT TO
AGING SHOWN HERE ON THE RIGHT
HAVE BEEN CATALYZED.
FOR INSTANCE, THE AVAILABILITY
OF THE ACCURATE D3 CREATINE
MUSCLE MASS MEASURES MAKE
MICROBIOME MUSCLE MASS
ASSOCIATIONS A PARTICULARLY
INTERESTING TARGET.
ON THE LAST SLIDE I WANT TO
ACKNOWLEDGE THE AMAZING
CONTRIBUTIONS OF OUR
PARTICIPANTS.
MANY INVESTIGATORS HAVE
CONTRIBUTED, PARTICULARLY THE
CURRENT CO-PIs AND THE PIs
OF THE CONTRIBUTING CENTERS AS
WELL AS THE FUNDING FROM THE NIH
THAT HAVE MADE ALL OF THIS
POSSIBLE.
THANK YOU VERY MUCH.
>>TERRIFIC!
THANK YOU DR. ERIC ORWOLL.
GREAT PRESENTATION AND OVERVIEW
IN EXPLAINING HOW THE VAST
AMOUNT OF RESEARCH THAT WAS DONE
IN THE Mr. OS COHORT.
I'LL OPEN IT UP FOR QUESTIONS
FROM OUR PANEL.
SHELLY?
>>HARRY, CONTHE GRATES.
WHAT A TOUR DE FORCE AND WHAT A
PRODUCTIVE COHORT THAT HAS MADE
SUCH IMPORTANT DISCOVERIES.
THE QUESTION I HAD RELATES TO
THE APPLICATION OF D3 CREATINE
IN AGING STUDIES.
THE CREATINE CLEARANCE WOULD BE
EXPECTED TO DECREASE WITH
ADVANCING AGE AND DUE TO OTHER
INCREASING PREVALENCE OF KIDNEY
DISEASE WITH ADVANCING AGE.
HOW MIGHT THAT EFFECT CREATINE
CLEARANCE AND THE ESTIMATES OF
SKELETAL MUSCLE MASS BASED ON D3
CREATINE DIPOLLUTION?
>>GREAT QUESTION.
OBVIOUSLY THERE ARE A NUMBER OF
ELEMENTS OF CREATINE BIOLOGY
THAT HAVE TO BE TAKEN INTO
ACCOUNT HERE.
ONE BEING RENAL FUNCTION.
AND WE HAVE LOOKED THAT PRETTY
CAREFULLY AND IT TURNS OUT THAT
CHANGES IN RENAL FUNCTION DON'T
MAKE MUCH DIFFERENCE PRIMARILY
BECAUSE WHAT YOU'RE LOOKING AT
HERE, THE ENDPOINT IS CREATINE
RATIO TO UNLABELED CREATINE.
SO THE CREATININE FUNCTION
REALLY DOESN'T PLAY A PART SINCE
YOU'RE LOOKING AT THE RATIO.
AND THE LABELED CREATINE AND THE
UNLABELED CREATINE ARE HANDLED
BASICALLY THE SAME BY THE
KIDNEY.
AT ANY RATE, RENAL FUNCTION
DOESN'T SEEM TO PLAY MUCH OF A
PART.
>>THANK YOU FOR THAT: I ALSO
WAS GOING TO ASK --
[ INAUDIBLE ]
>>ALSO IMPORTANT QUESTIONS.
SO HAVEN'T BEEN COMPLETELY
EXPLORED, OUR EXPERIENCE WITH
Mr. OS IS OF COURSE WITH
AMBULATORY COMMUNITY DWELLING
MEN, RATHER THAN THE KIND OF ILL
CONDITIONS THAT YOU ALLUDED TO.
THOSE STUDIES ARE ONGOING.
AND I THINK THOSE ANSWERS WILL
COME IN THE FUTURE.
>>FOLLOW-UP --
[ INAUDIBLE ]
WE END UP WITH A LOT OF
WOMEN -- IT WOULD BE WONDERFUL
TO BE ABLE TO DO COGNITIVE
FUNCTIONS --
[ INAUDIBLE ]
>>SO COGNITION WITH SOME BROAD
MEASURES AT LEAST, LIKE TRAILS
BEE AND GENERAL STUFF, HAVE BEEN
PART OF THE Mr. OS PHENOTYPING
FROM THE BEGINNING.
SO, WE HAVE SOME ESTIMATES OF
COGNITION OVER THE 20-YEAR SPAN.
AND THAT'S BEEN THE SOURCE OF A
NUMBER OF PUBLICATIONS.
I THINK GOING FORWARD COGNITION
MIGHT BE A REALLY INTERESTING
THING TO INCLUDE.
WE THOUGHT ABOUT BRAIN
DONATIONS.
HAVEN'T DONE ANYTHING ABOUT IT.
I GUESS THIS IS A GOOD TIME TO
ENCOURAGE PEOPLE WHO WANT TO
JUMP IN TO TAKE ADVANTAGE OF THE
Mr. OS COHORT TO DO SO WITH
ANCILLARY STUDIES.
SO, COME AT US.
>>THANK YOU.
REALLY GREAT TALK.
AND I GUESS IN THESE KINDS OF
LONGITUDINAL STUDIES IN THE
CONTEXT OF AGING ON AN
INDIVIDUAL BASIS, YOU CAN GET
ENTRAPPANCY OF CHRONOLOGICAL AGE
VERSUS THE PATTERNS THAT YOU'RE
SEEING IN YOUR DATA OR SOME --
INDIVIDUALS ARE CHRONOLOGICALLY
OLDER OR THE OTHER WAY AROUND?
IS THAT IN THIS CONTEXT, DID
Mr. OS GIVE YOU INSIGHTS INTO
AGING MECHANISMS?
IS THAT ONE OF YOUR APPROACHES?
>>YOU MEAN SORT OF BIOLOGICAL
CLOCKS?
THAT KIND OF THING?
>>WE HAVE THOUGHT ABOUT
TRANSFORMING PROTEOMICS DATA AND
WE ARE ADDITIONALLY GAINING SOME
EXPERIENCE WITH METABOLOMICS AND
OTHER OMICS INTO AN AGING CLOCK
OR BIOLOGICAL CLOCK.
VIOLENT DONE THAT SO FAR.
I THINK THERE ARE SOME
OPPORTUNITIES TO DO SO BUT RIGHT
NOW, WE DON'T HAVE PROTEOMICS
MEASURES OTHER THAN AT BASELINE.
OBVIOUSLY WHAT WOULD BE IDEAL IS
TO HAVE LONGITUDINAL MEASURES OF
PROTEOMICS, METABOLOMICS AND
OTHER THINGS TO INCORPORATE.
THAT'S ONE OF THE THINGS THAT I
THINK WOULD REALLY BENEFIT THE
BIOLOGICAL CLOCK DEVELOPMENT AND
HYPOTHESIS.
SO, IT'S A GREAT DIRECTION.
HAVEN'T PROCEEDED WITH IT YET.
>>THE LONGITUDINAL WOULD BE
GREAT.
SOUNDS LIKE IT WOULD BE GREAT TO
HAVE EXTRA FUNDING TO DO THAT.
>>YES, IT WOULD, INDEED.
[ LAUGHS ]
>>AND RELATED TO THAT, I GUESS
IT WOULD BE MORE OF A
LONGITUDINAL QUESTION.
WHEN YOU SEE THESE CHANGES, YOU
ALWAYS ASK ARE THEY CAUSAL OR
COMPENSATORY?
I THINKFUL INFLAMMATORY STUFF AS
BAD BUT I GUESS YOUR DATA
ANALYSIS WILL GET INTO THAT AS
WELL?
>>YES, EXACTLY.
THESE ARE OBSERVATIONAL STUDIES.
ALTHOUGH WE CAN INFER COGNITION,
WE CAN'T DEMONSTRATE IT.
SO, FOR INSTANCE, THE LONGEVITY
CONSORTIUM IS LOOKING NOT ONLY
AT THESE SORTS OF OBSERVATIONAL
STUDIES BUT ALSO HOPING TO
DEVELOP INTERVENTIONS THAT CAN
BE TESTED.
BOTH IN ANIMAL MODELS AND IN
HUMAN MODELS TO GET MORE
CAUSATION.
>>THANK YOU.
>>MONICA?
>>YES, SO, THAT WAS A FANTASTIC
TALK.
I REALLY ENJOYED IT AND SORRY TO
BRING THE WOMAN PERSPECTIVE IN
HERE BUT A LOT OF WOMEN ARE
TAKING DRUGS, ANTI-PROSIS DRUGS,
FOUR EXTENDED PERIODS OF TIME.
AND I'M CURIOUS IF ANY -- IF
THESE INTERVENTIONS ARE GIVEN TO
MEN AND IF THERE IS ANYTHING
UNDERSTOOD ABOUT THEIR IMPACT --
OBVIOUSLY IN BONE -- BUT MUSCLE
HEALTH, ESPECIALLY USING SOME OF
THE NEW TECHNOLOGIES?
>>YES, IT'S A GREAT QUESTION.
IT TURNS OUT THAT -- OBVIOUSLY
OSTEOPOROSIS HAPPENS IN MEN AS
WELL.
NOT INFREQUENTLY.
AND THAT OSTEOPOROSIS THERAPY IN
MEN IS UNDERTAKEN
PROPORTIONATELY MUCH LESS THAN
IN WOMEN.
THERE ARE SOME MEN IN Mr. OS,
A SMALL PROPORTION, THAT USE
OSTEOPOROSIS THERAPIES.
AND WE THOUGHT ABOUT HOW WE
COULD LEVERAGE THE TREATMENTS TO
TRY AND UNDERSTAND THEIR
INFLUENCE.
WE HAVEN'T UNDERTAKEN THOSE
STUDIES.
THERE ARE STUDS OUTSIDE Mr. OS
THAT DO SUGGEST THAT WHAT YOU
PAUSE IT MAY BE TRUE.
THAT INTERVENTIONS DIRECTED AT
BONE MAY HAVE INFLUENCERS ON
MUSCLE.
AGAIN, NOTHING VERY DEFINITIVE
AS OF YET BUT THE RELATIONSHIP
BETWEEN MUSCLE AND BONE IS
INTIMATE AND YOU WOULD EXPECT
THAT SOME INTERVENTION THREAT
WOULD INFLUENCE MUSCLE.
CAN'T CONCLUDE VERY MUCH FROM
THOSE STUDIES YET.
SORRY ABOUT THE NOISE.
I'M IN CALIFORNIA AND THEY ARE
CUTTING DOWN A TREE OUTSIDE OF
MY WINDOW.
>>ALMOST AS BAD AS JEN'S
JACKHAMMERS YESTERDAY.
>>YES.
>>THANK YOU FOR A GREAT
PRESENTATION.
JUST A FOLLOW-UP TO DR. SNYDER'S
COMMENT.
I WONDER IF IN ADDITION TO
COGNITION YOU MIGHT THINK OF
COLLECTING SOME ULTIMATE
BIOMARKERS AND IMAGING DATA.
THE REASON I SAY THIS IS BECAUSE
SO MUCH IMPRESSED IN ASSESSING
THE RELATIONSHIP BETWEEN
PRE-CLINICAL ALZHEIMER'S AND
GAIT CHANGES AND EVENTUALLY
MOBILITY CHANGES.
YOUR COHORT IS VERY WELL PLACED
GIVEN YOU HAVE BEEN FOLLOWING UP
FOR SUCH A LONG TIME.
TO START COLLECTING SOME
BIOMARKERS DATA ON THE
ALZHEIMER'S SIDE AND THAT COULD
BE DONE AS AN INDEPENDENT RO1 OR
ANCILLARY STUDY.
BUT I WONDER IF YOU THOUGHT
ABOUT THAT AS WELL.
>>WE HAVE THOUGHT ABOUT IT.
AGAIN, WE ARE A BUNCH OF
PRIMARILY A BUNCH OF
MUSCULOSKELETAL TYPES RATHER
THAN COGNITION AND ALZHEIMER'S
TYPES.
BUT I AGREE THE STUDY IS VERY
WELL POSITIONED TO LOOK AT
BIOMARKERS FOR COGNITION.
OVER 20 YEARS.
SO AGAIN, THIS IS A PERFECT KIND
OF ANCILLARY STUDY THAT I THINK
SHOULD BE ENTERTAINED BY PEOPLE
IN COGNITION.
SO AGAIN, BRING IT ON.
>>THANK YOU.
>>ALL RIGHT, I THINK WE HAVE
TIME FOR THE LAST TWO QUESTIONS.
>>WHAT PROPORTION OF THE COHORT
WAS MINORITIES AND
NATIVE-AMERICANS?
I'M CONCERNED ABOUT -- THE
REASON I SAY THAT IS, WORKING
WITH CHEROKEES FOR SO LONG, A
LONG TIME AGO I WAS TOLD THAT
THEY ARE LACTOSE INTOLERANT AND
I THINK IT'S A COMMON TRAIT
AMONG A LOT OF NATIVE-AMERICANS.
AND THAT MAY ACCOUNT FOR LODI
TERRY CALCIUM INTAKE -- ACCOUNT
FOR LOW DIAGNOSIS OF CALCIUM IN
TAKE.
LODI TERRY.
>>LESS THAN WE HOPED DESPITE
ACTIVE ATTEMPTS TO ENCOURAGE IT.
ABOUT 10% WAS OVERALL COHORT.
WE CONSIDERED TO BE MINORITY.
A VAR SMALL PERCENTAGE WERE
NATIVE.
WE THOUGHT ON NUMEROUS OCCASIONS
HOW TO LEVERAGE EVEN THAT SMALL
PROPORTION OF MINORITIES AND
JUST HAVEN'T THOUGHT WE HAD THE
POWER TO DO ANYTHING VERY
EFFECTIVE IN THAT REGARD.
OBVIOUSLY WE WOULD BE OPEN TO
ANY NOVEL APPROACH THAT IS MIGHT
ALLOW US TO TAKE ADVANTAGE OF
THE SMALL PROPORTION OF
MINORITIES THAT WE HAVE.
>>AND SUSAN?
>>ERIC, THAT WAS REALLY, REALLY
TERRIFIC.
AMAZING WORK THAT YOU HAVE DONE.
>>THANK YOU.
>>REALLY IMPRESSIVE.
A QUESTION FOR YOU.
SO, AS YOU KNOW, THERE IS SORT
OFOG GOING DEBATE IN THE BONE
WORLD WHETHER OR NOT WE SHOULD
REALLY USE FRAC OR NOT BECAUSE
IT'S MISSING IMPORTANT THINGS
SUCH AS FALLS AND I KNOW YOU SEE
THESE PEOPLE EVERY FOUR MONTHS.
SO THE QUESTION IS, HAVE YOU
THOUGHT ABOUT, OR DO YOU HAVE
FALLS DATA AND HAVE YOU THOUGHT
ABOUT RE-THINKING FRACS OR SOME
TYPE OF RISK PREDICTION WHICH
WOULD INCLUDE FALLS IN THIS MALE
POPULATION?
BECAUSE THAT WOULD JUST BE SO
VALUABLE TO BE ABLE TO GET A
BETTER RISK PREDICTION.
AND ALSO RATHER THAN 10 YEARS
OUT TO DO SOMETHING SHORTER THAT
WOULD BE CLINICALLY RELEVANT
LIKE FIVE YEARS OUT.
>>BOTH OF THOSE THINGS ARE
REALLY INTERESTING TO ME.
WE HAVE LOOKED AT FRAC.
AND Mr. OS IN COMPARISON AND
TOGETHER IN NUMEROUS
PUBLICATIONS.
MOST RECENTLY, NICK HARTLEY FROM
THE GROUP, HAS LOOKED AT THE
Mr. OS DATA TO EXAMINE EXACTLY
THOSE ISSUES.
THE INFLUENCE OF FALLS AND MOST
RECENTLY, THE INFLUENCE OF
MUSCLE AND MUSCLE DENSITY.
SO YOU MIGHT LOOK AT A COUPLE OF
HIS RECENTLY PUBLICATIONS.
IT LOOKS FROM THE Mr. OS
ANALYSIS THAT YOU MIGHT EXPECT A
CHANGE IN FRACS IN THE NEAR
FUTURE AND INCORPORATE QUESTIONS
ABOUT FALLS AND INCORPORATE
QUESTIONS ABOUT MUSCLE.
SO, IT'S BEEN VERY ACTIVE AS A
Mr. OSFRACS COLLABORATION.
LOOK FOR NICK HARVEY AND HIS
PUBLICATIONS.
>>THANKS.
OF.
>>THANK YOU AGAIN, ERIC FOR A
REALLY TERRIFIC TALK.
WE APPRECIATE YOU TAKING THE
TIME OUT SPEAKING WITH US AND
ANSWERING MANY QUESTIONS AND
PERHAPS YOU MAY BE CONTACTED IN
THE FUTURE WITH SOME NEW
COLLABORATIONS T SOUNDS LIKE.
>>I THINK THAT WOULD BE
FABULOUS.
THANK YOU VERY MUCH.
>>THANK YOU VERY MUCH.
ALL RIGHT, NEXT WE HAVE OUR NEXT
SPEAKER.
SO DR. RICHARD HODES WOULD YOU
LIKE TO INTRODUCE OUR NEXT
SPEAKER?
>>IT'S MY PRIVILEGE TO
INTRODUCE DR. SUSAN WHO WAS
APOINTED AS THE FOUNDING DEPUTY
DIRECTOR OF ARPH, AN AGENCY
WHICH NIH LOOKS AT WITH GREAT
INTEREST AS A PARTNER AND
COLLABORATIONS.
SUSAN HAS HAD A DISTINGUISHED
CAREER WHICH PROVIDES HER WITH A
STRONG BACKGROUND FOR
APPOINTMENT AS AN OUTSTANDING
FOUNDING DIRECTOR.
SHE PREVIOUSLY LED STRATEGY
ANALYSIS AND RISK MANAGEMENT FOR
ARPAH AND ACTING DEPUTY DIRECTOR
FOR A BIT OF TIME PRIOR TO THAT.
SHE WAS AT HRSA PRIOR TO THAT
WHERE SHE WAS THE FOUNDING
DIRECTOR FOR THE CENTER FOR
INNOVATION AND HEALTH RESOURCES
AND SERVED IN THE WHITE HOUSE
AND ASSISTANT DIRECTOR FOR
NATIONAL HEALTH SECURITY,
INTERNATIONAL AFFAIRS IN THE
OFFICE OF SCIENCE AND
TECHNOLOGY, OSDP.
OUR ACADEMIC BACKGROUND INCLUDED
FASFA DEGREE AND DOCTORATES FROM
YY OF WISCONSIN MAD SONG AND
MICROBIOLOGY AND IMMUNOLOGY AND
FELLOWSHIP IN AAAS AT STANFORD.
SO CAREER IN PUBLIC SERVICE AND
ACADEMICS THAT MAKE HER A STRONG
AND OPTIMAL CANDIDATE AND NOW
SELECTEE FOR THE POSITION OF
DEPUTY DIRECTOR OF ARPAH.
I THINK MANY OF US AT NIH AND
NIA AND IN THE COUNCIL LOOK
FORWARD TO HEARING FROM YOU.
SO ONE OF THE EARLIEST
OPPORTUNITIES WE INTERACT.
SO WELCOME, PLEASE TAKE IT AWAY.
>>THANK YOU!
I WAS ABLE TO JOIN FOR A LITTLE
BIT OF THE SCALE OF THAT
PRESENTATION AND I KEPT THINKING
TO MYSELF, A YEAR FROM NOW, I
WANT TO BE ABLE TO TELL A GREAT
STORY ABOUT THE RESEARCH WE HAVE
FUNDED AND THE POTENTIAL FOR IT
TO TRANSFORM SOME PART OF THE
ECOSYSTEM.
SO THANK YOU FOR LETTING ME JOIN
YOUR GROUP TODAY.
I'M HAPPY TO WALK YOU THROUGH
WHERE WE ARE, WHERE WE ARE GOING
AND THEN WELCOME QUESTIONS.
I KNOW WE ARE RUNNING A LITTLE
BIT OVER ON TIME BUT I BLOCKED
MY AFTERNOON OFF FOR THIS.
SO I CAN TAKE QUESTIONS IF YOU
ALL HAVE THE TIME TO DO THAT.
SO WHY DON'T I JUST JUMP IN.
AR APPROXIMATE.
AH, ADVANCED HEALTH RESEARCH
AGENCY ADVANCED PROJECTS
RESEARCH AGENCY FOR HEALTH
MODELS ADD DARPA.
OUR GOAL IS REALLY TO MAKE SURE
THAT WE ARE ACCELERATING BETTER
OUTCOMES FOR EVERYONE.
SIMILAR TO HOW DARPA REALLY
WORKED TO DISRUPT AND INNOVATE
WITHIN THE DEFENSE ARENA.
SO THEIR MISSION WAS VERY MUCH
STREAMLINED.
OF COURSE TO THE DEFENSE
ECOSYSTEMS.
OUR IS EVERYONE, THE AMERICAN
PUBLIC AND REALLY TRYING TO OPEN
UP EVERYTHING WE DO TO REALLY
FUND THOSE TRANSFORMATIONAL
ACTIVITIES WHERE 3-5 YEARS FROM
NOW OR 10 YEARS FROM NOW, WE SAY
TO OURSELVES, OH, MY GOSH, WE
NEVER THOUGHT WE WOULD GET HERE.
NEVER THOUGHT WE WOULD DO
SOMETHING TO SUPPORT SLOWING
DOWN OR REDUCING AGING.
WE WERE JUST HEARING ABOUT.
SOMETHING JUST SLIGHTLY
TRANSFORMATIONAL.
THAT'S OUR MISSION AND WHAT
DRIVES US EVERY DAY.
NEXT SLIDE.
WE ARE VERY FORTUNATE TO HAVE
SUCH GREAT SUPPORT FOR THIS
ADMINISTRATION.
SO PRESIDENT BIDEN WHO IS A
STRONG SUPPORTER FOR HEALTH AND
SCIENCE BOTH AT THIS TIME AND AS
VICE PRESIDENT, WAS REALLY
TRANSNORIMATIONAL IN SAYING WE
NEED AN AGENCY LIKE ARPAH, AN
ORGANIZATION THAT IS CONNECTED
TO WORLD CLASS RESEARCH
SCIENTISTS LIKE THOSE AT NIH BUT
WHO CAN TAKE ON THESE HIGH RISK,
HIGHER REWARD TASTES NO ONE ELSE
CAN TAKE.
WE UNDERSTAND THAT FAILURE IS
PART OF WHAT WE GOING TO BE
WORKING TOWARDS.
BUT WE TELL OURSELVES IT'S NOT
FAILURE IF YOU LEARN SOMETHING.
IF WE SHARED THAT LEARNING WITH
OTHERS.
THAT'S WHERE WE ARE PLACED AND
WE WANT TO MAKE SURE THAT WE ARE
JUST BREAKING THE MOLD ON HOW WE
SUPPORT FUNDAMENTAL RESEARCH AND
THE DEVELOPMENT OF COMMERCIAL
PRODUCTS THAT ARE AVAILABLE TO
EVERYONE IN THE HEALTH
ECOSYSTEM.
NEXT SLIDE.
WE TALK A LOT RIGHT NOW AS WE
ARE BUILDING THE AGENCY ABOUT
WHAT IS IT THAT IS DRIVING US?
AND WE ANCHOR OURSELVES IN THE
CONCEPT OF THE SLOW SPUTNIK
MOMENTS.
WE THINK ABOUT WHEAT ARE IN AN
ERA OF COMPLEX TECHNOLOGY WITH
MASSIVE ECONOMIC AND SOCIAL
DISRUPTIONS.
POWERFUL BIOLOGICAL FACTORS
INCLUDING WHAT WE LIVED THROUGH,
THE PANDEMIC, BUT ALSO KNOWING
EMERGING BIOTECHNOLOGIES ARE
CHANGING ALMOST DAILY, WEEKLY,
MONTHLY AND THERE IS SO MUCH
POTENTIAL TO LEVERAGE THESE
TECHNOLOGIES TO BE
TRANSFORMATIONAL.
OUR PROMISE IS OUR PROGRAM
MANAGERS WHICH WE WILL TALK
ABOUT, THEY ARE THE ENGINE THAT
DRIVES US, THEY WILL DESIGN,
BUILD AND LAUNCH THESE SOLUTIONS
TO CREATE THE BEST VERSIONS OF
OUR HEALTH FUTURE.
NEXT SLIDE.
SO MUCH LIKE KNOWING WHAT
ANCHORS US IS THERE IS A SPUTNIK
MOMENT, A NEED FOR
TRANSFORMATIONAL APPROACHES TO
DISRUPTION AND INNOVATION IN THE
HEALTH ECOSYSTEM.
WE ALWAYS ARE CHALLENGING
OURSELVES WITH THESE MANAGE IF
STATEMENT.
IMAGINE IF YOU COULD TRANSFORM
THE ECOSYSTEM.
A FEW EXAMPLES HERE.
WHAT IF WE HAD CELL THERAPY THAT
COULD BE BUILT AND ASSEMBLED ON
DEMAND?
AND READILY PROGRAMMED FOR EACH
NOW DISEASE TARGET?
WHAT IF MRIs COULD BE
DELIVERED IN YOUR HOME?
WHAT ABOUT A PERSONALIZED CANCER
VACCINE COST THE SAME AS A CUP
OF COFFEE?
IF WE ARE ABLE TO ACHIEVE THIS
WITHIN THE HEALTH ECOSYSTEM, WE
COULD ALL REALIZE A BETTER
HEALTH FUTURE.
NEXT SLIDE.
SO, WHERE WE ARE PLACED, WE SORT
OF LOOK AT IT AS HAVING THE BEST
OF BOTH WORDS WORLDS.
ON THE ONE HAND, WE HAVE DIRECT
AUTHORITY AND DIRECT
RELATIONSHIP WITH HHS SECRETARY.
SO WE HAVE THE ABILITY TO GO AND
DIRECTLY SORT OF SEEK GUIDANCE
AND OFFER SOLUTIONS AND HAVE
THAT RELATIONSHIP BUT WE ARE
ALSO DIRECTLY CONNECTED TO OUR
COLLEAGUES AT NIH.
SO WE ARE A DOTTED LINE TO THE
NIH DIRECTOR AND WHAT WE ARE
HOPING TO DO IS BUILD OUT THE
NIH AND ICs AS PARTNERS.
KEY PARTNERS, INDIVIDUALS WHO
HAVE SUCH DEPTH AND BREATH OF
EXPERIENCE IT WILL ONLY ALLOW US
TO BECOME BETTER AS WE DEVELOP
OUR PROGRAMS AND HIRE OUR
PROGRAM MANAGER BY BEING THIS
CONNECTION TO OUR NIH
COLLEAGUES.
WE GENERALLY HAVE TWO BIG SIDES
OF THE ORGANIZATION.
WE HAVE OUR PROGRAM MANAGERS AND
WE'LL TALK ABOUT THOSE.
THOSE ARE THE ONES THAT ARE
REALLY GOING TO DRIVE WHAT WE DO
AS AN AGENCY.
AND THEN WE HAVE BUSINESS TEAM
MEMBERS.
SO THOSE ARE THE ONES THAT KEEP
THE LIGHTS ON AND MAKE SURE THAT
FOLKS GET PAID AND WE HAVE SEATS
TO SIT IN AND CONTRACTS TO BE
LET AND SO IT'S THOSE TWO LARGE
DIVISIONS.
AND AT A GLANCE, WE RECEIVE 1--
ONE BILLION DOLLARS IN.
IF YOU Y22 AND ANOTHER WORN.5 IN
FY23 -- 1.5 -- WE HAVE 2 1/2
BILLION DOLLARS WE ARE LOOKING
TO EXPEND OVER THE NEXT COW OF
YEARS.
EVERYTHING WE DO IS EXTRAMURAL.
IT'S GOING TO BE DISEASE
AGNOSTIC AND THE MONEY GOES OUT.
WE DON'T HAVE BRICKS AND MORTAR
OR LABS.
THE PROGRAM MANAGERS ARE THE
ENGINE.
THEY DRIVE THE IDEAS AND THEY
DRIVE THE DECISION-MAKING.
OUR GOAL IS TOW REMAIN LEAN AND
NIMBLE.
WHEN YOU LOOK AT HOW BIG OF AN
ORGANIZATION WE WILL BE, WE HOPE
TO HAVE A VERY BALANCED APPROACH
BETWEEN THE PROGRAM MANAGERS AND
THE BUSINESS TEAM MANAGERS BUT
THE TOTAL FOOTPRINT OF
POTENTIALLY 100 OR SO PROGRAM
MANAGERS DEPENDING ON THE BUDGET
AND THEN THE BUSINESS SIDE WE'LL
HAVE 100 OR SO BUSINESS MEMBERS.
AND THE GOAL IS TO FUND THIS
HIGH UNCERTAINTY, HIGH
CONSEQUENCE RESEARCH.
SO THINGS THAT ARE ON THE CUSP
OF RISK THAT NO ONE ELSE CAN
TAKE ON.
AND WE ARE WILL BE TO ACCEPT
THAT RISK TO TRANSFORM THE
HEALTH ECOSYSTEM.
NEXT SLIDE.
SO, THIS IS THE GENERAL WAY WE
THINK ABOUT PROGRAM FOUNDATION.
SO THE FIRST IS, IT'S PROGRAM
MANAGERCENTRIC.
SO MUCH LIKE DARPA, WE WILL NOT
FUND PROGRAMS UNLESS WE HAVE A
PROGRAM MANAGER WHO COMES IN
WITH AN IDEA OF SOMETHING
RELATED TO THAT PROGRAM THAT IS
NEW AND NOVEL AND BASED ON THE
QUESTIONS THAT IS SOMETHING THAT
REALLY ARE THIS FRAMEWORK THAT
ALLOWS US TO CONSIDER THE
UNIQUENESS OF THE PROGRAM AND
THE WAY THE PROGRAM MANAGER
SEEKS TO ACTUALLY FIELD THAT
PROGRAM.
SO LOOKING AT THE PROGRAM
MANAGER IDENTIFYING DIFFICULT
HEALTH RELATED CHALLENGES THAT
IS RIGHT FOR SOLVING.
SO, THE CHALLENGES THAT WE WANT
TO TAKE - ARE THOSE THAT SHOULD
NOT BE EASILY SOLVABLE THROUGH
TRADITIONAL ACTIVITY.
SO IT'S SOMETHING THAT OUR
COLLEAGUES AT NIH THROUGH THEIR
PROCESSES, THEIR INNOVATING AND
PUSHING AT THE CUTTING-EDGE OF
RESEARCH AND TECHNOLOGY AND THIS
WOULD BE ONE STEP FURTHER DOWN
THE PIKE WHERE JUST WOULDN'T BE
APPROPRIATE FOR THE WAY THAT
THEIR FUNDING ACTIVITIES NOW.
BUT WE ALSO LOOK FOR
PARTNERSHIPS.
WHEN WE ARE GOING TO TAKE ON
THIS RESPONSIBILITY OF FUNDING
IT, WE HAVE OUR COLLEAGUES AT
NIH TO HELP WITH THE GUIDING THE
PROGRAMS.
ONCE WE HAVE IDENTIFIED THE
CHALLENGE, WE HAVE OUR PROGRAM
MANAGERS ONBOARD, WE GO TO THE
NEXT STEP WHICH IS THE LAUNCH.
SO THE PROGRAM MANAGER WILL
OVERSEE SEVERAL GROUPS OF
PERFORMERS AIMED AT SOLVING
PROBLEMS.
SO THIS IS ALL CONTRACTOR OR
COOPERATIVE AGREEMENT FUNDING.
NOT GRANTEES.
WE MAKE SURE THAT THE PROGRAM OR
PERFORMERS ARE ABLE TO COMPETE
TO CARRY OUT THE POTENTIAL
INNOVATIVE SOLUTIONS TO THE
CHALLENGE.
SO IT'S A LITTLE BIT DIFFERENT
THAN THE GRANT-BASED MODEL WHERE
THERE IS ACTUALLY CONTRACT OR
COOPERATIVE AGREEMENT BASED.
NEXT SLIDE.
BECAUSE WE HAVE THE ABILITY TO
SUPPORT CONTRACTS, WE WANT TO
REALLY MAKE SURE WE HAVE A
ROBUST EVALUATION PROCESS IN
PLACE.
SO WE WILL FUND MULTIPLE
PERFORMERS FOR ANY PARTICULAR
PROGRAM AND REALLY HELPING THAT
THE BEST PERFORMER WAS ABLE TOL
CONTRIBUTE THE SOLUTIONS THAT WE
NEED.
AND SO FOR EXAMPLE WE HAVE
PEOPLE WORKING ON A PARTICULAR
PROGRAM AREA.
WE'LL DESIGN A SERIES OF PHASE
GATES AND MILESTONES FOR US TO
BE ABLE TO EVALUATE, ARE THESE
PERFORMERS MEETING THOSE
STRUCTURED CRITERIA?
AND IF THEY ARE NOT, OUR GOAL IS
TO BE ABLE TO TAKE THOSE
RESOURCES THAT HAVE BEEN APPLIED
TO THE PERFORMERS THAT ARE
WORKING IN THIS SPACE THAT ARE
FAILING AND THEN REAPPLY THEM
EITHER TO THE PERFORMER THAT IS
WORKING OR TO OTHER AREAS WITHIN
THE ORGANIZATION.
AND BY DOING THIS APPROACH, WHAT
WE ARE HOPING IS THAT OF THE
PERFORMERS, ONE OR MORE THAT
REACHES THROUGH ALL THE VARIOUS
MILESTONES ANDISTS TO REACH THE
FINAL STATE OF THE PROGRAM OR
ACTIVITY THAT WE WERE HOPING TO
SEE FROM WITHIN THAT PERFORMER
COHORT.
NEXT SLIDE.
WE ARE NOT DONE THERE.
SO OUR BIG GOAL WITH OR PROGRAMS
IS TRANSITION.
SO, GIVING THE PROGRAM MANAGERS
AND THE PERFORMERS ALL THE
RESOURCES NECESSARY TO REACH
SUCCESS AND THEN TAKING WHATEVER
SUCCESS LOOKS LIKE, WHATEVER
THAT PRODUCT IS AND WORKING WITH
OUR TRANSITION PARTNERS SO THAT
WHEN THE CHALLENGE, PER SE IS
SOLVED, THE PROJECT CAN THEN
TRANSFER TO OTHER PARTNERS WHO
HAVE BEEN INVOLVED IN THE START
AND CAN SCALE THE SOLUTION TO
THE COMMUNITY THAT WOULD BE --
THAT WOULD BENEFIT FROM HAVING
THAT SOLUTION IN THEIR
ECOSYSTEM.
SO, THE GOAL IS TO TAKE
EVERYTHING THAT WE DO, STOP AT
SOME POINT AND TRANSITION IT TO
OTHERS WHO CAN TAKE IT ON TO
WHATEVER THE NEXT STEPS ARE IN
THAT PRODUCT DEVELOPMENT
PATHWAY.
>>NEXT SLIDE.
THE PROGRAM MANAGERS ARE THE
CENTER OF THEUBE VERSE.
WE BRING THEM ON FOR 3-6 YEARS
SO THERE IS AN URGENCY THEY ALL
HAVE TO BE ABLE TO MAKE SURE
THEY ARE COMING IN WITH WELL
DEFINED CHALLENGES.
WE SUPPORT THEM WITH ESSENTIALLY
WRAP AROUND SERVICES FROM
EVERYTHING HOW TO WORK IN THE
FEDERAL GOVERNMENT, HOW TO DO
CONTRACTING, HOW TO LEAD TEAMS,
HOW TO MAKE SURE THAT YOU'RE
WORKING WELL WITH TRANSITION
PARTNERS FROM THE BEGINNING OF
YOUR TENURE.
AND THEN MOVE THEIR PROGRAMS
TOWARDS SOLUTIONS.
SO THEY HAVE THROUGH-6 YEARS
WITH US AND -- 3-6 YEARS AND AND
THEN THE PROGRAMS WILL LAST 2-4
YEARS.
AND THEY WILL BE HANDOFFS ON
OCCASION BETWEEN PROGRAM
MANAGERS THAT ARE OUTGOING AS
THEIR 6 YEARS COMES TO AN END
AND IN COMING WHEN THEY ARE JUST
STARTING AND THEY WILL HAND OVER
OR TAKE ON SOME PROGRAMS THAT
WERE ALREADY IN THE PIPELINE.
NEXT SLIDE.
WE FULLY RECOGNIZE THAT A
HEALTHY ECOSYSTEM IS VERY
COMPLEX.
MUCH MORE COMPLEX THAN YOU WOULD
SEE WITH DARPA OR ANYWHERE ELSE.
SOME OF THE OTHER ARPAs IN THE
FEDERAL GOVERNMENT.
AND WE WANT TO MAKE SURE WE ARE
EMBRACING THIS COMPLEXITY BY
PARTNERING WITH OUR COLLEAGUES
WITHIN HHS, FEDERAL GOVERNMENT,
INDUSTRY, ACADEMIA, PATIENT
GROUPS, HEALTH CARE PROVIDERS
AND THE AMERICAN PUBLIC BOTH ON
THE WHAT IS THE MOST URGENT AND
PRESSING NEEDS WITHIN THE
HEALTHY ECOSYSTEM AND ALSO AS WE
ARE DEVELOPING THESE
CAPABILITIES, WHAT DOES SUCCESS
LOOK LIKE FOR TRANSITION MAKING
SURE THEY ARE SUPPORTING THE
BROADEST SET OF CONSTITUENCIES
WITHIN THE HEALTHY ECOSYSTEM.
NEXT SLIDE.
SEE JUST TO TALK ABOUT WHAT WE
HAVE DONE AT NIH.
I CAN'T EMPHASIZE ENOUGH HOW
MUCH WE WANT TO MAKE SURE THAT
WE ARE PARTNERING WITH OUR
AMAZING COLLEAGUES AT NIH.
SO WE HAVE ALREADY HAD SEVERAL
OPPORTUNITIES TO WORK TOGETHER
MOSTLY NOW IT'S JUST TALKING AND
WE ARE HOPING THAT AT SOME POINT
IT'S ACTUALLY DOING MORE OF THE
TALKING, EXCHANGING TECHNICAL
INFORMATION, POTENTIALLY
COFUNDING VARIOUS ACTIVITIES.
REALLY MAKING SURE THAT WE ARE
OPTIMALLY LEVERAGING OUR
RELATIONSHIP WITHIN NIH.
SO WE HAVE DONE SEVERAL.
WE DID THE KICKOFF EVENT AT
HOWARD, A NUMBER OF DIFFERENT
SPEAKING ENGAGEMENTS THAT THE
DIRECTOR OF ARPAH ENGAGED IN
FROM -- YOU CAN READ THOSE.
SO JUST REALLY MAKING SURE THAT
WE ARE OPEN AND TRANSPARENT AND
REALLY MAKING SURE THAT WE ARE
REACHING ACROSS THE CAMPUS IT
OUR NIH COLLEAGUES SO WE CAN
BUILD THOSE PARTNERSHIPS.
AND WE HAVE SEVERAL THINGS WE
ARE GOING AT OR ABOUT DOING IN
THE FUTURE.
AND ALL OF WHICH WE ARE VERY,
VERY EXCITED ABOUT.
NEXT SLIDE.
I TALK A LITTLE BIT ABOUT THE
PROGRAM MANAGER, PROGRAM LIFE
CYCLE.
THIS GIVES A LITTLE BIT MORE OF
THE -- A LITTLE MORE OF THE
DETAILS.
I'M NOT GOING TO GO INTO ALL OF
THE SPECIFIC ELEMENTS.
YOU HAVE THE SLIDES.
REALLY THE GOAL IS TO MAKE SURE
THAT WE HAVE A CONSISTENT
SUCCESSFUL APPROACH FOR ALL THE
PROGRAM MANAGERS THAT COME ON
THAT WE HAVE WELL DEFINED
PROBLEMS.
THE PROGRAMS ARE DESIGNED TO
ADDRESS THOSE PROBLEMS AND THAT
AT THE END OF THE TENURE OF THE
PROGRAM MANAGER OR THE PROGRAM,
THAT WE CAN SUCCESSFULLY
COMMERCIALIZE OR TRANSITION AS
APPROPRIATE THE VARIOUS PRODU
PRODUCTS.
NEXT SLIDE.
SO THIS IS WHERE WE ARE STARTING
FROM OUR TECHNICAL STRATEGY.
SO WITHIN THE FIRST MONTH OR SO
OF COMING ONBOARD WAS THINKING
ABOUT HOW TO STRUCTURE OUR
PORTFOLIOS.
SO WE COVER THE BREATH OF THE
HEALTHY ECOSYSTEM BUT PUSHING
PUSHING TOWARDS THOSE AREAS THAT
ARE PARTICULARLY IN NEED OF
INNOVATION.
SO, WE SETTLED ON THESE FOUR
DIFFERENT LARGE DOMAINS THAT
WE'LL BE SUPPORTING PROGRAMS IN.
THE FIRST IS HEALTH SCIENCE
FUTURES.
AND THAT IS REALLY THINKING
ABOUT PLATFORMS THAT CAN APPLY
TO A BROAD RANGE OF DISEASES.
SO RATHER THAN GO ON THE DISEASE
BY DISEASE SPECIFIC PURSUIT OF
VARIOUS THERAPEUTICS AND
INTERVENTIONS, THIS IS SAYING
WHAT CAN WE DO FROM A PLATFORM
PERSPECTIVE THAT WOULD ALLOW US
TO ADDRESS AS MANY OF THESE
CHALLENGES AS POSSIBLE WITH A
SINGLE TOOL OR A SINGLE
PLATFORM.
SCALABLE SOLUTIONS IS REALLY
THINKING ABOUT HOW TO WE MAKE
SURE THAT THE SOLUTIONS THAT ARE
BEING DEVELOPED, AND THERE ARE
SOME SOLUTIONS THAT WORK AT A
SMALL SCALE FOR A SMALL
POPULATION, BUT REALLY NEED SOME
INNOVATION TO REACH EVERYONE AND
REACH EVERYONE WHO NEEDS THE
INTERVENTION AND THE THERAPY
VACCINE, WHATEVER IT HAPPENS TO
BE.
AND TO DO SO QUICKLY.
SO LOOKING AT BOTH GEOGRAPHY,
MANUFACTURING, DATA INFORMATION,
ECONOMIES OF SCALE.
SO TAKING EXISTING PRODUCTS AND
EXISTING 50s SAYING, HOW CAN
WE HELP SCALE THESE SOY THAT
EVERYONE CAN BENEFIT?
PROACTIVE HEALTH IS THINKING
ABOUT KEEPING PEOPLE FROM BEING
PATIENTS IN THE FIRST PLACE.
SO LOOKING AT PREVENTIVE
PROGRAMS IN DIFFERENT WAYS THAT
THINKING ABOUT CHARACTERIZING
DISEASE RISK AND PROMOTING
TREATMENTS AND BEHAVIORS THAT
AMOUNT THOSE THREATS SO WE CAN
MITIGATE THE POTENTIAL TO HEALTH
IMPACTS BY UP STREAMING BY BEING
PROACTIVE ABOUT THE
INTERVENTIONS THAT WILL BE
PURSUING AND THEN RESILIENT
SYSTEM SYSTEM.
THIS IS ABOUT HOW DO WE CREATE A
BETTER HEALTH CARE SYSTEM?
SO LOOKING AT CAPABILITIES,
BUSINESS MODELS, INTEGRATION
THAT ALLOWS US TO WEATHER CRISIS
SUCH AS PANDEMICS, SOCIAL
DISRUPTIONS, CLIMATE CHANGE,
ECONOMIC INSTABILITY.
SYSTEMS THAT ARE SUSTAINED
BETWEEN CRISIS FROM THE
MOLECULAR TO THE SOCIETAL.
AND I THINK WE HAVE SEEN THIS.
I HAVE BEEN IN GOVERNMENT FOR
QUITE SOMETIME AND IN LEADERSHIP
POSITIONS IN THE HEALTH
INNOVATION FOR QUITE SOMETIME
AND THERE IS NOTHING MORE
FRUSTRATING WHEN YOU HAVE ANG
EMERGENT CRISIS AND EVERYTHING
RUSHES TO FIND A SOLUTION AND
THERE IS NEVER TIME TO ACTUALLY
GET FROM SOLUTION IDEATION TO
DEPLOYMENT OF SOMETHING THAT IS
SUSTAINABLE BEFORE THAT CRISIS
ENDS UP PASSING AND ATTENTION
GETS DILUTED IN OTHER CRISIS
COME ON.
AND THEN YOU FIND YOURSELF IN
THAT SAME SITUATION TWO, 5, 10
YEARS LATER AND IT'S ALMOST
LIKE, GROUNDHOG DAY WHERE YOU'RE
SAYING, WE WERE JUST HERE AND WE
DIDN'T ACTUALLY DEVELOP
SOMETHING THAT WAS READY TO BE
PUT IN PLACE RAPIDLY TO MITIGATE
THE CIRCUMSTANCES OF THE
EMERGING ISSUE.
SO THINKING ABOUT WHAT RESILIENT
SYSTEMS AND HEALTH CARE LOOKS
LIKE.
NEXT SLIDE.
OY TALKED A LOT ABOUT THE
PROGRAM MOTHER-IN-LAW.
THIS IS WHERE WE CAN USE YOUR
HELP.
-- MANAGER.
WE ARE LOOKING FOR INDIVIDUALS
WHO WILL COME ON TO CHAMPION THE
VARIOUS PORTFOLIO AREAS WITH
PROGRAMS THAT WE ALL KNOW ARE SO
CRUCIAL AND IMPORTANT.
AGING IS ONE OF THOSE HOW DO WE
AGE MORE HEALTHY?
HOW DO WE ACTUALLY THINK ABOUT
THE -- WHETHER OR NOT THERE ARE
BEHAVIORAL HEALTH OR CLINICAL
CARE, INTERVENTIONS THAT WOULD
ALLOW US TO AGE BETTER TO REDUCE
THE POTENTIAL DISEASES THAT COME
ON WITH AGING.
SO REALLY THINKING ABOUT THAT AS
AN OPPORTUNITY TO IDENTIFY
PROGRAM MANAGERS WHO ARE
PASSIONATED ABOUT THIS SECTOR
AND THEY ARE WILLING TO COME ON
FOR 3-6 YEARS, TAKE ON REALLY
HARD PROBLEMS AND BE GIVEN ALL
THE RESOURCES NECESSARY TO BE
SUCCESSFUL.
AND IT IS FULLY SUPPORTIVE.
WE HAVE BUSINESS AND TECHNICAL
TEAMS THAT WILL ALLOW SOMEONE
WHO MAYBE NEVER WORKED IN
GOVERNMENT, NO THE TO HAVE TO
WORRY ABOUT HOW DOES THAT WORK.
BECAUSE WE'LL SUPPORT OR FILL IN
THE GAPS ASSOCIATED WITH THAT
WITH OUR TEAM.
AND THEN THE RESPONSIBILITY ONCE
THEY ARE IN THE DOOR, AND THEY
HAVE IDENTIFIED THE PROBLEMS, IS
TO ASSEMBLE A TEAM FROM
INDUSTRY, ACADEMIA AND
GOVERNMENT AND GO OUT AND SOLVE
THE PROBLEMS.
NEXT SLIDE.
PEOPLE ASK US, WHAT ARE THE
CRITERIA FOR OUR PROGRAM
MANAGER?
AND THE ANSWER IS, WE DON'T HAVE
ANY SET CRITERIA THAT ONE NEEDS
TO HAVE GONE THROUGH THE PHASE
GATES ASSOCIATED WITH IT.
WE ARE LOOKING FOR UNCOMMON
PEOPLE WITH UNCOMMON TRAITS.
SO PEOPLE WHO HAVE EXPERTISE
THAT ARE JUST INIZATIONABLY
CURIOUS.
HOW COME THIS?
HOW DOES THIS WORK THIS WAY?
IT'S HELPFUL TO HAVE AN
INTERDISCIPLINARY TRACK RECORD.
SO THEY WORKED IN ACADEMIA,
GOVERNMENT, PRIVATE SECTOR AND
MORE THAN ONE PORTFOLIO AREA.
IT'S NOT A -- IF YOU DON'T HAVE
THAT, YOU CAN'T BE HIRED.
IT'S JUST THAT IT WOULD BE
HELPFUL TO YOU AND THEM AS THEY
ARE WORKING WITHIN THE
GOVERNMENT.
SERIOUSLY SO YOU ONLY HAVE 3-6
YEARS.
WE NEED PEOPLE WHO WAKE UP EVERY
DAY WHO ARE READY TO JUST KEEP
PUSHING ALONG AND IT IS INTENSE
TRYING TO MAKE SURE THAT YOU CAN
CONTRIBUTE SOMETHING OF
SIGNIFICANCE COMING OUT OF HERE
IN YOUR LIMITED TENURE HERE.
AND NO FEAR OF FAILURE.
SO FAILURE TO US IS NOT THAT THE
PROGRAM DIDN'T WORK.
THE FAILURE IS IF TWEE DIDN'T
LEARN ANYTHING.
AND IF WE DIDN'T TAKE THOSE
FINDINGS OF IF SOMETHING FAILED
AND SHARE IT SO NOT ONLY ARE WE
LEARNING WITHIN THE ORGANIZATION
WHY SOMETHING DIDN'T WORK BUT WE
GIVE THAT KNOWLEDGE OUT TO
EVERYONE ELSE WHO MAY BE
THINKING ABOUT THE SAME TYPE OF
ACTIVITY OR PORTFOLIO.
IN WHICH CASE, THEN IT'S NOT A
FAILURE, IT'S AN INCREDIBLE
VALUE TO THE RESEARCH THAT IS
GOING ON.
AND THEN TECHNICAL HONESTY.
OUR GOAL IS TO BE ABLE TO
TRANSITION PRODUCTS THAT CAN GO
OUT AND BE EFFECTIVE IN THE
HEALTHY ECOSYSTEM.
SO ALL ALONG THE WAY WE HAVE TO
MAKE SURE THAT THEY HAVE THE
HIGHEST LEVEL OF INTEGRITY TO
MAKE SURE THAT WE ARE BUILDING
SOMETHING THAT WILL WORK AND IS
SUSTAINABLE.
AND THEN THERE ARE DIFFERENT
APPROACHES TO THE CAREER STAGE,
I'M NOT GOING IN THERE.
YOU CAN READ THOSE.
BUT REALLY THAT IDEA IS THAT
THERE IS NO ONE TYPE OF
INDIVIDUAL THAT WE ARE LOOKING
FOR IN THE PROGRAM MANAGER.
WE ARE LOOKING FOR EVERYONE WHO
SORT OF HAS SOME COMPOSITION OF
IDEAS OF THESE CRITERIA AND IS
REALLY EXCITED ABOUT COMING TO
JOIN US.
NEXT SLIDE.
THESE ARE THE QUESTIONS.
SO THIS IS HOW WE THINK ABOUT
WHETHER OR NOT A PROGRAM MANAGER
HAS CONCEPTUALIZED THE CHALLENGE
AND THE SOLUTION IN A WAY THAT
WE CAN UNDERSTAND AND ASSESS HOW
UNIQUE IT IS AND WHETHER OR NOT
IT IS GOING TO HAVE A
TRANSFORMATIONAL IMPACT.
SO THESE ARE DERIVED FROM THE
DARPA QUESTIONS AND THEY ARE
VERY SIMPLE TO WRITE.
THEY ARE MISLEADINGLY HARD TO
ADDRESS.
ESPECIALLY WE HAVE A REALLY
STRONG TECHNICAL TEAM THAT IS
EVALUATING EVERY SUBMISSION AND
REALLY TOO IING TO MAKE SURE
THAT THE BEST ANSWERS ARE COMING
THROUGH FROM THE POTENTIAL
PROGRAM MANAGERS.
WE DID ADD TWO CRITERIA.
SO FIRST 8 COME FROM TARP A THE
LAST TWO ARE ONES WE ADDED
BECAUSE THEY ARE SO IMPORTANT
FOR OUR HEALTH ASPECT OF BEING
IN OUR BOAT.
THE FIRST IS WE WANT TO MAKE
SURE THAT THERE IS EQUITABLE
ACCESS FOR ALL PEOPLE.
SO, ENSURING THAT COST,
ACCESSIBILITY AND USER
EXPERIENCE WILL ALL BE ADDRESSED
IN TERMS OF THE PROGRAM.
AND THEN THE LAST ONE IS
MISPERCEPTION OR MISUSE.
WE KNOW THAT THERE ARE
CHALLENGES IN SCIENCE
COMMUNICATION AND ASSEMBLY FROM
THE BROADER PUBLIC AND SO MAKING
SURE THAT IF WE ARE DESIGNING A
PROGRAM OR A PARTICULAR SOLUTION
FROM WITHIN THE PROGRAM AREA,
THINKING REALLY CRITICALLY, LIKE
HOW COULD THIS POTENTIALLY BE
MISPERCEIVED OR MISUSED?
AND THEN HOW WOULD WE MITIGATE
THAT AND MAKE SURE THAT IS BUILT
IN FROM THE PROGRAM DESIGN IN
THE FIRST PLACE?
NEXT SLIDE.
SO, HOW DO WE THINK ABOUT
SUCCESS?
WE TALKED ABOUT THE WELL DEFINED
PROBLEMS.
WE TALKED ABOUT THE PROGRAM LIFE
CYCLE.
THE GOAL IS, THESE PRODUCTS OR
ACTIVITIES WE ENGAGE IN, THEY
CAN MEANINGFULLY HELP REAL
PEOPLE WHO WANT THEM AND WILL
ADOPT THEM.
WE TALK ABOUT SEPARATING THE
IMPROBABLE FROM IMPOSSIBLE.
OCCASIONALLY YOU SAY YOU WANT TO
DO THIS THING AND YOU GET A
CONSTITUENCY THAT SAYS, THAT IS
IMPOSSIBLE.
WE DON'T THINK ANYTHING IS
IMPOSSIBLE.
WE THINK WITH THE RIGHT THINKING
WE CAN TAKE IT TO IMPROBABLE AND
THAT IS REALLY WHERE WE WANT TO
EXIST IS THOSE THINGS THAT
SEEMINGLY ARE IMPOSSIBLE, WHAT
CAN WE DO TO DESIGN A PROGRAM TO
MAKE THEM MEASURE IN THE
IMPROBABLE SIDE AND THEN WE'LL
TAKE ON THAT RISK AND WITH THE
RIGHT PROGRAM MANAGERS AND THE
RIGHT FUNDING, WE'LL SEE IF WE
CAN ADDRESS IT.
AND THEN AGAIN, DELIVER A BETTER
HEALTH RESULTS TO EVERYONE.
SO, WE, IT'S WIDE OPEN THE WAY
WE ARE THINKING ABOUT HOW WE
PRIORITIZE WITHIN THE HEALTHY
ECOSYSTEM AND SO LOOKING FOR THE
PROGRAM MANAGERS TO HELP DRIVE
THAT.
AND OUR FUNDING WILL BE VERY
FLEXIBLE, CONTRACTS AND
COOPERATIVE AGREEMENTS, OTHER
TRANSACTIONAL AUTHORITY IS IT'S
NOT GRANTS BASED WHICH IS AGAIN
A UNIQUE CAPABILITY WE HAVE
WITHIN THE NIH ECOSYSTEM.
NEXT SLIDE.
THE LAST THING I WANT TO TALK
ABOUT AND I'LL STOP AND OPEN UP
FOR QUESTIONS, THE WAY WE ARE
THINKERRING ABOUT ENSURING THAT
WE CAN TAKE A PRODUCT AND REALLY
TRANSITION IT TO THE CURRENT
SECTOR OR CURRENT MARKET.
WHICH IS CRITICALLY IMPORTANT
FOR THE VAST MAJORITY OF WHAT WE
DO.
WE ARE BUILDING IN, DEVELOPED AN
ENTIRELY NYE OFFICE DIFFERENT
THAN DARPA AND THE OTHERS AND IT
SPECIFICALLY IS DEDICATED TO
TRANSITION OF PATIENTS.
SO WE HAVE A SUPPORT PROGRAM.
WHEN A PROGRAM MANAGER IS
DESIGNING THAT PROGRAM, WE WILL
DO A NUMBER OF DIFFERENT
ACTIVITIES INCLUDING MARKET
ACCESSMENT AND HUMAN SUBJECT
DESIGN TO SUPPORT OMIZEDING THAT
PROGRAM.
MAKING SURE THAT DURING BAA
DEVELOPMENT, THE WE THINK WHO
ARE THE PERFORMERS AND HOW CAN
WE LEVERAGE INNOVATION HUBS TO
BE ABLE TO SUPPORT THE PROGRAM
DEVELOPMENT.
WE'LL DO VENTURE CAPITAL STYLE
DUE DILIGENCE MAKING SURE THE
PERFORMERS CAN BE TRUSTED WITH
THE RESOURCES THAT WE ARE
AFFORDING THEM, THE TIME WE ARE
AFFORDING THEM.
AND VALIDATE THE TRANSITION
POTENTIAL.
LOOK AT A LOT OF EARLY PROGRAM
PERFORMS.
I TALKED ABOUT THAT.
BRINGING FROM INVESTORS, TRYING
TO MAKE SHUSH THAT WE IDENTIFY
MITIGATING RISK.
THE REGULATORY PROCESS IS HUGELY
COMPLEX MAKING SURE THAT ANY OF
THE PERFORMERS AND THE PROGRAM
MANAGERS UNDERSTAND THAT.
AND MAKING SURE THAT WE PROTECT
IT, HELP COMPANY FORMATION.
SO IF A PRODUCT CAN GO OFF AND
BECOME A COMPANY, MAKING SURE
THAT IT IS DONE IN A SUSTAINABLE
WAY, HELPING WITH LEGAL AND
MARKETING SERVICES AND THEN
ULTIMATELY TRANSITIONING THE
OUTPUTS AS WE SAY TO SURVIVE IN
THE WILD SO THEY CAN TRANSITION
TO THE THIRD PARTY INVESTMENTS
AND THEN CONTINUE WITH
MENTORSHIP AND ACCESS TO KEY
CUSTOMERS AND INVESTORS.
I THINK -- NEXT SLIDE.
SO THESIS ARULE JUST -- WHERE WE
ARE NOW.
SO WE ARE STANDING UP AND
ACHIEVING A LOT OF EXTERNAL
ENGAGEMENT, POTENTIAL
COOPERATIVE PARTNERS TO REALLY
MAKE SURE THAT WE ARE SETTING
OUR AGENCY UP FOR SUCCESSFUL
NEXT SLIDE.
THAT'S IT.
SO, OUR CALL TO ACTION IS, IF
YOU KNOW OF ANY PROGRAM MANAGERS
THAT REALLY EMBODY THAT
INNOVATIVE SPIRIT AND THAT RISK
TAKING, WE ARE ACTIVELY LOOKING
FOR PROGRAM MANAGER APPLICANTS
RIGHT NOW.
OUR GOAL IS TO HIRE 10-20 THIS
YEAR.
WE HAVE NONE.
AND OUR GOAL IS TO SCALE THAT TO
POTENTIALLY UP TO 30 BY THE END
OF NEXT FISCAL YEAR.
SO WE ARE IN THE RAPID GROWTH
PHASE WHICH MEANS THAT IF YOU
HAVE A PROGRAM MANAGER WITH A
GREAT IDEA IN AN AREA YOU'RE
PARTICULARLY PASSIONATE ABOUT,
THEY STAND A BETTER CHANCE RIGHT
NOW OF MAKING IT THROUGH THE
PIPELINE QUICKLY WHILE WE ARE
STILL IN THIS PHASE.
I WILL STOP THERE AND HAPPY TO
TAKE ANY QUESTIONS THAT YOU MAY
HAVE.
>>THAT WAS GREAT.
I HAVE SO MANY QUESTIONS.
LET ME TAKE THE LIBERTY OF
ASKING A COUPLE OF MANY AND I'LL
TRY TO MAKE THEM GENERAL.
FIRST UNDERSTANDING THE
IMPORTANCE OF THE PROGRAM
OFFICER.
DO THE IDEAS AND PROPOSALS COME
FROM THE PROGRAM MANAGER TO
ARPAH OR DO YOU IN ANY WAY REACH
OUT SOLICITING INTEREST IN
CERTAIN AREAS CENTRALLY?
SO IS IT DETERMINING OR DO YOU
DEPEND ON THE PROGRAM OFFICER?
AND THEN THE SECOND PART AND
IT'S RELATED.
MANY OF US, NIH PARTICULAR ARE
SENSITIVE TO THE IMPORTANT BUT
AT TIMES CONTROVERSIAL
RELATIONSHIP BETWEEN NIH AND
ARPAH.
WHAT DO YOU SEE AS THE
NON-CONTROVERSIAL, PURELY
PRODUCTIVE WAYS THAT WE CAN
INTERACT WITH ARPH WITHOUT
RAISING CONCERNS ABOUT THE NEED
FOR THESE TO BE THROUGH THESE
DISTINCT AGENCY?
>>IT'S BOTH.
RIGHT NOW WE HAVE A OPEN
SOLICITATION FOR PROGRAM
MANAGERS COMING IN AND BRINGING
WITH THEM THEIR PROBLEMS.
SO IT'S VERY MUCH A PUSH
FUNCTION.
YOU NEED TO DO MORE IN WHATEVER
PARTICULAR HEALTHY ECOSYSTEM
DOMAIN OR BIOTECH DOMAIN.
BUT WE ARE ALSO DOING THE EVENTS
LIKE THIS WHERE WE KNOW WE WANT
TO FUND RESEARCH.
WE WANT TO FUND SOMETHING IN
THIS SPACE.
AND SO, PROACTIVELY REACHING OUT
TO YOUR COMMUNITY OR OTHER
COMMUNITIES WHERE WE ARE HOPING
THAT BY OUR PARTICIPATION IN
YOUR EVENTS, WE ACTUALLY CAN GET
PROGRAM MANAGER.
SOMEONE ON THIS CALL OR SOMEONE
YOU KNOW WHO IS LIKE, I LOVE TO
DO THAT.
LIKED YOUR CONSTITUENCY AND YOUR
COLLEAGUES.
AND THEN THAT WAY, TRYING TO
BALANCE THE PUSH AND PULL
FUNCTION SO WE GET A REALLY
ROBUST, BROAD SET OF ACTIVITIES
THAT CROSS OUR PORTFOLIO AREAS.
IN TERMS OF PRODUCTIVE
ENGAGEMENT WITH OUR NIH
COLLEAGUES, THAT FOR ME IS ONE
OF MY PRIORITIES.
I HAVE HAD THE OPPORTUNITY TO
WORK NEAR NIH -- THIS IS MY
FIRST OPPORTUNITY TO WORK AT
NIH.
I'M SUPER EXCITED ABOUT IT AND I
HAVE SUCH TREMENDOUS RESPECT FOR
THE COLLEAGUES AND EVERYTHING
YOU DO WITHIN YOUR ICs.
SO TRYING TO FIGURE OUT WHAT IS
THE ROUTINE ENGAGEMENT THAT WE
HAVE WITH YOU SUCH THAT YOU KNOW
WHAT WE ARE DOING, WE CAN
BENEFIT FROM KNOWING WHAT YOU'RE
DOING.
WE DON'T DUPLICATE ACTIVITIES.
WE DON'T COMPETE FOR THE
POTENTIAL PARTNERS TO DO THE
WORK WE NEED TO DO.
UNLESS WE ARE ACTUALLY IN A
PLACE WHERE WE CAN DO SORT OF --
I DON'T KNOW WE CAN DO
CO-FUNDING.
I WOULD HAVE TO ASK OUR BUDGET
FOLKS.
BUT CAN WE WORK IN PARALLEL WITH
ON THE SAME TYPE OF PROBLEM?
WE'LL TAKE SOME OF THE RISKIER
ASPECT, YOU TAKE SOME OF THE
WORK THAT YOU KNOW YOU CAN DO
WITHIN YOUR -- WHATEVER THE
STRUCTURES ARE WITHIN YOUR IC,
BUT WE COME TOGETHER TO HAVE
THESE VERY PRODUCTIVE
RELATIONSHIPS.
AND I THINK ONE OF MY GOALS AS
WE GET PROGRAM MANAGERS ON, AND
THE PROGRAM MANAGERS ARE
INTERESTED IN DOING SOMETHING
THAT WE KNOW IS ALREADY THE
TOPICALLY ONGOING AT NIH, NOT
BEING SHY.
LIKE NOT LIKE LET'S NOT HUDDLE
AND JUST PRETEND NO ONE ELSE IS
DOING IT.
LET'S TALK ABOUT WHAT WE THINK
WE ARE GOING TO DO AND GET
FEEDBACK.
THERE IS A LIKELIHOOD AND I SAY
THIS ALL THE TIME.
WITHIN THE ICs YOU'RE THE
LEADING EDGE TECHNICAL EXPERTS
WITHIN THOSE AREAS.
AND SO FOR US, THE HUBRIS
THINKING WE ARE THE FIRST PEOPLE
TO THINK OF IT, PROBABLY WON'T
WORK OUT SO WELL.
SO WE THINK OF SOMETHING LIKE,
WE HAVE TO DO THIS, GOING OVER
TO THE IC AND HAVING A
CONVERSATION AND HAVING THE IC
SAY TO US, WELL, WE TRIED THAT
THREE YEARS AGO AND HERE IS WHY
IT DIDN'T WORK.
OR WE ALREADY HAVE THREE
PROGRAMS THAT ARE WORKING IN
THAT SPACE AND ALLOWING US TO
TAILOR OUR PROGRAM TO OCCUPY
UNIQUE SPACES.
SO I SEE GREAT POSITIVE
POTENTIAL TO WORK WITH
COLLEAGUES AT NIH AND I'M
HOPEFUL IT'S A BIDIRECTIONAL
RELATIONSHIP.
IF WE CAN'T TAKE THAT RISK, PASS
IT TO US SO WE MIGHT BE ABLE TO
THINK ABOUT IT IF WE HAVE THE
RIGHT PROGRAM MANAGER IN PLACE.
I HOPE TO HAVE IT.
>>GREAT EXCITING ANSWER.
SHALL WE TAKE QUESTIONS FROM
SOME OF OUR MEMBERS?
SHELLY?
>>THANK YOU VERY MUCH FOR YOUR
VERY INSPIRATIONAL TALK.
I WAS VERY ENERGIZED BY YOUR
BOLD WISH AND EXPEDITING
INNOVATION.
THE QUESTION I HAD IS A
CLARIFYING ONE.
DO YOU ENVISION THAT THE
PRODUCTS AND THE PROJECTS WILL
BE INITIATED BY THE PROGRAM
STAFF?
OR DO YOU SEE A PROCESS FOR
INVESTIGATOR INITIATIVE PROPOSAL
TO BE REVIEWED AND THEN COULD
THOSE LEAD TO FUNDING?
>>IT'S A REALLY GOOD QUESTION.
SO, THE VAST MAJORITY ARE GOING
TO COME IN AS PROGRAM MANAGER
DESIGNED PROGRAMS SO THEY COME
IN WITH THE PROBLEMS THAT THEY
COME UP WITH THE PROGRAM DESIGN
AND THEN WE FUND PERFORMERS THAT
ARE ALIGNED THE ASPECTS OF THEIR
PROGRAM DESIGN.
BUT WE ARE GOING TO HAVE AN OPEN
VAA AND WHAT THAT MEANS IS THAT
IT'S SORT OF GOING TO LAY OUT
SOME FOUNDATIONAL PRINCIPLES
ABOUT WHAT ARE WE LOOKING FOR IN
INNOVATION ACROSS THE HEALTHY
ECOSYSTEM?
SO IT'S NOT DEFINED TO A
SPECIFIC DISEASE OR A SPECIFIC
SOLUTION SET BUT IT'S RATHER
MORE OPEN AND IT SAYS,
PARAPHRASING, WHAT IS IS IT WE
ARE NOT DOING?
WHAT IS IT NOT BEING FUNDED THAT
IS PARTICULARLY INNOVATIVE THAT
WE WOULD REALLY WANT TO -- THAT
LIKE AN INVESTIGATOR SAYS, YOU
KNOW, ARPAH YOU NEED TO FUND
THIS TYPE OF RESEARCH PORTFOLIO.
AND I DON'T WANT TO OVER PROMISE
BUT REALLY GOOD IDEAS COME
THROUGH THAT TYPE OF AN OPEN
VAA.
AND THAT WOULD ALLOW US TO SAY,
OH, MY GOSH, WE HAVE NOT -- WE
DON'T HAVE A PORTFOLIO OR A
PROGRAM MANAGER AND THEN BEFORE
WE FUND IT OF COURSE, WE WOULD
HAVE TO FIND A PROGRAM MANAGER
THAT COULD RUN THAT PARTICULAR
ACTIVITY.
IN AN IDEAL WORLD YOU'D HAVE AN
INVESTIGATOR WHO PUTS IN
SOMETHING IN THE OPEN VAA THAT
SAYS YOU MUST FUND THIS.
AND THEN RAISES THEIR HAND AND
SAYS, I WILL BECOME YOUR PROGRAM
MANAGER.
AND IF IT WORKS OUT WE HAVE THE
IDEA AND THE PROGRAM MANAGER AT
THE SAME TIME.
SO, THERE IS AN OPPORTUNITY
OUTSIDE OF THE PROGRAM MANAGERS
THROUGH THESE OPEN VAAs THAT
WE'LL PUT OUT THERE.
WE'RE HOPING TO BE ABLE TO GET
OUR OPEN VAA OUT.
WE ARE BRAND NEW AND VERY
EXCITED.
WITHIN THE NEXT SIX MONTHS
HOPING TO GET A OPEN VAA OUT
THERE TO START TO GENERATE THESE
INVESTIGATOR OF-INITIATED IDEAS.
>>ABC ANNOUNCEMENTS AND I THINK
NIH HAS THE AUTHORITY AND HAS
USED IT INFREQUENTLY, CORRECT?
>>YES, ABSOLUTELY.
I GUESS IT'S THE CLOSEST THING
IN THE CONTRACT WORLD TO A
UNSOLICITED GRANT MECHANISM,
REALLY.
>>THAT'S RIGHT.
ANN: THANK YOU VERY MUCH.
THIS WAS REALLY EXCITING.
I HAVE A KIND OF -- I'M AN
ECONOMIST BY TRAINING AND I HAVE
A QUESTION ABOUT, SO WE PAY FOR
THE HIGH-UNCERTAINTY HIGH
CONSEQUENCE RESEARCH AND THEN
WHAT STOPS THAT FROM IN 5 YEARS
TIME BEING A DRUG THAT APPEARS
ON THE MARKET WITH A PRICE TAG
OF 36,000?
I MEAN, I ASSUME THAT WAS UNDER
PART 9 OF YOUR 10 QUESTIONS BUT
IT IS ONE THAT I THINK CERTAINLY
HAS BIG CONSEQUENCES FOR US ALL
BEING ABLE TO BENEFIT FROM THIS.
>>ABSOLUTELY.
IT IS PART OF -- BUILT INTO PART
9 ENSURING EQUITABLE ACCESS.
IT WILL BE A VERY PROACTIVE PART
OF WHAT WE ARE THINKING ABOUT SO
YOU HAVE YOUR PROBLEM.
HERE IS HOW YOU'RE DESIGNING
YOUR PROGRAM.
HERE IS WHAT YOU ARE THINK THE
SOLUTION S HOW IS THAT GOING TO
BE EQUITABLE?
AND REALLY MAKING SURE, WE'LL
CALL IT PROWELL CONDUCT
PROFILES.
SO IF YOU'RE GOING TO CREATE A
PRODUCT, PART OF YOUR TARGET
PRODUCT PROFILE HAS TO BE COST
EFFECTIVE.
AND SO, WHAT DOES YOUR PRODUCT
HAVE TO LOOK LIKE TO ACHIEVE
COST EFFECTIVE NATURE?
SO WE TALKED ABOUT THE CANCER
VACCINE FOR THE PRICE OF A CUP
OF COFFEE.
SO IT'S ON OUR MIND AND IT WILL
BE A CONSTRAINT FOR SOME OF OUR
PROGRAMS WHERE WE SAY, IF IT'S
GOING TO COST US 36,000 DOLLARS
A TREATMENT DOSE AND THAT'S THE
OUT OF REACH FOR SO MANY PEOPLE
WHO MAY HAVE THAT CONDITION,
THEN IT'S NOT FOR US.
UNLESS THERE IS A WAY WE CAN
TAKE IT FROM 36,000 DOLLARS AND
WE CAN SCALE IT SO THAT IT
BECOMES 3.60 OR SOMETHING LIKE
THAT.
WE ARE ALSO PUTTING IN PLACE,
AND THIS -- MANY ARE FAMILIAR
WITH IT, IT IS AN LC PROGRAM SO
THE ETHICS LEGAL AND SOCIETAL
IMPLICATIONS ABOUT MAKING SURE
WE HAVE A MATURE WAY TO THINK
ABOUT OUR PORTFOLIO AND PROGRAMS
SPECIFICALLY.
AND PART OF WHAT THEY ARE TASKED
WITH IS THIS EVALUATION COST
BENEFIT AND IMPACT TO SOCIETY.
SO, WE ARE BAKING IT IN IN A
NUMBER OF DIFFERENT WAYS BECAUSE
YOU'RE RIGHT.
THERE IS BOST DEVELOPING
SOMETHING THAT MAYBE IS SO
UNIQUE THAT ONE COULD SAY, WELL,
WE SHOULD CHARGE 36,000 DOLLARS
A YEAR.
BUT IT'S NOT IN LINE WITH WHAT
OUR GOALS ARE AS AN AGENCY.
>>THANK YOU.
>>SUSAN?
>>SUSAN: THIS WAS REALLY,
REALLY EXCITING.
SO I HAVE A QUESTION SORT OF
ABOUT TRYING TO GET MY HEAD
AROUND THIS IN TERMS OF, CAN YOU
GIVE US AN EXAMPLE OF -- I WAS
NOT CLEAR ON HOW SPECIFIC THIS
WOULD BE VERSUS HOW BROAD
FINDINGS COULD BE OR PROGRAM
MANAGER INDIVIDUAL AN IDEA TO DO
SOMETHING REALLY BROAD, REALLY
FOCUSED AND MAYBE AN EXAMPLE OF
SOMETHING THAT WAS A SUCCESS
VERSUS SOMETHING THAT WAS A
FAILURE AND WHY.
JUST TO GET A BETTER GRASP.
>>THE GOOD NEWS IS WE HAVEN'T
HAD ANY SUCCESS SYSTEM OR
FAILURES YET BECAUSE WE HAVEN'T
SPENT ANY MONEY.
BUT GIVE US TIME.
I CAN GIVE YOU A COUPLE OF IDEAS
THAT HAVE COME THROUGH.
SO AS WE INTERVIEWED THESE
PROGRAM MANAGERS AND THEY ARE
TELLING US OR GIVING US THEIR
PITCH FOR WHAT THEY WOULD WANT
TO WORK ON.
SO SOMETHING AS SMALL AS LIVING
CELLS THAT COULD IMPLANTED AND
SECRETE SMALL BIOMOLECULES TO
TARGET CERTAIN DISEASE STATES OR
CERTAIN THERAPEUTIC
INTERVENTION.
AND IT WOULD NEED TO BE
NECESSARILY TAILORED TO THE
PHYSIOLOGY OF THE INDIVIDUAL TA
IS RECEIVING THE LIVE
REPLICATING CELLS THAT ARE
PRODUCING THE SMALL MOLECULES.
SO SOMETHING ON THAT SCALE.
AND THEN ALL THE WAY ON THE
SCALE WHERE WE ARE LOOKING AT
USING AIML TO HELP FILL IN THE
GAPS FOR BEHAVIORAL HEALTH
CHALLENGES.
SO INDIVIDUALS WHO ARE POTENTIAL
RISK OF ABUSING OPIOIDS OR GOING
THROUGH RECOVERY AND TRYING TO
CREATE AT SCALE SORT OF
COMPANION TO ALLOW US, AN AI
COMPANION ALLOWING 24-7 INTIMATE
CULTURALLY APPROPRIATE AND
TAILORED CARE FOR THE
INDIVIDUALS KNOWING THAT THAT IS
GOING TO BE AN INCREDIBLY --
LIKE THAT ON RISK, WHEN YOU TALK
ABOUT RISK, THAT ONE IS GOING TO
BE SUPER HIGH RISK AND THERE IS
SO MUCH CHALLENGES ASSOCIATED
WITH IT.
SO THINKING ABOUT THAT.
WE HAD OTHER PEOPLE PROPOSE
CHANGES TO CITY DESIGN TO CREATE
A HEALTH AND WELLNESS
ENVIRONMENT.
WE HAD PEOPLE TALK ABOUT HEALTHY
BUILDINGS.
I MEAN JUST A NUMBER OF
DIFFERENT ASPECTS OF THE HEALTHY
ECOSYSTEM WHICH GETS US SUPER
EXCITED AND THAT'S EXACTLY WHERE
WE WANT TO BE IS NOT JUST A
BIOTECH COMPANY.
WE WANT TO BE AN ORGANIZATION
THAT CAN SUPPORT INNOVATION
ACROSS THE HEALTH ECOSYSTEM.
ASK ME IN A YEAR AND I'LL GIVE
YOU A MORE BIG ANSWER ABOUT WHAT
WORKED AND WHAT HAS NOT WORKED.
>>THANK YOU.
>>I THINK WE JUST HAVE TIME FOR
MAYBE ONE MORE QUESTION.
SO SHARON DO YOU WANT TO ASK
YOUR QUESTION?
>>THANK YOU.
IT WAS A WONDERFUL TALK.
I REALLY AM VERY EXCITED.
I REALLY APPRECIATED IT.
HAVING BEEN INVOLVED IN ANOTHER
KIND OF GRAND CHALLENGE LIKE
THIS, AND KNOWING THAT
COMMERCIALIZATION IS ONE OF
THOSE THINGS ON YOUR LAST SLIDE
IT SOUNDS LIKE IT'S NOT ONLY
FINANCIAL.
YOU'RE GOING TO LOOK AT THE
GREATER GOOD AND SOCIETAL
IMPACTS BECAUSE WE CAN ALL, I'M
SURE, THINK OF SO MANY EXAMPLES
OF MAJOR PUBLIC HEALTH
INNOVATIONS OR CLIMATE CHANGE
INNOVATIONS THAT MAY NOT BRING
IN THE DOLLARS IMMEDIATELY BUT
WOULD BE SO ESSENTIAL TO ADVANCE
THE GREATER GOOD.
SO, I JUST WANT TO MAKE SURE
EXPLICITLY THAT WILL BE FACTORED
IN?
>>IT REALLY IS.
OUR CHALLENGE IS, WE HAVE LIMIT
DOLLARSS AND WE DON'T HAVE
DOLLARS FOR SUSSTATEMENT.
SO IF BEE DEVELOP SOMETHING THAT
HAS THAT IMPACT FOR THE GREATER
GOOD, WHICH I HOPE WE DO.
ONE OF THE THINGS I DID IN MY
PREVIOUS WORK AT THE HEALTH
RESOURCES AND SERVICES
ADMINISTRATION IS TO THINK MORE
POPULATION LEVEL IMPROVEMENTS.
THAT'S WHERE I SORT OF WORKED ON
MY REN ORIVATION TO THINK ABOUT
HOW DO WE CHANGE THE WHOLE
SYSTEM?
HOW DO WE BENEFIT WHOLE
POPULATIONS?
THE CHALLENGE IS, AND YOU CAN
APPRECIATE THIS, YOU CAN COME UP
WITH AN INCREDIBLY SMART DESIGN
OR CAPABILITY OR WHATEVER IT
HAPPENS TO BE, POLICY AND
PROCEDURES AND TECHNOLOGY, BUT
IF YOU DON'T HAVE A SUSTAINMENT
PARTNER AND IF THERE IS JUST A
RELIANCE ON THE GOVERNMENT FOR
SUSTAINMENT, IT STARTS TO
CONSTRAIN WHAT YOU CAN
MEANINGFULLY DEVELOP AND THEN
TRANSITION.
SO WE HAVE TO KEEP THAT IN MIND
THAT DOESN'T MEAN WE CAN'T
DEVELOP NOVEL PARTNERSHIPS FOR
SUSSTATEMENT AND THERE IS A LOT
OF ORGANIZATIONS THAT WE CAN
POTENTIALLY TRY TO PARTNER WITH
FOR NON-BIOTECH INNOVATIONS.
AND THAT IS SOMETHING WE'LL LOOK
AT.
BUT I DO HOPE WE CAN INNOVATE ON
A LEVEL OF IMPACT.
>>SUSAN, THANK YOU VERY MUCH
FOR YOUR TALK WE REALLY
APPRECIATE THIS OVERVIEW AND
WISH YOU ALL THE BEST.
WE ARE DRINKING FROM THE FIRE
HYDRANT AND SETTING UP A NEW
AGENCY LIKE THIS.
WE DO LOOK FORWARD TO
COLLABORATIONS AND PLEASE REACH
OUT TO US AT ANY TIME.
BECAUSE WE HAVE A LOT OF
PRIORITIES WITH OUR AGING
POPULATION AND OBVIOUSLY WE HOPE
THAT ARPAH WILL BE AN INTEGRAL
PART OF SOLVING SOME OF THESE
ISSUES THAT WE HAVE.
>>THANK YOU.
AND LIKEWISE.
PLEASE DO NOT HESITATE TO REACH
OUT TO US.
WE WOULD LOVE NOTHING MORE THAN
TO DEVELOP A STRONG PARTNERSHIP
SO WE CAN EXCHANGE IDEAS AND
ACTIVITIES AND EVERYTHING.
>>SURE THING.
THANK YOU, AGAIN.
>>THANK YOU.
>>YES.
>>ALL RIGHT, THANK YOU ALL.
NEXT UP NOW WE'LL MOVE ON WITH
OUR PROGRAM.
NEXT WILL BE ASKING DR. LUIGI
FERRUCCI, OUR HEAD OF OUR
CLINICAL CENTER TO GIVE OUR
INTRAMURAL PROGRAM REPORT.
SO LUIGI?
>>LUIGI FERRUCCI: THANK YOU.
--
[ INAUDIBLE ]
*6 WORLD EXPERT IN NON CODING --
I THINK NEW FRONTIER OF
GENOMICS.
AND SHE HAS BEEN REVIEWING VERY
RECENTLY AND WE SUBMIT THAT ONE
RESPONSE TO THE REPORT WAS
ABSOLUTELY POSITIVE AND SHE WILL
INCLUDE IN HER PRESENTATION SOME
ANSWER TO THE COMMENT FROM THE
BOARD OF SCIENTIFIC COUNCIL.
THE SECOND TALK WILL BE GIVEN
FROM DR. RANHAN SEN, CHIEF OF
THE MOLECULAR BIOLOGY AND
IMMUNOLOGY.
DR. SEN IS A VERY WELL-KNOWN
IMMUNOLOGIST.
HIS WORK ON NF-kB AND
CONTRIBUTED SUBSTANTIALLY IN THE
FUNCTION OF THIS VERY IMPORTANT
SYSTEM.
IT IS SOMETIMES SLOWLY
PROGRESSIVELY CONVINCING --
ABOUT AGING AND SO I THINK HE
WILL TALK TO YOU ABOUT SOME
REALLY GREAT WORK.
AND AFTER THAT, I WILL GIVE YOU
SOME DESCRIPTION ABOUT WHAT
HAPPENED IN THE IP IN THE LAST
YEAR.
I WILL TRY TO SHORTEN MY
PRESENTATION AND GIVEN THE FACT
WE HAVE ACCUMULATED SOME DELAY.
WITHOUT HESITATION, I ASK MYRIAM
GOROSPE TO SHARE HER SLIDES.
>>MYRIAM GOROSPE: SO THANK YOU
ALSO SENIOR LEADERSHIP AND
COUNCIL MEMBERS FOR GIVING ME AN
OPPORTUNITY TO PRESENT AN UPDATE
IN THE LABORATORY OF GENETICS
AND GENOMICS IN OCTOBER 2021.
AND I'LL START WITH THIS BIC
PICTURE VIEW OF HOW WE
CONTRIBUTE TO THE MISSION OF
THE.
THIS IA TO REDUCE DELAY AND
PREVENT ASSOCIATED DISEASE AND
DISABILITY IN THE LABORATORY OF
GENETICS AND GENOMICS BY
CONTRIBUTING TOOLS AAPPROACHS
AND METHODS AND EXPERTISE OF
CELL AND MOLEC LABILES WHICH IS
WHAT WE ARE ALL IN IN LGG.
SO THE LABORATORY IS COMPRISED
OF THREE SECTIONS.
HEADED BY THREE SENIOR
INVESTIGATORS.
AND VERY BRIEFLY, WE DON'T
WANT --
[ INAUDIBLE ]
AS YOU'LL SEE ALL OF US FOCUS
VERY MUCH ON THE PROCESS OF GENE
REGULATION, FLOW OF GENETIC
INFORMATION IN ONE WAY OR
ANOTHER.
WE FOCUS ON POST TRANSCRIPTIONAL
GENE REGULATORY PROCESSES IN
AGING PARADIGMS AND FOCUSES ON
TELOMERE MAINTENANCE AND
TELOMERE FUNCTION.
WE ALSO HAVE TWO INVESTIGATORS.
LOOKING AT CHROMATIN REMODELING
AND REGENERATION AND ANOTHER
LOOKS AT ONLY DYNAMICS AS WELL
BUT FOCUSING STRONGLY ON
COMPUTATIONAL BASIS OF GENE
REGULATION.
WE ALSO HAVE ANOTHER JUNIOR
INVESTIGATOR IN THE LAB, AN
INDEPENDENT RESEARCH
COLLABORATOR.
AND THE HER RESEARCH FOCUSES ON
OUTCOMES OF SENESCENCE IN THE
CONTEXT OF AGING, IN PARTICULAR
ARTHROSCLEROSIS.
AND THE FINAL GROUP IS LED BY
THE COMPUTATIONAL GENETICS AND
COMPUTATIONAL CORE, AND SUPPORTS
US AND COMPLIMENTS WHAT WE DO
WITH SUPPORT AND THE CORE OF
COURSE SUPPORTS MANY PROGRAMS
ACROSS.
SO WHAT I'D LIKE TO DO TODAY IS
TOUCH ON TWO THINGS.
SWONE GIVE YOU A BRIEF UPDATE OF
WHAT EACH OF THESE SECTIONS AND
UNITS HAVE DONE OVER THE PAST
YEAR SINCE WE WERE REVIEWED.
AND THEN I'LL CONCLUDE WITH
SPECIFIC WAYS IN WHICH WE ARE
ADDRESSING THE VERY HELPFUL AND
VALUABLE RECOMMENDATIONS AND
ADVICE.
SO I'LL START WITH THE PROGRESS
UPDATES.
SO WE DON'T HAVE DEDICATED A BIT
OF TIME OVER THE PAST FEW YEARS
LOOKING AT DATA.
OVER THE PAST YEAR, THESE
EFFORTS HAVE LED TO A NUMBER OF
PUBLICATIONS.
ONE OF WHICH IDENTIFIES SUBSETS
OF mRNAs WHO TRANSLATION AND
STABILITY ARE CONTROLLED BY TOP
3.
IN ANOTHER ARTICLE THEY HAVE
ESTABLISHED THAT TOP 3 DATA IS
DISPENSABLE FOR VIOLATES
REPLICATION.
THIS IS A POINT THAT HASH MADE
EARLIER AND THEY BROUGHT
SUPPLIES TO THIS QUESTION.
AND IN ANOTHER ARTICLE THEY HAVE
A CATALOG, TRANSCRIPTION FACTORS
IMPORTANT FOR HUMAN EMBRYONIC
STEM CELLS.
MY OWN LAB CONTINUES TO LOOK AT
GENE REGULATION, VERY MUCH
FOCUSED ON REGULATION OF RNA
FROM THE POINTED OF
TRANSCRIPTION UNTIL THE RNA IS
USED FOR SYNTHESIS AND MOST
FOCUS IS ON THE FACTORS, RNA
BINDING PROTEINS THAT DRIVE THIS
POST TRANSCRIPTIONAL MESSENGER
RNA.
OVER THE PAST YEAR, WE HAVE MADE
PROGRESS IN FOUR DIFFERENT AREAS
OF EFFORT IN THE LABORATORY.
WE HAVE IDENTIFIED SIGNALING
PATHWAYS THAT ARE CRITICAL IN
THE PROCESS OF CELL SENESCENCE
AND LOOKED AT TISSUE AGING.
WE ALSO HAVE IDENTIFIED SOME
LONGER CODING RNAs ESSENTIAL
FOR MUSCLE REGENERATION AS WELL
AS MACROPHAGES THAT CHANGE
ACROSS THE LIFESPAN IN THE
MUSCLES.
WE HAVE HAD THE OPPORTUNITY TO
DO A HISTORICAL REVIEW OF RNAs
FOR THE PAST 25 YEARS.
AND RECENTLY WE WERE ABLE TO
BEGIN TO LOOK AT CIRCULAR
RN56789s.
NOT REVIEWED IN 2021 BECAUSE SHE
HAD JUST MOVED TO THE LGG, BUT
OVER THE PAST YEAR, HER WORK HAS
CONTINUED TO BE -- TO MAKE
EXCITING PROGRESS.
IN THREE OF THE ARTICLES, SHE
HAS BEEN ABLE TO IDENTIFY THE
PROTEIN RAT 1 AS BEING A KEY
MOLECULAR FACTOR IN MAINTENANCE.
SHE ALSO DEVELOPED A METHOD THAT
IS QUITE USEFUL IN BEING ABLE TO
MEASURE CONVENIENTLY TELOMERE
DYSFUNCTION AND SHE HAS LOOKED
AT INTERVENTIONS -- IN SHORT
TELOMERE SYNDROMES IN HUMANS.
MOVING ON TO THE TENURED TRACK
INVESTIGATORS AND LOOKING AT
EPIGENETIC MECHANISMS OF TISSUE
AGING.
THIS IS A PERIOD FOR HER OVER
THE PAST YEAR.
AND I'M EXCITED TO TELL YOU THAT
ONE OF HER MAJOR PROJECTS IN THE
LAB WHICH LOOKS AT TISSUE
REGENERATION, LIVER
REGENERATION,S AS A FUNCTION OF
AGE IN MUSCLE WITH LOOKING AT
CHROMATIN CHANGES IS NOW IN
FINAL STAGE LESS OF REVISION.
ALSO CONTINUING TO LOOK AT RNA
DYNAMICS OVER THE PAST YEAR AND
THIS WORK HAS LED TO ADDITIONAL
ARTICLES, ONE OF WHICH ALSO I'M
EXCITED TO SAY CAPTURES A LOT OF
WORK THEY HAVE DONE OVER THE
PAST COUPLE OF YEARS IN MOUSE
MODELS OF AGING LOOKING AT RNA
DYNAMICS, IN PARTICULAR LOOKING
AT RNA LENGTH AND USING
TECHNIQUES SUCH AS SEQUENCING
WITH A VERY STRONG AND
CUTTING-EDGE COMPUTATIONAL
SUPPORT WHICH IS ACTUALLY LED TO
THE DEVELOPMENT OF SOFTWARE AND
OTHER APPROACHES IN-HOUSE BY THE
TEAM.
LEADING THE PROGRAM, THE NEWEST
IN THE LGG.
SHE HAS BEEN DEVELOPING CELL AND
MOUSE MODELS OF VASCULAR
SENESCENCE AND IDENTIFYING DRUGS
THAT TARGET SINESENCE IN THIS
NICHE.
SHE ALSO HAD BEEN QUITE BUSY
OVER THE PAST YEAR AND ONE OF
THE RECENT STUDIES IN WHICH SHE
HAS LOOKED AT SINGLE CELL
POPULATIONS IN THE
ARTHROSCLEROSIS NICHE IN MOUSE
IS NOW AGAIN IN FINAL STAGES.
SO REVISION AND PLANS TO SEND IT
BACK IN THE FUTURE.
AND FINALLY, WE HAVE BEEN QUITE
BUSY SUPPORTING ALL OF THE
GROUPS WHILE THE GROUPS IN.
THIS IA BY PROVIDING DIVERSE
OMICS DATA BY COORDINATING DATE
TA SCIENCE EXPERTISE, BY
ACQUIRING AND MAINTAINING
INSTRUMENTS AND SOFTWARE THAT
ALLOWS US TO BUILD MUCH OF THE
WORK WE DO.
AND IN SOME CASES, BY WORKING
WITH US WITH INDIVIDUAL GROUPS
TO SET UP SPECIFIC PROJECTS THAT
REQUIRE EXPERTISE THAT WE DON'T
HAVE IN OUR OWN GROUPS.
AND THEY ARE ABLE TO VERY
QUICKLY HELP US DEVELOP METHODS
AND APPROACH THAT IS WE CAN USE.
SO THIS IS THE UPDATE OVER THE
PAST YEAR BY ALL OF THE TEAMS
THAT COMPRISE THE LGG.
AND SO WHAT I'D LIKE TO DO IN
THE REMAINING FEW MINUTES IS
TELL YOU HOW WE ADDRESSED THE
RECOMMENDATIONS AND ADVICE FROM
THE BSC.
SO THE BSC PROPOSED OR SUGGESTED
THAT MORE VERIFICATION OF
FINDINGS AND MODELS IN PATIENT
SAMPLES AND WE HAVE TAKEN THIS
ADVICE VERY SERIOUSLY.
WE HAVE ADDITIONAL SENESCENCE
MODELS WE ARE BEGINNING TO
PUBLISH, INCLUDING MODELS OF
SENESCENCE SIGNALING AND
TELOMERE ATTRITION.
SO THESE ACTUALLY INCLUDING
MOUSE MODELS OF SENESCENCE.
AND WE ARE ALSO VERY KEEN ON
FOLLOWING THE ADVICE OF
BRANCHING OUT AND EXPANDING INTO
PATIENT SAMPLES AND WE ARE
TEAMING UP WITH THE LARGE
ENTERPRISE AT NIA.
WE HAVE BEEN LOOKING AT MUSCLE
AND SKIN IN THIS SPACE AND IN
OTHER EFFORTS, WE ARE LOOKING AT
LIVER FROM PATIENTS AS A
FUNCTION OF AGE AND WE HAVE
BEEN, AS I MENTI MENTIONED EARL,
LOOKING AT ALS SAMPLES FROM
HUMAN BIOPSIES AND NECROPSY.
TO ILLUSTRATE THIS POINT, THIS
IS A PROJECT THAT SEEKS TO
CATALOG CHANGES ACROSS THE HUMAN
LIFESPAN USING A VERY HEALTHY
COHORT OF INDIVIDUALS OF
DIFFERENT AGES FROM 20S TO THEIR
80s.
AND A NUMBER OF TISSUES HAVE
BEEN COLLECTED IN THIS STUDY.
IN THIS CASE WE LOOKED AT SKIN
BIOPSIES COLLECTED FROM THE
PARTICIPANTS FROM WHICH WE
OBTAINED FIBROBLASTS AND THEN
COLLECT RNA, WHICH WE ARE NOW
STUDYING AND PROTEINS THAT WAS
STUDIED IN THE ARTICLE THAT WE
LISTED A FEW MONTHS AGO.
AND HERE ANALYSIS OF PROTEINS
LED US TO IDENTIFY SPECIFIC
PATHWAYS THAT WERE CHANGING AS A
FUNCTION OF AGING IN THIS
COHORT.
THE BSC ALSO INDICATED THAT WE
SHOULD BEGIN TO DESCRIBE MORE
TRANSLATIONAL STUDIES TO MAKE
OUR EFFORTS IN THIS SPACE MORE
IMPACTFUL.
WE ARE ALSO TAKING THIS
RECOMMENDATION TO HEART.
WE HAVE WORKED WITH IN STUDIES
LED BY OTHERS LOOKING AT NOVEL
THINGS ELIMINATES SENESCENCEIS
AND TRACK INHABITORS TO CREATE
DRUGS THAT ONE CAN EXPLOIT AND
ADDITIONAL EFFORTS ARE ONGOING.
ONE OF THESE STUDIES TO
ILLUSTRATE THIS POINTED SO AFTER
CAUSING CELL DAMAGE IN
FIBROBLASTS AND OTHER CELLS, IS
THE CELL RESPONSE INCLUDES
ACTIVATION OF THE KINASE SAR?
THAT CELL IS MORE LIKELY TO
UNDERGO SENESCENCE.
BUT IF SARIS INHIBITED OR IS
SILENCERRED OR OTHERWISE
IMPAIRED, THAT CELL IS MORE
LIKELY TO UNDERGO APOPTOSIS AND
WE CAN TEST THESE DRUGS IN
PRE-CLINICAL PROD ELSE SUCH AS
THIS ONE.
THIS IS A MOUSE IN WHICH
SENESCENCE IS TRYING TO APPLY
INJECTION.
TREATMENT WITH THESE TWO
INHIBITORS TP1 AND 2 CAUSE
NUMBER OF SENESCENCE CELLS TO
DECREASE AS YOU CAN SEE IN THIS
SLIDE.
THE BSC ALSO ENCOURAGED FOR
OTHER SUPPORT PROGRAM AND IN
PARTICULAR THE DEVELOPMENT OF
ADDITIONAL MODELS.
AND WE ARE VERY THANKFUL TO THE
OFFICIAL SCIENTIFIC DIRECTOR
WHICH HAS COMMITTED PEOPLER
ADDITIONAL FUNDS TO STUDY
SENESCENCE AND MODELS AS WELL AS
BY CREATION OF AN ADDITIONAL
POSTBAC POSITION FOR MOUSE WORK.
MOUSE MODELS THAT WE ARE
ADOPTING AND DEVELOPING INCLUDE
A MODEL WHICH WE ARE TESTING THE
GINGER NONE A DRUG AND OTHER
INHIBITORS AND OF TEADB AND I'LL
USE MY LAST SLIDE TO ILLUSTRATE
THIS POINT.
IN ANOTHER RECENT ARTICLE, WE
DISCOVERED THAT SENESCENT CELLS
EXPRESS BOTH TRKB AND BDNF.
AND THIS PARADIGM IS ONE THAT WE
THOUGHT WAS ON THE --
RESTRICTED.
BUT SENESCENCE ACQUIRED THIS
PHENOTYPE AS WELL.
AND IN FACT, IF THIS AUDIO CRIN
OR RESPONSE IS IMPAIRED IN ANY
WAY, THOSE CELLS ARE MORE LIKELY
TO DIE THROUGH APOPTOSIS.
AND SO WE CAN USE INHIBITORS OF
TRKB IN PARTICULAR TO TEST THE
POSSIBILITY OF INTERFERING WITH
THE SENESCENCE PROCESS IN THIS
MANNER.
AND SO HERE TWO INHIBITORS TO
BLOCK TRKB ACTIVITY.
THIS WILL INJECT -- IN THREE
MONTHS AND AS I CAN SEE IN
KEEPING IN LINE WITH LIVER, THE
NUMBER OF SENESCENCE CELLS
DECLINE AS A FUNCTION OF
ADMINISTRATION OF THE DRUG.
THE FINAL RECOMMENDATION FOR
WHICH WE ARE SUPER GRATEFUL TO
THE BSC IS THAT A STAFF
SCIENTIST BIOINFOMATIC EXPERT BE
ADDED TO THE LAB.
SO WESTERN ABLE TO RECRUIT
DR. CHRISTINA MASON -- SO WE
WERE ABLE TO RECRUIT -- SHE
JOINEDIS 2022 AND SHE ALREADY
ENRICHED THE PROGRAMMING IN
MANY, MANY DIFFERENT WAYS.
SO WITH THIS, I WILL THANK THE
GROUP THAT I'M SO EXCITED TO BE
A PART OF AND SO PROUD OF
WORKING WITH.
AND I WILL THANK ALL OF YOU FOR
YOUR ATTENTION AND END HERE.
THANK YOU.
>>THANK YOU.
GIVEN THE FACT THAT WE ARE LATE,
WHY DON'T WE GO ON AND SEE THE
OTHER PRESENTATION AND THEN
PEOPLE CAN ASK THEIR QUESTIONS.
>>OKAY.
>>RAB JAN YOU CAN START SHARING
YOUR SCREEN.
>>RANHAN SEN: OKAY, I WILL.
IS THAT VISIBLE AND I CAN BE
HEARD?
>>YES.
>>THANK YOU VERY MUCH FOR THE
KIND INTRODUCTION.
GOOD AFTERNOON COUNCIL MEMBERS
AND NIA LEADERSHIP AND OF COURSE
ALL OF OUR COLLEAGUES WITH THE
NIA.
IT'S MY PRIVILEGE TODAY TO
INTRODUCE TO YOU THE LABORATORY
OF MOLECULAR BIOLOGY AND
IMMUNOLOGY WHICH IS A PART OF
THE INTRAMURAL RESEARCH PROGRAM
OF THE NATIONAL INSTITUTE ON
AGING.
AT THE MOMENT, WE ARE SIX
INVESTIGATORS.
SUNG IS A TENURE-TRACK
INVESTIGATOR INTERESTED IN
TRANSCRIPTIONAL REGULATION.
AND THE OTHER FIVE OF US ARE
TENURED SENIOR INVESTIGATORS
THAT HEAD OUR INDEPENDENT
SECTIONS OF WHICH I WILL TALK
ABOUT IN THE NEXT FEW MINUTES.
A DEPUTY LAB CHIEF AND ALL OF US
ARE INTIMATELY INVOLVED IN EACH
OTHER'S PROGRAMS WITHIN THE LAB.
AND I WILL OFTEN REFER TO IT IN
SHORT AS LMBI.
THE RESEARCH PROGRAMS SHARE THE
GOALS OF ELUCIDATING MOLECULAR
AND CELLULAR MECHANISMS TO
REGULATE IMMUNITY AND THEREBY
UNDERSTAND THE DECLINE IN
RESPONSES.
AS YOU ALL KNOW, THE COVID
PANDEMIC OVER THE LAST FEW YEARS
HAS REALLY HIGHLIGHTED AGAIN THE
NEED TO UNDERSTAND AND
AMELIORATE THE AGE ASSOCIATE
SAID IMMUNE DYSFUNCTION IN
HUMANS.
GIVEN THE NEW SYSTEM IS VERY
BROAD-BASED, I HAVE A SLIDE TO
SHARE WITH YOU TO GIVE YOU
ASTHENIES OUR INVESTIGATORS THAT
ARE INVOLVED IN MANY ASPECTS OF
IMMUNITY I.
SO IN THE BACKGROUND HERE, WE
START WITH IMMUNE DEVELOPMENT
AND THIS COULD BE IMMUNE CELLS
OF THE INNATE IMMUNE SYSTEM OR
ADAPTIVE IMMUNE SYSTEM.
ONCE THESE CELLS EXIST IN THE
ORGANISM THEY ARE THERE TO
MOUNTAIN IMMUNE RESPONSE SHOULD
THE ORDER OF THEM BE FACED WITH
SUCH A NEED.
THAT IMMUNE RESPONSE THEN LEADS
TO SO-CALLED EFFECTOR FUNCTIONS.
THOSE ARE FUNCTIONS MEDIATED
BOTH BY SOLUBLE MEDIATORS OR BY
THE CELLS THEMSELVES THAT TRY TO
GET RID OF THE INVADING PATHOGEN
OR THE DANGER THAT THE ORGANISM
FACES.
ADAPTIVE IMMUNITY IN PARTICULAR,
HAS THE EXTREMELY IMPORTANT
PROPERTY OF BEING ABLE TO
DEVELOP MEMORY.
AND MEMORY IS THE BASIS FOR ALL
VACCINATION AND ALSO THE REASON
WHY ONCE INFECTED WITH ONE
PATHOGEN ONE IS LESS SUSCEPTIBLE
TO THAT SAME PATHOGEN LATER ON.
AND FINALLY, THE IMMUNE RESPONSE
HAS TO BE REGULATED.
TOO MUCH OF AN IMMUNE RESPONSE
LEADS TO IMMUNITY AND TOO LITTLE
OF IMMUNE RESPONSE LEADS TO
IMMUNODEFICIENCY.
THERE IS A SILTS BALANCE THAT
THE IMHUGE SYSTEM HAS TO
ACHIEVE -- SUBTLE BALANCE.
OUR INVESTIGATORS ADDRESS MANY
OF THE THESE ASPECTS OF IMMUNITY
IN THEIR INDIVIDUAL RESEARCH
PROGRAM.
FOR THE PRESENTATION THIS
AFTERNOON, I THOUGHT I WOULD
FOCUS ON THE RECENT ADVANCES
MADE BY THREE OF OUR
INVESTIGATORS, MA -- AND ALSO
GIVE OFF A SENSE OF WHAT THE
THREE OF US DO AND HOPE TO GIVE
YOU THEIR UPDATE IN THE NEXT
TIME WE PRESENT TO THE COUNCIL.
NOW AT THIS POINT, SUN'S LAB
JUST PUBLISHED THE DEVELOPMENT
AND USE OF AN EXTREMELY VALUABLE
REAGENT.
MA'S LAB WORKS ON THE
TRANSCRIPTION FACTOR NF-kB T
IS CENTRAL EVOLVED IN
ESSENTIALLY ALL IN FLAM TORY
RESPONSES.
SO SHE HAS GENERATED IN MICE,
THESE REPORTER ALLELES OF TWO OF
THE DIFFERENT FAMILY MEMBERS OF
THE NF-kB FAMILY.
IN THIS CASE, RAD A PROTEIN IS
TAGGED WITH THE GFB.
THE REL IS TAGGED WITH A
DIFFERENT COLORED MARKER.
SHE HAS SHOWN THESE FUSION
PROTEINS DO NOT EFFECT
DEVELOPMENT IN THE MOUSE SO THEY
ARE EXPRESSED IN ALL CELLS.
AND YOU CAN THEN BREED A MOUSE
THAT HAS AN ALLELE FUSED TO A
GREEN TO ONE THAT HAS A WELL
FUSED TO A RED FLUORESCENT
PROTEIN TO GENERATE DOUBLE
EXPRESSERS WHERE ONE ALLELE OF
EACH OF THESE PROTEINS IS
CHECKED.
REALLY BRIEFLY A SENSE OF WHAT
CAN BE ACHIEVED FROM THESE
ANIMALS.
SO THE FIRST TIME IN PRIMARY
CELLS, YOU CAN FOLLOW THE
ABUNDANCE OF SPECIFIC PROTEINS
BECAUSE THEY HAVE BEEN EXPRESSED
FROM THE ENDOGENOUS LOCUS.
YOU CAN TAKE A TISSUE, PURIFY
THE CELLS OF INTEREST AND
MEASURE THE LEVELS OF THE
PROTEIN BECAUSE THESE ARE FUSION
PROTEINS THAT EXPRESS.
WE CAN ALSO ASSAY IN THE CELLS
THE PRESENCE OF
HOMOHETERODIMERS.
HOW MUCH VED COUPLED WITH GREEN
OR HOW MUCH GREEN IS BY ITSELF,
ET CETERA.
AND FINALLY ONE CAN ISOLATE
CELLS FROM THE MICE AND
STIMULATE THEM IN CULTURE
BECAUSE THE TRANSCRIPTION FACTOR
IS INVOLVED IN RESPONSE TO EXOG
FLUS OR ENDOGENOUS DANGER
SIGNALS AND FOLLOW THE KINETICS
AND ASK WHAT HAPPENS TO EACH OF
THESE KINDS OF PROTEINS WHEN A
CELL IS STIMULATED?
SO THE DEVELOPMENT OF THIS
EXTREMELY IMPORTANT REAGENT AND
ITS APPLICATION TO ONE
BIOLOGICAL PROBLEM, F NCAPA B
ACTIVATION WAS PUBLISHED BY A
GROUP IN CELL REPORTS, TO
CONSIDERABLE INTEREST FROM THE
EXTRAMURAL COMMUNITY AND
HIGHLIGHTED IN OUR OWN LOCAL
PUBLICATION, THE NIH CATALYST,
AS A STUDY OF SOME IMPORTANCE.
THE DOCTOR WHO HEADS THE
IMMUNOREGULATION SECTION HAS
BEEN INTERESTED IN THAT
INTERFACE BETWEEN HOW THE NEW
SYSTEM IS REGULATED SO AS NOT TO
BECOME TOO MUCH OR NOT TO BE TOO
LITTLE.
BUT IN THE SET OF EXPERIMENTS
I'M GOING EMPHASIZE THIS
AFTERNOON, IS THIS ANALYSIS
WHERE THIS SECTION BEGAN TO
STUDY THE POTENTIAL ROLE OF
ADAPTIVE IMMUNE CELLS IN THE
CONTEXT OF ALZHEIMER'S DISEASE
MOUSE MODELS.
AND THE THRUST OF THE FIRST
PAPER THAT WAS PUBLISHED LAST
YEAR, OR NOW TWO YEARS AGO, IS
THAT IN THIS PARTICULAR MODEL
WHICH FOR THOSE OF YOU WHO
STUDIED THESE AS A TRIPLE
TRANSGENIC MODEL OF AD IN THE
MOUSE, YOU CAN SEE IN THE
NORMAL, CONTEXT OF THE TRIPLE
TRANSGENIC, YOU HAVE PLATS SHOWN
IN THE GREEN AS EXPECTED
ACTIVATED MICROGLIA SHOWN IN THE
RED OVER HERE, BUT WHEN THIS
GENETIC MODEL IS MOVED INTO THE
BACKGROUND OF A MOUSE THAT DOES
NOT HAVE B CELLS.
IT HAS EVERY OTHER KIND OF
IMMUNE CELL PRESENT INCLUDING
THE ADAPTIVES IMMUNE T-CELLS,
THOSE MICE HAVE SUBSTANTIALLY
REDUCED A DATA BLACKS AND
ACTIVATED MICROGLIA.
SO CONCLUDING FROM THESE
OBSERVATIONS, B CELLS ARE
INTIMATELY INVOLVED IN THE
PROGRESSION AND MANIFESTATION OF
THE PHENOTYPES OF AD IN THIS
MOUSE MODEL.
AND THEIR FUTURE WORK WILL TRY
TO DISSECT WHAT IS ACTUALLY
GOING ON.
THE RESULTS SO FAR SHOW THAT A
KIND OF IMMEAN CELL IS
INTIMATELY INVOLVED.
AND FINALLY THE THIRD RESULT
THAT I WILL ELABORATE ON TO SOME
EXTENT, IS DEVELOPED BY A LAB
WHO HEADS UP THE LYMPHOCYTE
SECONDS AND FOR MANY YEARS HAS
BEEN THE DRIVER OF STUDYING
HUMAN IMMUNITY AND HOW IT
CHANGES WITH AGE IN OUR
INSTITUTE, IN OUR INTRAMURAL
PROGRAM.
AND IN THIS CASE, HE HAS LOOKED
AT THE SO-CALLED ALPHA BETA
T-CELL RECEPTOR REPERTOIRE.
LET ME JUST GIVE ONE SENTENCE OR
TWO SENTENCE UPDATE OF WHAT THE
IMPLICATION OF THIS IS.
NOW IT HAS BEEN PROPOSED FOR
MANY YEARS, MOSTLY BASED ON
CROSS SECTIONAL STUDIES EVEN IN
MICE, THAT ONE OF THE REASONS
FOR THE IMMUNE DECLINE THAT
OCCURS WITH AGE IS BECAUSE THERE
AREN'T CELLS THERE THAT WOULD
RECOGNIZE THE POTENTIAL ANTIGEN
OR PATHOGEN WHEN IT COMES INTO
THE ORGANISM.
AND THIS IS BECAUSE THE LARGE
RANDOMLY ASSORTED REPERTOIRE OF
B-CELL RECEPTORS AND T-CELL
RECEPTORS, THE ANTIBODIES OF THE
T-CELL RECEPTORS IN THE CASE OF
T-CELLS, HAVE REDUCED IN THEIR
COMPLEXITY.
AND SO, THIS IS A HYPOTHESIS
THAT HAS BEEN AROUND FOR A
WHILE.
AND DIRECTLY TESTED THIS USING
THE INVALUABLE RESOURCE OF THE
LONGITUDINAL STUDY ON AGING TO
LOOK WITHIN INDIVIDUALS OF
DIFFERENT AGES SEPARATED BY NINE
YEARS.
SO 15 MALES SEPARATED BY NINE
YEARS ACROSS THE AGING SPECTRUM.
15 FEMALES.
PURIFIED CD4 AND CD8 MEMORY
CELLS, BEING THE HALLMARK OF
ADAPTIVE IMMUNITY.
FIGURED OUT WHAT THEIR
COMPLEXITY OF THE T-CELL
RECEPTOR ALPHA AND BETA CHANGES
USING RNA-SEQ.
AND THE RESULTS ARE VERY
BEAUTIFULLY SUMMARIZED ON THIS
RIGHT PANEL SHOWING THE
DIVERSITY OF THESE CELLS IS MUCH
HIGHER IN YOUNGER INDIVIDUALS
AND NOW GIVES YOU A NUMBER FOR
THE RATE AT WHICH THIS DIVERSITY
REDUCES WITH AGE.
SO YOU WANT TO FIGURE OUT HOW
MANY FEWER WIDELY DIVERSELY
EXPRESSING T-CELL RECEPTORS AS A
PRESENTS AS A FUNCTION OF AGE IN
HUMANS.
HE DOES THIS FOR CD4 AND CD8.
SO WITH THOSE THREE EXAMPLES
WANT I WANT TOED TO EMPHASIZE IS
GIVE YOU ASCENSUS OF THE RANGE
OF OUR ENTERPRISE FROM OUR
MECHANISTIC STUDIES GOING
THROUGH TO MOUSE MODELS AND
PHYSIOLOGICAL SITUATIONS AS
DIVIDED FROM THE KIND OF
EXPERIMENT I SHOWED YOU FROM THE
OTHER LAB, ALL THE WAY TO HUMAN
IMMUNITY AND THE IMPLICATIONS OF
T-CELL RECEPTOR REPERTOIRE
DECLINE IN LEADING TO IMMUNE
DYSFUNCTION WITH AGE.
THE OTHER THREE INVESTIGATORS
HAVE CORRESPONDINGLY INTERESTING
RESEARCH PROGRAMS SO DR. GEAR
HEART, HER LAB IS SPECIFICALLY
LOOKING AT THE ANTIBODY IN A
DIFFERENT CONTEXT.
WHAT HAPPENS IN THE B CELLS IN
AGING.
HOW IS HIGH AFFINITY ANTIBODIES
GENERATED DURING IMMUNE
RESPONSES?
IS THERE A ROLE FOR ANTIBODIES
IN ARTHROSCLEROSIS?
AND THE LATEST PROJECT IN THE
LAB LOOKS AT CHANGES IN
HEMATOPOIETIC STEM CELLS THAT
MIGHT LEAD TO REDUCED ANTIBODY
DIVERSITY WITH AGE.
DR. MICHAEL'S SECTION IS
STUDYING REP DECLARATION STRESS.
AND WE TAKE REPLICATION STRESS.
THIS IS REPLICATION AS IN DNA
REP SITUATION DURING THE CELL
CYCLE.
WE THINK THIS IS AN EXTREMELY
IMPORTANT AREA THAT SYNERGIZES
WITH IMMUNITY BECAUSE ONE OF THE
FUNDAMENTAL PRINCIPLES OF
ADAPTIVE IMMUNITY IS A SO-CALLED
PHENOMENON OF CLONAL SELECTION.
IN A NAIVE INDIVIDUAL YOU HAVE A
LARGE DIVERSITY CELLS THAT COULD
POTENTIALLY RECOGNIZE MANY
DIFFERENT KINDS OF ANTIGEN.
THESE HAVE BEEN GENERATED
AGNOSTIC OF WHAT ANTIGEN HUMAN
LIFE OR HUMAN ORGANISM MIGHT
FACE.
BUT WHEN SUCH AN ORGANISM COMES
ALONG, FULL OF ANTIGENS,
ANTIGEN-SPECIFIC CELLS, SOME
LIMITED, VERY LIMITED NUMBER OF
SELECTED AND CLONALLY EXPANDED
GO THROUGH 8, 10, 12 ROUNDS OF
DIVISION TO CREATE A POOL OF
CELLS THAT CAN MOUNT A GOOD
IMMUNE RESPONSE.
AND MICHAEL'S LAB LOOKS AT THE
STRESS THAT IS INVOLVED DURING
THIS CELL DIVISION AND DURING
DNA REPLICATION.
AND THEY HAVE IDENTIFIED THAT
EARLY REPLICATING REGIONS OF THE
CHROMOSOME USE A DIFFERENT
SUBSET OF PROTEINS TO SENSE A
STRESS TO THE NUCLEOSOME, A
STRESS TO THE REPLISOME, EXCUSE
ME, BLOCKED BECAUSE OF SOME DANA
DAMAGE WHICH REVENTS REPLICATION
TO TAKE PLACE.
AND MY OWN PROGRAM HAS THREE
MAJOR COMPONENTS TO UNDERSTAND
MOLECULAR MECHANISM OF CELL
SPECIFIC GENE EXPRESSION, WHICH
WE DO IN ANALYSIS OF DEVELOPMENT
AND THE EXPRESSION OF
IMMUNOGLOBULIN.
HEAVY CHAIN LOCUS.
WE ARE INTERESTED IN STUDYING
GENE REGULATION BY NF-kB, AN
AREA WE SYNERGIZE AND COMPLIMENT
MIA'S PROGRAM.
AND FINALLY A PART, INTEGRAL
PART OF THE HUMAN IMMUNE STUDIES
THAT WAS MENTIONED JUST A FEW
MINUTES AGO.
I WOULD LIKE TO CONCLUDE,
THOUGH, WITH A BIT OF SELF
REALIZATION THAT OCCURRED TO US
ABOUT 6-8 MONTHS AGO.
AND THIS IS IT.
EVEN THOUGH EACH OF OUR
INVESTIGATORS HAD THEIR OWN
RESEARCH PROGRAMS THAT THEY
WERE -- HAD BEEN FOLLOWING UP,
IT TURNS OUT THAT THERE WERE
ASPECTS THAT WERE POTENTIALLY
SHARED THAT WE WERE NOT USING TO
OUR ADVANTAGE AS MUCH AS WE
COULD.
SO FOR EXAMPLE, MIA AND MYSELF,
HAD BEGUN TO LOOK AT MICROGLIAL
GENE EXPRESSION FROM THE
PERSPECTIVE OF NF-kB
ACTIVATION.
WE -- BUT AT THE SAME TIME --
THEY DEVELOPED MODELS IN THE
ROLE OF B CELLS.
WE STUDIED B CELLS FOR A LONG
TIME, AS HAS DR. GEAR HEART'S
LAB.
NOW MIA'S LAB IS LOOKING AT CD8
CELLS IN THIS CONTEXT IN THESE
MODELS.
SO WE THOUGHT THIS IS THE PRIME
OPPORTUNITY FOR US NOT ONLY TO
DRIVE OUR OWN PROGRAMS BUT TO
COME TOGETHER IN A WAY TO
UNDERSTAND, TO BRING OUR
COMPLEMENTARY INTERESTS AND
EXPERTISE IN IMMUNITY AND
INFLAMMATORY GENE EXPRESSION TO
UNDERSTAND INFLAMMATORY
INTERACTIONS IN AD RELATED
DEMENTIAS.
WE HAVE NOW COME TOGETHER TO
FOCUS ON A LIMITED NUMBER OF
MODELS WHERE WE CAN BRING TO
FOCUS OUR INTERESTS IN THE
INTERMISSION, BE THAT
INVESTIGATORS HERE, OUR INTEREST
IN B-CELL OR T-CELLS TO
COORDINATE AND COORDINATELY
STUDY THE POTENTIAL ROLE OF
IMMUNITY.
INNATE OR ADAPTIVE.
AND ITS ROLE IN AGE RELATED
DEMENTIA.
SO I CERTAINLY AM VERY EXCITED
ABOUT THE POSSIBILITIES THAT ALL
SIXER OF US CAN CONTRIBUTE TO
THIS STORY AND BE ABLE TO
HOPEFULLY CLEARLY DELINEATE THE
POSSIBLE ROLLS OF INNATE AND
AADAPTIVE IMMUNITY DURING THE
NEURODEGENERATIVE DISEASES.
FINALLY, THE LABORATORY ALSO
OVER SEAS THE IRB, INTRAMURAL
PROGRAM, OVERSEEN HERE BY HUANG.
AND I GIVE YOU A SENSE OF OUR
THREE WONDERFUL PERSONNEL THAT
RUN THE CORE, SERVICE THE ENTIRE
IRB -- AND THE IDEA OF THE
VARIOUS INSTRUMENTATIONS WE HAVE
AVAILABLE, NOT JUST FOR THE USE
OF NIA BUT THE ENTIRE IRB.
WITH THAT I'LL STOP AND SEE IF
THERE IS ANY QUESTIONS.
THANK YOU VERY MUCH FOR YOUR
ATTENTION.